The O O
gammaPE O O
complex O O
contains O O
both O O
SATB1 O O
and O O
HOXB2 O O
and O O
has O O
positive O O
and O O
negative O O
roles O O
in O O
human O O
gamma O O
- O O
globin O O
gene O O
regulation O O
. O O

A O O
large O O
nuclear O O
protein O O
complex O O
, O O
termed O O
gammaPE O O
( O O
for O O
gamma O O
- O O
globin O O
promoter O O
and O O
enhancer O O
binding O O
factor O O
) O O
, O O
binds O O
to O O
five O O
sites O O
located O O
5 O O
' O O
and O O
3 O O
' O O
of O O
the O O
human O O
y O O
- O O
globin O O
gene O O
. O O

Two O O
proteins O O
, O O
SATB1 O O
( O O
special O O
A O O
- O O
T O O
- O O
rich O O
binding O O
protein O O
1 O O
) O O
and O O
HOXB2 O O
, O O
can O O
bind O O
to O O
yPE O O
binding O O
sites O O
. O O
SATB1 O O
binds O O
to O O
nuclear O O
matrix O O
- O O
attachment O O
sites O O
, O O
and O O
HOXB2 O O
is O O
a O O
homeodomain O O
protein O O
important O O
in O O
neural O O
development O O
that O O
is O O
also O O
expressed O O
during O O
erythropoiesis O O
. O O

The O O
present O O
work O O
showed O O
that O O
antisera O O
directed O O
against O O
either O O
SATB1 O O
or O O
HOXB2 O O
reacted O O
specifically O O
with O O
the O O
entire O O
gammaPE O O
complex O O
in O O
electrophoretic O O
mobility O O
shift O O
assays O O
( O O
EMSAs O O
) O O
, O O
suggesting O O
that O O
the O O
two O O
proteins O O
can O O
bind O O
to O O
the O O
gammaPE O O
binding O O
site O O
simultaneously O O
. O O

When O O
SATB1 O O
or O O
HOXB2 O O
was O O
expressed O O
in O O
vitro O O
, O O
they O O
could O O
bind O O
independently O O
to O O
gammaPE O O
binding O O
sites O O
in O O
EMSA O O
. O O

Interestingly O O
, O O
the O O
proteins O O
expressed O O
in O O
vitro O O
competed O O
effectively O O
with O O
each O O
other O O
for O O
the O O
gammaPE O O
binding O O
site O O
, O O
suggesting O O
that O O
this O O
may O O
occur O O
under O O
certain O O
conditions O O
in O O
vivo O O
. O O

Transient O O
cotransfections O O
of O O
a O O
HOXB2 O O
cDNA O O
and O O
a O O
y O O
- O O
globin O O
- O O
luciferase O O
reporter O O
gene O O
construct O O
into O O
cells O O
expressing O O
SATB1 O O
suggested O O
that O O
SATB1 O O
has O O
a O O
positive O O
and O O
HOXB2 O O
a O O
negative O O
regulatory O O
effect O O
on O O
transcription O O
. O O

Taking O O
into O O
account O O
their O O
potentially O O
opposing O O
effects O O
and O O
binding O O
activities O O
, O O
SATB1 O O
and O O
HOXB2 O O
may O O
modulate O O
the O O
amount O O
of O O
gamma O O
- O O
globin O O
mRNA O O
expressed O O
during O O
development O O
and O O
differentiation O O
. O O

An O O
enhancer O O
20 O O
kilobases O O
upstream O O
of O O
the O O
human O O
receptor O O
activator O O
of O O
nuclear O O
factor O O
- O O
kappaB O O
ligand O O
gene O O
mediates O O
dominant O O
activation O O
by O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
. O O
Receptor O O
activator O O
of O O
nuclear O O
factor O O
- O O
kappaB O O
ligand O O
( O O
RANKL O O
) O O
is O O
a O O
TNF O O
- O O
like O O
factor O O
that O O
is O O
both O O
produced O O
by O O
osteoblasts B-CellLine B-CellLine
, O O
mesenchymal B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
and O O
activated O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
required O O
for O O
osteoclast B-CellLine B-CellLine
maturation O O
and O O
survival O O
. O O

The O O
gene O O
is O O
up O O
- O O
regulated O O
by O O
the O O
two O O
primary O O
calcemic O O
hormones O O
, O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
[ O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
] O O
and O O
PTH O O
. O O

Previous O O
studies O O
have O O
indicated O O
that O O
five O O
enhancer O O
regions O O
located O O
significantly O O
upstream O O
of O O
the O O
mouse O O
Rankl O O
transcriptional O O
start O O
site O O
mediate O O
up O O
- O O
regulation O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
and O O
PTH O O
. O O
Previous O O
studies O O
have O O
indicated O O
that O O
five O O
enhancer O O
regions O O
located O O
significantly O O
upstream O O
of O O
the O O
mouse O O
Rankl O O
transcriptional O O
start O O
site O O
mediate O O
up O O
- O O
regulation O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
and O O
PTH O O
. O O

The O O
most O O
distal O O
of O O
these O O
, O O
termed O O
mRLD5 O O
, O O
is O O
highly O O
conserved O O
in O O
the O O
human O O
gene O O
at O O
- O O
96 O O
kb O O
where O O
it O O
was O O
also O O
shown O O
to O O
be O O
functionally O O
active O O
. O O
Four O O
additional O O
mouse O O
Rankl O O
upstream O O
enhancers O O
are O O
also O O
highly O O
conserved O O
in O O
the O O
human O O
gene O O
at O O
- O O
20 O O
, O O
- O O
25 O O
, O O
- O O
75 O O
, O O
and O O
- O O
87 O O
kb O O
. O O
The O O
most O O
distal O O
of O O
these O O
, O O
termed O O
mRLD5 O O
, O O
is O O
highly O O
conserved O O
in O O
the O O
human O O
gene O O
at O O
- O O
96 O O
kb O O
where O O
it O O
was O O
also O O
shown O O
to O O
be O O
functionally O O
active O O
. O O
Four O O
additional O O
mouse O O
Rankl O O
upstream O O
enhancers O O
are O O
also O O
highly O O
conserved O O
in O O
the O O
human O O
gene O O
at O O
- O O
20 O O
, O O
- O O
25 O O
, O O
- O O
75 O O
, O O
and O O
- O O
87 O O
kb O O
. O O

In O O
the O O
present O O
studies O O
, O O
we O O
characterized O O
the O O
activity O O
of O O
these O O
regions O O
, O O
explored O O
their O O
capacity O O
to O O
mediate O O
the O O
actions O O
of O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
, O O
and O O
identified O O
the O O
vitamin O O
D O O
response O O
elements O O
contained O O
within O O
the O O
two O O
most O O
proximal O O
segments O O
. O O

Interestingly O O
, O O
whereas O O
the O O
most O O
distal O O
of O O
the O O
five O O
enhancers O O
is O O
the O O
dominant O O
mediator O O
of O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
activity O O
in O O
the O O
mouse O O
Rankl O O
gene O O
, O O
that O O
role O O
in O O
the O O
human O O
gene O O
is O O
manifested O O
by O O
the O O
most O O
proximal O O
element O O
at O O
- O O
20 O O
kb O O
. O O

Importantly O O
, O O
activity O O
at O O
this O O
region O O
in O O
response O O
to O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
was O O
associated O O
with O O
a O O
significant O O
increase O O
in O O
histone O O
acetylation O O
as O O
well O O
as O O
the O O
enhanced O O
recruitment O O
of O O
RNA O O
polymerase O O
II O O
. O O

Both O O
likely O O
reflect O O
the O O
primary O O
role O O
of O O
this O O
enhancer O O
in O O
human O O
RANKL O O
gene O O
expression O O
. O O

Our O O
studies O O
confirm O O
the O O
complex O O
nature O O
of O O
RANKL O O
regulation O O
and O O
indicate O O
that O O
although O O
the O O
five O O
enhancers O O
are O O
evolutionarily O O
conserved O O
across O O
several O O
species O O
, O O
their O O
relative O O
contributions O O
to O O
RANKL O O
expression O O
in O O
response O O
to O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
may O O
be O O
different O O
. O O

Dynamic O O
regulation O O
of O O
Pdx1 O O
enhancers O O
by O O
Foxa1 O O
and O O
Foxa2 O O
is O O
essential O O
for O O
pancreas B-CellLine B-CellLine
development O O
. O O
Dynamic O O
regulation O O
of O O
Pdx1 O O
enhancers O O
by O O
Foxa1 O O
and O O
Foxa2 O O
is O O
essential O O
for O O
pancreas B-CellLine B-CellLine
development O O
. O O

The O O
onset O O
of O O
pancreas B-CellLine B-CellLine
development O O
in O O
the O O
foregut B-CellLine B-CellLine
endoderm B-CellLine I-CellLine
is O O
marked O O
by O O
activation O O
of O O
the O O
homeobox O O
gene O O
Pdx1 O O
( O O
IPF1 O O
) O O
. O O
Pdx1 O O
is O O
essential O O
for O O
the O O
expansion O O
of O O
the O O
pancreatic B-CellLine B-CellLine
primordium I-CellLine I-CellLine
and O O
the O O
development O O
of O O
endocrine B-CellLine O
islets I-CellLine B-CellLine
. O O

The O O
control O O
of O O
Pdx1 O O
expression O O
has O O
been O O
only O O
partially O O
elucidated O O
. O O

We O O
demonstrate O O
here O O
that O O
the O O
winged O O
- O O
helix O O
transcription O O
factors O O
Foxa1 O O
and O O
Foxa2 O O
co O O
- O O
occupy O O
multiple O O
regulatory O O
domains O O
in O O
the O O
Pdx1 O O
gene O O
. O O

Compound O O
conditional O O
ablation O O
of O O
both O O
Foxa1 O O
and O O
Foxa2 O O
in O O
the O O
pancreatic B-CellLine B-CellLine
primordium I-CellLine I-CellLine
results O O
in O O
complete O O
loss O O
of O O
Pdx1 O O
expression O O
and O O
severe O O
pancreatic O O
hypoplasia O O
. O O

Mutant O O
mice O O
exhibit O O
hyperglycemia O O
with O O
severely O O
disrupted O O
acinar O O
and O O
islet B-CellLine B-CellLine
development O O
, O O
and O O
die O O
shortly O O
after O O
birth O O
. O O

Assessment O O
of O O
developmental O O
markers O O
in O O
the O O
mutant O O
pancreas B-CellLine B-CellLine
revealed O O
a O O
failure O O
in O O
the O O
expansion O O
of O O
the O O
pancreatic B-CellLine B-CellLine
anlage I-CellLine I-CellLine
, O O
a O O
blockage O O
of O O
exocrine O B-CellLine
and O O
endocrine O B-CellLine
cell O I-CellLine
differentiation O O
, O O
and O O
an O O
arrest O O
at O O
the O O
primitive O O
duct O O
stage O O
. O O

Comparing O O
their O O
relative O O
developmental O O
activity O O
, O O
we O O
find O O
that O O
Foxa2 O O
is O O
the O O
major O O
regulator O O
in O O
promoting O O
pancreas B-CellLine B-CellLine
development O O
and O O
cell O O
differentiation O O
. O O

Using O O
chromatin O O
immunoprecipitations O O
( O O
ChIP O O
) O O
and O O
ChIP O O
sequencing O O
( O O
ChIPSeq O O
) O O
of O O
fetal O O
pancreas B-CellLine B-CellLine
and O O
islet B-CellLine B-CellLine
chromatin O O
, O O
we O O
demonstrate O O
that O O
Foxa1 O O
and O O
Foxa2 O O
predominantly O O
occupy O O
a O O
distal O O
enhancer O O
at O O
- O O
6 O O
. O O
4 O O
kb O O
relative O O
to O O
the O O
transcriptional O O
start O O
site O O
in O O
the O O
Pdx1 O O
gene O O
. O O
Using O O
chromatin O O
immunoprecipitations O O
( O O
ChIP O O
) O O
and O O
ChIP O O
sequencing O O
( O O
ChIPSeq O O
) O O
of O O
fetal O O
pancreas B-CellLine B-CellLine
and O O
islet B-CellLine B-CellLine
chromatin O O
, O O
we O O
demonstrate O O
that O O
Foxa1 O O
and O O
Foxa2 O O
predominantly O O
occupy O O
a O O
distal O O
enhancer O O
at O O
- O O
6 O O
. O O
4 O O
kb O O
relative O O
to O O
the O O
transcriptional O O
start O O
site O O
in O O
the O O
Pdx1 O O
gene O O
. O O

In O O
addition O O
, O O
occupancy O O
of O O
the O O
well O O
- O O
characterized O O
proximal O O
Pdx1 O O
enhancer O O
by O O
Foxa1 O O
and O O
Foxa2 O O
is O O
developmental O O
stage O O
- O O
dependent O O
. O O
In O O
addition O O
, O O
occupancy O O
of O O
the O O
well O O
- O O
characterized O O
proximal O O
Pdx1 O O
enhancer O O
by O O
Foxa1 O O
and O O
Foxa2 O O
is O O
developmental O O
stage O O
- O O
dependent O O
. O O

Thus O O
, O O
the O O
regulation O O
of O O
Pdx1 O O
expression O O
by O O
Foxa1 O O
and O O
Foxa2 O O
is O O
a O O
key O O
early O O
event O O
controlling O O
the O O
expansion O O
and O O
differentiation O O
of O O
the O O
pancreatic B-CellLine B-CellLine
primordia I-CellLine I-CellLine
. O O

Opioid O O
- O O
induced O O
chemokine O O
expression O O
requires O O
NF O O
- O O
kappaB O O
activity O O
: O O
the O O
role O O
of O O
PKCzeta O O
. O O

Opioid O O
receptor O O
agonists O O
induce O O
broad O O
immunomodulatory O O
activity O O
, O O
which O O
substantially O O
alters O O
host O O
defense O O
and O O
the O O
inflammatory O O
response O O
. O O

Previous O O
studies O O
have O O
shown O O
that O O
the O O
MOR O O
selective O O
agonist O O
DAMGO O O
has O O
the O O
capacity O O
to O O
increase O O
the O O
expression O O
of O O
the O O
proinflammatory O O
chemokines O O
CCL2 O O
, O O
CCL5 O O
, O O
and O O
CXCL10 O O
in O O
human O O
PBMCs O B-CellLine
. O O
NF O O
- O O
kappaB O O
is O O
a O O
transcription O O
factor O O
that O O
plays O O
a O O
pivotal O O
role O O
in O O
innate O O
and O O
adaptive O O
immune O O
responses O O
. O O

We O O
report O O
that O O
NF O O
- O O
kappaB O O
is O O
a O O
vital O O
player O O
in O O
the O O
DAMGO O O
- O O
induced O O
, O O
MOR O O
- O O
mediated O O
regulation O O
of O O
chemokine O O
expression O O
. O O

Results O O
show O O
that O O
NF O O
- O O
kappaB O O
inhibitors O O
prevent O O
the O O
induction O O
of O O
CCL2 O O
expression O O
in O O
response O O
to O O
DAMGO O O
administration O O
and O O
that O O
the O O
NF O O
- O O
kappaB O O
subunit O O
, O O
p65 O O
, O O
is O O
phosphorylated O O
at O O
serine O O
residues O O
311 O O
and O O
536 O O
in O O
response O O
to O O
MOR O O
activation O O
. O O

Furthermore O O
, O O
we O O
demonstrate O O
that O O
PKCzeta O O
is O O
phosphorylated O O
following O O
DAMGO O O
- O O
induced O O
MOR O O
activation O O
, O O
and O O
this O O
kinase O O
is O O
essential O O
for O O
NF O O
- O O
kappaB O O
activation O O
as O O
well O O
as O O
CCL2 O O
expression O O
and O O
transcriptional O O
activity O O
. O O

Finally O O
, O O
ChIP O O
analysis O O
shows O O
that O O
DAMGO O O
administration O O
induces O O
binding O O
of O O
p65 O O
to O O
the O O
enhancer O O
region O O
of O O
the O O
CCL2 O O
promoter O O
. O O
Finally O O
, O O
ChIP O O
analysis O O
shows O O
that O O
DAMGO O O
administration O O
induces O O
binding O O
of O O
p65 O O
to O O
the O O
enhancer O O
region O O
of O O
the O O
CCL2 O O
promoter O O
. O O

These O O
data O O
are O O
consistent O O
with O O
the O O
notion O O
that O O
MOR O O
activation O O
promotes O O
a O O
proinflammatory O O
response O O
, O O
which O O
involves O O
NF O O
- O O
kappaB O O
activation O O
. O O

Our O O
results O O
also O O
suggest O O
a O O
significant O O
and O O
novel O O
role O O
for O O
PKCzeta O O
as O O
an O O
essential O O
participant O O
in O O
the O O
MOR O O
- O O
mediated O O
regulation O O
of O O
proinflammatory O O
chemokine O O
expression O O
. O O

Identification O O
of O O
a O O
novel O O
cell O O
type O O
- O O
specific O O
intronic O O
enhancer O O
of O O
macrophage O B-CellLine
migration O O
inhibitory O O
factor O O
( O O
MIF O O
) O O
and O O
its O O
regulation O O
by O O
mithramycin O O
. O O
Identification O O
of O O
a O O
novel O O
cell O O
type O O
- O O
specific O O
intronic O O
enhancer O O
of O O
macrophage O B-CellLine
migration O O
inhibitory O O
factor O O
( O O
MIF O O
) O O
and O O
its O O
regulation O O
by O O
mithramycin O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
determine O O
the O O
genetic O O
regulation O O
of O O
macrophage O B-CellLine
migration O O
inhibitory O O
factor O O
( O O
MIF O O
) O O
. O O

DNase O O
I O O
hypersensitivity O O
was O O
used O O
to O O
identify O O
potential O O
hypersensitive O O
sites O O
( O O
HS O O
) O O
across O O
the O O
MIF O O
gene O O
locus O O
. O O

Reporter O O
gene O O
assays O O
were O O
performed O O
in O O
different O O
human O B-CellLine
cell O I-CellLine
lines O I-CellLine
with O O
constructs O O
containing O O
the O O
native O O
or O O
mutated O O
HS O O
element O O
. O O

Following O O
phylogenetic O O
and O O
transcription O O
factor O O
binding O O
profiling O O
, O O
electrophoretic O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
and O O
RNA O O
interference O O
were O O
performed O O
and O O
the O O
effects O O
of O O
incubation O O
with O O
mithramycin O O
, O O
an O O
antibiotic O O
that O O
binds O O
GC O O
boxes O O
, O O
were O O
also O O
studied O O
. O O

An O O
HS O O
centred O O
on O O
the O O
first O O
intron O O
of O O
MIF O O
was O O
identified O O
. O O
An O O
HS O O
centred O O
on O O
the O O
first O O
intron O O
of O O
MIF O O
was O O
identified O O
. O O

The O O
HS O O
acted O O
as O O
an O O
enhancer O O
in O O
human B-CellLine O
T I-CellLine B-CellLine
lymphoblasts I-CellLine I-CellLine
( O O
CEMC7A B-CellLine B-CellLine
) O O
, O O
human B-CellLine O
embryonic I-CellLine O
kidney I-CellLine B-CellLine
cells I-CellLine I-CellLine
( O O
HEK293T B-CellLine B-CellLine
) O O
and O O
human B-CellLine O
monocytic I-CellLine B-CellLine
cells I-CellLine I-CellLine
( O O
THP B-CellLine O
- I-CellLine O
1 I-CellLine O
) O O
, O O
but O O
not O O
in O O
a O O
fibroblast B-CellLine B-CellLine
- I-CellLine I-CellLine
like I-CellLine I-CellLine
synoviocyte I-CellLine I-CellLine
( I-CellLine I-CellLine
FLS I-CellLine I-CellLine
) I-CellLine I-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
( O O
SW982 B-CellLine B-CellLine
) O O
or O O
cultured B-CellLine O
FLS I-CellLine B-CellLine
derived I-CellLine O
from I-CellLine O
rheumatoid I-CellLine O
arthritis I-CellLine O
( I-CellLine O
RA I-CellLine O
) I-CellLine O
patients I-CellLine O
. O O
Two O O
cis O O
- O O
elements O O
within O O
the O O
first O O
intron O O
were O O
found O O
to O O
be O O
responsible O O
for O O
the O O
enhancer O O
activity O O
. O O

Mutation O O
of O O
the O O
consensus O O
Sp1 O O
GC O O
box O O
on O O
each O O
cis O O
- O O
element O O
abrogated O O
enhancer O O
activity O O
and O O
EMSA O O
indicated O O
Sp1 O O
binding O O
to O O
one O O
of O O
the O O
cis O O
- O O
elements O O
contained O O
in O O
the O O
intron O O
. O O
Mutation O O
of O O
the O O
consensus O O
Sp1 O O
GC O O
box O O
on O O
each O O
cis O O
- O O
element O O
abrogated O O
enhancer O O
activity O O
and O O
EMSA O O
indicated O O
Sp1 O O
binding O O
to O O
one O O
of O O
the O O
cis O O
- O O
elements O O
contained O O
in O O
the O O
intron O O
. O O

SiRNA O O
knock O O
- O O
down O O
of O O
Sp1 O O
alone O O
or O O
Sp1 O O
and O O
Sp3 O O
together O O
was O O
incomplete O O
and O O
did O O
not O O
alter O O
the O O
enhancer O O
activity O O
. O O

Mithramycin O O
inhibited O O
expression O O
of O O
MIF O O
in O O
CEMC7A B-CellLine B-CellLine
cells O I-CellLine
. O O

This O O
effect O O
was O O
specific O O
to O O
the O O
intronic O O
enhancer O O
and O O
was O O
not O O
seen O O
on O O
the O O
MIF O O
promoter O O
. O O
This O O
effect O O
was O O
specific O O
to O O
the O O
intronic O O
enhancer O O
and O O
was O O
not O O
seen O O
on O O
the O O
MIF O O
promoter O O
. O O

These O O
results O O
identify O O
a O O
novel O O
, O O
cell O O
type O O
- O O
specific O O
enhancer O O
of O O
MIF O O
. O O
These O O
results O O
identify O O
a O O
novel O O
, O O
cell O O
type O O
- O O
specific O O
enhancer O O
of O O
MIF O O
. O O

The O O
enhancer O O
appears O O
to O O
be O O
driven O O
by O O
Sp1 O O
or O O
related O O
Sp O O
family O O
members O O
and O O
is O O
highly O O
sensitive O O
to O O
inhibition O O
via O O
mithramycin O O
. O O

Analysis O O
of O O
a O O
SNP O O
linked O O
to O O
lactase O O
persistence O O
: O O
An O O
exercise O O
for O O
teaching O O
molecular O O
biology O O
techniques O O
to O O
undergraduates O O
. O O

Recent O O
experimental O O
evidence O O
indicates O O
that O O
the O O
ability O O
of O O
adults O O
to O O
tolerate O O
milk O O
, O O
cheese O O
, O O
and O O
other O O
lactose O O
- O O
containing O O
dairy O O
products O O
is O O
an O O
autosomal O O
dominant O O
trait O O
that O O
co O O
- O O
evolved O O
with O O
dairy O O
farming O O
in O O
Central O O
Europe O O
about O O
7 O O
, O O
500 O O
years O O
ago O O
. O O

Among O O
persons O O
of O O
European O O
descent O O
, O O
this O O
trait O O
is O O
strongly O O
associated O O
with O O
a O O
C O O
to O O
T O O
substitution O O
at O O
a O O
polymorphic O O
site O O
13 O O
, O O
910 O O
bp O O
upstream O O
of O O
the O O
lactase O O
gene O O
. O O

This O O
mutation O O
results O O
in O O
the O O
persistent O O
expression O O
of O O
lactase O O
into O O
adulthood O O
enabling O O
individuals O O
carrying O O
a O O
T O O
( O O
- O O
13 O O
, O O
910 O O
) O O
allele O O
to O O
digest O O
lactose O O
as O O
adults O O
. O O

In O O
this O O
report O O
, O O
we O O
describe O O
a O O
laboratory O O
exercise O O
for O O
an O O
undergraduate O O
molecular O O
biology O O
course O O
in O O
which O O
students O O
determine O O
their O O
own O O
genotype O O
at O O
the O O
- O O
13 O O
, O O
910 O O
polymorphic O O
site O O
and O O
correlate O O
this O O
with O O
their O O
ability O O
to O O
tolerate O O
dairy O O
products O O
. O O

The O O
exercise O O
is O O
used O O
as O O
a O O
tool O O
to O O
teach O O
basic O O
molecular O O
biology O O
procedures O O
such O O
as O O
agarose O O
gel O O
electrophoresis O O
, O O
PCR1 O O
, O O
and O O
DNA O O
sequencing O O
. O O

Students O O
are O O
actively O O
engaged O O
in O O
the O O
learning O O
process O O
, O O
not O O
only O O
by O O
analyzing O O
their O O
own O O
DNA O O
but O O
also O O
by O O
applying O O
their O O
knowledge O O
and O O
skills O O
to O O
answer O O
an O O
authentic O O
question O O
. O O

The O O
exercise O O
is O O
also O O
integrated O O
with O O
lecture O O
material O O
on O O
the O O
control O O
of O O
gene O O
expression O O
at O O
the O O
transcriptional O O
level O O
, O O
in O O
particular O O
, O O
how O O
transcription O O
factors O O
can O O
influence O O
the O O
activity O O
of O O
a O O
promoter O O
by O O
binding O O
to O O
cis O O
- O O
acting O O
DNA O O
regulatory O O
elements O O
located O O
within O O
the O O
proximal O O
promoter O O
of O O
a O O
gene O O
or O O
distant O O
enhancer O O
regions O O
. O O

Cohesin O O
mediates O O
chromatin O O
interactions O O
that O O
regulate O O
mammalian O O
beta O O
- O O
globin O O
expression O O
. O O

The O O
beta O O
- O O
globin O O
locus O O
undergoes O O
dynamic O O
chromatin O O
interaction O O
changes O O
in O O
differentiating O O
erythroid B-CellLine B-CellLine
cells I-CellLine I-CellLine
that O O
are O O
thought O O
to O O
be O O
important O O
for O O
proper O O
globin O O
gene O O
expression O O
. O O

However O O
, O O
the O O
underlying O O
mechanisms O O
are O O
unclear O O
. O O

The O O
CCCTC O O
- O O
binding O O
factor O O
, O O
CTCF O O
, O O
binds O O
to O O
the O O
insulator O O
elements O O
at O O
the O O
5 O O
' O O
and O O
3 O O
' O O
boundaries O O
of O O
the O O
locus O O
, O O
but O O
these O O
sites O O
were O O
shown O O
to O O
be O O
dispensable O O
for O O
globin O O
gene O O
activation O O
. O O

We O O
found O O
that O O
, O O
upon O O
induction O O
of O O
differentiation O O
, O O
cohesin O O
and O O
the O O
cohesin O O
loading O O
factor O O
Nipped O O
- O O
B O O
- O O
like O O
( O O
Nipbl O O
) O O
bind O O
to O O
the O O
locus O O
control O O
region O O
( O O
LCR O O
) O O
at O O
the O O
CTCF O O
insulator O O
and O O
distal O O
enhancer O O
regions O O
as O O
well O O
as O O
at O O
the O O
specific O O
target O O
globin O O
gene O O
that O O
undergoes O O
activation O O
upon O O
differentiation O O
. O O
Nipbl O O
- O O
dependent O O
cohesin O O
binding O O
is O O
critical O O
for O O
long O O
- O O
range O O
chromatin O O
interactions O O
, O O
both O O
between O O
the O O
CTCF O O
insulator O O
elements O O
and O O
between O O
the O O
LCR O O
distal O O
enhancer O O
and O O
the O O
target O O
gene O O
. O O
We O O
found O O
that O O
, O O
upon O O
induction O O
of O O
differentiation O O
, O O
cohesin O O
and O O
the O O
cohesin O O
loading O O
factor O O
Nipped O O
- O O
B O O
- O O
like O O
( O O
Nipbl O O
) O O
bind O O
to O O
the O O
locus O O
control O O
region O O
( O O
LCR O O
) O O
at O O
the O O
CTCF O O
insulator O O
and O O
distal O O
enhancer O O
regions O O
as O O
well O O
as O O
at O O
the O O
specific O O
target O O
globin O O
gene O O
that O O
undergoes O O
activation O O
upon O O
differentiation O O
. O O
Nipbl O O
- O O
dependent O O
cohesin O O
binding O O
is O O
critical O O
for O O
long O O
- O O
range O O
chromatin O O
interactions O O
, O O
both O O
between O O
the O O
CTCF O O
insulator O O
elements O O
and O O
between O O
the O O
LCR O O
distal O O
enhancer O O
and O O
the O O
target O O
gene O O
. O O

We O O
show O O
that O O
the O O
latter O O
interaction O O
is O O
important O O
for O O
globin O O
gene O O
expression O O
in O O
vivo O O
and O O
in O O
vitro O O
. O O

Furthermore O O
, O O
the O O
results O O
indicate O O
that O O
such O O
cohesin O O
- O O
mediated O O
chromatin O O
interactions O O
associated O O
with O O
gene O O
regulation O O
are O O
sensitive O O
to O O
the O O
partial O O
reduction O O
of O O
Nipbl O O
caused O O
by O O
heterozygous O O
mutation O O
. O O

This O O
provides O O
the O O
first O O
direct O O
evidence O O
that O O
Nipbl O O
haploinsufficiency O O
affects O O
cohesin O O
- O O
mediated O O
chromatin O O
interactions O O
and O O
gene O O
expression O O
. O O

Our O O
results O O
reveal O O
that O O
dynamic O O
Nipbl O O
/ O O
cohesin O O
binding O O
is O O
critical O O
for O O
developmental O O
chromatin O O
organization O O
and O O
the O O
gene O O
activation O O
function O O
of O O
the O O
LCR O O
in O O
mammalian O O
cells O O
. O O

ERG O O
promotes O O
T O O
- O O
acute O O
lymphoblastic O O
leukemia O O
and O O
is O O
transcriptionally O O
regulated O O
in O O
leukemic B-CellLine B-CellLine
cells I-CellLine I-CellLine
by O O
a O O
stem B-CellLine B-CellLine
cell I-CellLine I-CellLine
enhancer O O
. O O
ERG O O
promotes O O
T O O
- O O
acute O O
lymphoblastic O O
leukemia O O
and O O
is O O
transcriptionally O O
regulated O O
in O O
leukemic B-CellLine B-CellLine
cells I-CellLine I-CellLine
by O O
a O O
stem B-CellLine B-CellLine
cell I-CellLine I-CellLine
enhancer O O
. O O

The O O
Ets O O
- O O
related O O
gene O O
( O O
ERG O O
) O O
is O O
an O O
Ets O O
- O O
transcription O O
factor O O
required O O
for O O
normal O O
blood B-CellLine B-CellLine
stem I-CellLine I-CellLine
cell I-CellLine I-CellLine
development O O
. O O
ERG O O
expression O O
is O O
down O O
- O O
regulated O O
during O O
early O O
T O O
- O O
lymphopoiesis O O
but O O
maintained O O
in O O
T O O
- O O
acute O O
lymphoblastic O O
leukemia O O
( O O
T O O
- O O
ALL O O
) O O
, O O
where O O
it O O
is O O
recognized O O
as O O
an O O
independent O O
risk O O
factor O O
for O O
adverse O O
outcome O O
. O O

However O O
, O O
it O O
is O O
unclear O O
whether O O
ERG O O
is O O
directly O O
involved O O
in O O
the O O
pathogenesis O O
of O O
T O O
- O O
ALL O O
and O O
how O O
its O O
expression O O
is O O
regulated O O
. O O

Here O O
we O O
demonstrate O O
that O O
transgenic O O
expression O O
of O O
ERG O O
causes O O
T O O
- O O
ALL O O
in O O
mice O O
and O O
that O O
its O O
knockdown O O
reduces O O
the O O
proliferation O O
of O O
human O O
MOLT4 B-CellLine B-CellLine
T I-CellLine I-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

We O O
further O O
demonstrate O O
that O O
ERG O O
expression O O
in O O
primary O O
human O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cells I-CellLine I-CellLine
is O O
mediated O O
by O O
the O O
binding O O
of O O
other O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
oncogenes O O
SCL O O
/ O O
TAL1 O O
, O O
LMO2 O O
, O O
and O O
LYL1 O O
in O O
concert O O
with O O
ERG O O
, O O
FLI1 O O
, O O
and O O
GATA3 O O
to O O
the O O
ERG O O
+ O O
85 O O
enhancer O O
. O O
We O O
further O O
demonstrate O O
that O O
ERG O O
expression O O
in O O
primary O O
human O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cells I-CellLine I-CellLine
is O O
mediated O O
by O O
the O O
binding O O
of O O
other O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
oncogenes O O
SCL O O
/ O O
TAL1 O O
, O O
LMO2 O O
, O O
and O O
LYL1 O O
in O O
concert O O
with O O
ERG O O
, O O
FLI1 O O
, O O
and O O
GATA3 O O
to O O
the O O
ERG O O
+ O O
85 O O
enhancer O O
. O O

This O O
enhancer O O
is O O
not O O
active O O
in O O
normal O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
but O O
in O O
transgenic O O
mice O O
targets O O
expression O O
to O O
fetal O O
liver B-CellLine B-CellLine
c I-CellLine I-CellLine
- I-CellLine I-CellLine
kit I-CellLine I-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
adult O O
bone B-CellLine B-CellLine
marrow I-CellLine I-CellLine
stem I-CellLine O
/ O O
progenitors O O
and O O
early O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
- I-CellLine I-CellLine
) I-CellLine I-CellLine
CD8 I-CellLine I-CellLine
( I-CellLine I-CellLine
- I-CellLine I-CellLine
) I-CellLine I-CellLine
double I-CellLine I-CellLine
- I-CellLine I-CellLine
negative I-CellLine I-CellLine
thymic I-CellLine I-CellLine
progenitors I-CellLine I-CellLine
. O O

Taken O O
together O O
, O O
these O O
data O O
illustrate O O
that O O
ERG O O
promotes O O
T O O
- O O
ALL O O
and O O
that O O
failure O O
to O O
extinguish O O
activity O O
of O O
stem B-CellLine B-CellLine
cell I-CellLine I-CellLine
enhancers O O
associated O O
with O O
regulatory O O
transcription O O
factors O O
such O O
as O O
ERG O O
can O O
contribute O O
to O O
the O O
development O O
of O O
leukemia O O
. O O

Differentiation O O
and O O
fiber O O
type O O
- O O
specific O O
activity O O
of O O
a O O
muscle O O
creatine O O
kinase O O
intronic O O
enhancer O O
. O O
Differentiation O O
and O O
fiber O O
type O O
- O O
specific O O
activity O O
of O O
a O O
muscle O O
creatine O O
kinase O O
intronic O O
enhancer O O
. O O

BACKGROUND O O
: O O
Hundreds O O
of O O
genes O O
, O O
including O O
muscle O O
creatine O O
kinase O O
( O O
MCK O O
) O O
, O O
are O O
differentially O O
expressed O O
in O O
fast B-CellLine O
- I-CellLine O
and O O
slow B-CellLine O
- I-CellLine O
twitch I-CellLine O
muscle I-CellLine B-CellLine
fibers I-CellLine I-CellLine
, O O
but O O
the O O
fiber O O
type O O
- O O
specific O O
regulatory O O
mechanisms O O
are O O
not O O
well O O
understood O O
. O O

RESULTS O O
: O O
Modulatory O O
region O O
1 O O
( O O
MR1 O O
) O O
is O O
a O O
1 O O
- O O
kb O O
regulatory O O
region O O
within O O
MCK O O
intron O O
1 O O
that O O
is O O
highly O O
active O O
in O O
terminally O O
differentiating O O
skeletal B-CellLine B-CellLine
myocytes I-CellLine I-CellLine
in O O
vitro O O
. O O
RESULTS O O
: O O
Modulatory O O
region O O
1 O O
( O O
MR1 O O
) O O
is O O
a O O
1 O O
- O O
kb O O
regulatory O O
region O O
within O O
MCK O O
intron O O
1 O O
that O O
is O O
highly O O
active O O
in O O
terminally O O
differentiating O O
skeletal B-CellLine B-CellLine
myocytes I-CellLine I-CellLine
in O O
vitro O O
. O O

A O O
MCK O O
small O O
intronic O O
enhancer O O
( O O
MCK O O
- O O
SIE O O
) O O
containing O O
a O O
paired O O
E O O
- O O
box O O
/ O O
myocyte O O
enhancer O O
factor O O
2 O O
( O O
MEF2 O O
) O O
regulatory O O
motif O O
resides O O
within O O
MR1 O O
. O O
A O O
MCK O O
small O O
intronic O O
enhancer O O
( O O
MCK O O
- O O
SIE O O
) O O
containing O O
a O O
paired O O
E O O
- O O
box O O
/ O O
myocyte O O
enhancer O O
factor O O
2 O O
( O O
MEF2 O O
) O O
regulatory O O
motif O O
resides O O
within O O
MR1 O O
. O O

The O O
SIE O O
' O O
s O O
transcriptional O O
activity O O
equals O O
that O O
of O O
the O O
extensively O O
characterized O O
206 O O
- O O
bp O O
MCK O O
5 O O
' O O
- O O
enhancer O O
, O O
but O O
the O O
MCK O O
- O O
SIE O O
is O O
flanked O O
by O O
regions O O
that O O
can O O
repress O O
its O O
activity O O
via O O
the O O
individual O O
and O O
combined O O
effects O O
of O O
about O O
15 O O
different O O
but O O
highly O O
conserved O O
9 O O
- O O
to O O
24 O O
- O O
bp O O
sequences O O
. O O
The O O
SIE O O
' O O
s O O
transcriptional O O
activity O O
equals O O
that O O
of O O
the O O
extensively O O
characterized O O
206 O O
- O O
bp O O
MCK O O
5 O O
' O O
- O O
enhancer O O
, O O
but O O
the O O
MCK O O
- O O
SIE O O
is O O
flanked O O
by O O
regions O O
that O O
can O O
repress O O
its O O
activity O O
via O O
the O O
individual O O
and O O
combined O O
effects O O
of O O
about O O
15 O O
different O O
but O O
highly O O
conserved O O
9 O O
- O O
to O O
24 O O
- O O
bp O O
sequences O O
. O O

ChIP O O
and O O
ChIP O O
- O O
Seq O O
analyses O O
indicate O O
that O O
the O O
SIE O O
and O O
the O O
MCK O O
5 O O
' O O
- O O
enhancer O O
are O O
occupied O O
by O O
MyoD O O
, O O
myogenin O O
and O O
MEF2 O O
. O O
ChIP O O
and O O
ChIP O O
- O O
Seq O O
analyses O O
indicate O O
that O O
the O O
SIE O O
and O O
the O O
MCK O O
5 O O
' O O
- O O
enhancer O O
are O O
occupied O O
by O O
MyoD O O
, O O
myogenin O O
and O O
MEF2 O O
. O O

Many O O
other O O
E O O
- O O
boxes O O
located O O
within O O
or O O
immediately O O
adjacent O O
to O O
intron O O
1 O O
are O O
not O O
occupied O O
by O O
MyoD O O
or O O
myogenin O O
. O O

Transgenic O O
analysis O O
of O O
a O O
6 O O
. O O
5 O O
- O O
kb O O
MCK O O
genomic O O
fragment O O
containing O O
the O O
5 O O
' O O
- O O
enhancer O O
and O O
proximal O O
promoter O O
plus O O
the O O
3 O O
. O O
2 O O
- O O
kb O O
intron O O
1 O O
, O O
with O O
and O O
without O O
MR1 O O
, O O
indicates O O
that O O
MR1 O O
is O O
critical O O
for O O
MCK O O
expression O O
in O O
slow B-CellLine O
- I-CellLine O
and O O
intermediate B-CellLine O
- I-CellLine O
twitch I-CellLine O
muscle I-CellLine B-CellLine
fibers I-CellLine I-CellLine
( O O
types B-CellLine O
I I-CellLine O
and O O
IIa B-CellLine O
, O O
respectively O O
) O O
, O O
but O O
is O O
not O O
required O O
for O O
expression O O
in O O
fast B-CellLine B-CellLine
- I-CellLine I-CellLine
twitch I-CellLine I-CellLine
muscle I-CellLine I-CellLine
fibers I-CellLine I-CellLine
( O O
types B-CellLine O
IIb I-CellLine O
and O O
IId B-CellLine O
) O O
. O O

CONCLUSIONS O O
: O O
In O O
this O O
study O O
, O O
we O O
discovered O O
that O O
MR1 O O
is O O
critical O O
for O O
MCK O O
expression O O
in O O
slow B-CellLine O
- I-CellLine O
and O O
intermediate B-CellLine O
- I-CellLine O
twitch I-CellLine O
muscle I-CellLine B-CellLine
fibers I-CellLine I-CellLine
and O O
that O O
MR1 O O
' O O
s O O
positive O O
transcriptional O O
activity O O
depends O O
on O O
a O O
paired O O
E O O
- O O
box O O
MEF2 O O
site O O
motif O O
within O O
a O O
SIE O O
. O O
CONCLUSIONS O O
: O O
In O O
this O O
study O O
, O O
we O O
discovered O O
that O O
MR1 O O
is O O
critical O O
for O O
MCK O O
expression O O
in O O
slow B-CellLine O
- I-CellLine O
and O O
intermediate B-CellLine O
- I-CellLine O
twitch I-CellLine O
muscle I-CellLine B-CellLine
fibers I-CellLine I-CellLine
and O O
that O O
MR1 O O
' O O
s O O
positive O O
transcriptional O O
activity O O
depends O O
on O O
a O O
paired O O
E O O
- O O
box O O
MEF2 O O
site O O
motif O O
within O O
a O O
SIE O O
. O O

This O O
is O O
the O O
first O O
study O O
to O O
delineate O O
the O O
DNA O O
controls O O
for O O
MCK O O
expression O O
in O O
different O O
skeletal B-CellLine B-CellLine
muscle I-CellLine I-CellLine
fiber I-CellLine I-CellLine
types O O
. O O

Intragenic O O
enhancers O O
act O O
as O O
alternative O O
promoters O O
. O O

A O O
substantial O O
amount O O
of O O
organismal O O
complexity O O
is O O
thought O O
to O O
be O O
encoded O O
by O O
enhancers O O
which O O
specify O O
the O O
location O O
, O O
timing O O
, O O
and O O
levels O O
of O O
gene O O
expression O O
. O O

In O O
mammals O O
there O O
are O O
more O O
enhancers O O
than O O
promoters O O
which O O
are O O
distributed O O
both O O
between O O
and O O
within O O
genes O O
. O O

Here O O
we O O
show O O
that O O
activated O O
, O O
intragenic O O
enhancers O O
frequently O O
act O O
as O O
alternative O O
tissue O O
- O O
specific O O
promoters O O
producing O O
a O O
class O O
of O O
abundant O O
, O O
spliced O O
, O O
multiexonic O O
poly O O
( O O
A O O
) O O
( O O
+ O O
) O O
RNAs O O
( O O
meRNAs O O
) O O
which O O
reflect O O
the O O
host O O
gene O O
' O O
s O O
structure O O
. O O
meRNAs O O
make O O
a O O
substantial O O
and O O
unanticipated O O
contribution O O
to O O
the O O
complexity O O
of O O
the O O
transcriptome O O
, O O
appearing O O
as O O
alternative O O
isoforms O O
of O O
the O O
host O O
gene O O
. O O

The O O
low O O
protein O O
- O O
coding O O
potential O O
of O O
meRNAs O O
suggests O O
that O O
many O O
meRNAs O O
may O O
be O O
byproducts O O
of O O
enhancer O O
activation O O
or O O
underlie O O
as O O
- O O
yet O O
- O O
unidentified O O
RNA O O
- O O
encoded O O
functions O O
. O O

Distinguishing O O
between O O
meRNAs O O
and O O
mRNAs O O
will O O
transform O O
our O O
interpretation O O
of O O
dynamic O O
changes O O
in O O
transcription O O
both O O
at O O
the O O
level O O
of O O
individual O O
genes O O
and O O
of O O
the O O
genome O O
as O O
a O O
whole O O
. O O

Mapping O O
and O O
functional O O
characterisation O O
of O O
a O O
CTCF O O
- O O
dependent O O
insulator O O
element O O
at O O
the O O
3 O O
' O O
border O O
of O O
the O O
murine O O
Scl O O
transcriptional O O
domain O O
. O O

The O O
Scl O O
gene O O
encodes O O
a O O
transcription O O
factor O O
essential O O
for O O
haematopoietic O B-CellLine
development O O
. O O
Scl O O
transcription O O
is O O
regulated O O
by O O
a O O
panel O O
of O O
cis O O
- O O
elements O O
spread O O
over O O
55 O O
kb O O
with O O
the O O
most O O
distal O O
3 O O
' O O
element O O
being O O
located O O
downstream O O
of O O
the O O
neighbouring O O
gene O O
Map17 O O
, O O
which O O
is O O
co O O
- O O
regulated O O
with O O
Scl O O
in O O
haematopoietic B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

The O O
Scl O O
/ O O
Map17 O O
domain O O
is O O
flanked O O
upstream O O
by O O
the O O
ubiquitously O O
expressed O O
Sil O O
gene O O
and O O
downstream O O
by O O
a O O
cluster O O
of O O
Cyp O O
genes O O
active O O
in O O
liver B-CellLine B-CellLine
, O O
but O O
the O O
mechanisms O O
responsible O O
for O O
delineating O O
the O O
domain O O
boundaries O O
remain O O
unclear O O
. O O

Here O O
we O O
report O O
identification O O
of O O
a O O
DNaseI O O
hypersensitive O O
site O O
at O O
the O O
3 O O
' O O
end O O
of O O
the O O
Scl O O
/ O O
Map17 O O
domain O O
and O O
45 O O
kb O O
downstream O O
of O O
the O O
Scl O O
transcription O O
start O O
site O O
. O O

This O O
element O O
is O O
located O O
at O O
the O O
boundary O O
of O O
active O O
and O O
inactive O O
chromatin O O
, O O
does O O
not O O
function O O
as O O
a O O
classical O O
tissue O O
- O O
specific O O
enhancer O O
, O O
binds O O
CTCF O O
and O O
is O O
both O O
necessary O O
and O O
sufficient O O
for O O
insulator O O
function O O
in O O
haematopoietic B-CellLine B-CellLine
cells I-CellLine I-CellLine
in O O
vitro O O
. O O

Moreover O O
, O O
in O O
a O O
transgenic O O
reporter O O
assay O O
, O O
tissue O O
- O O
specific O O
expression O O
of O O
the O O
Scl O O
promoter O O
in O O
brain B-CellLine B-CellLine
was O O
increased O O
by O O
incorporation O O
of O O
350 O O
bp O O
flanking O O
fragments O O
from O O
the O O
+ O O
45 O O
element O O
. O O
Moreover O O
, O O
in O O
a O O
transgenic O O
reporter O O
assay O O
, O O
tissue O O
- O O
specific O O
expression O O
of O O
the O O
Scl O O
promoter O O
in O O
brain B-CellLine B-CellLine
was O O
increased O O
by O O
incorporation O O
of O O
350 O O
bp O O
flanking O O
fragments O O
from O O
the O O
+ O O
45 O O
element O O
. O O

Our O O
data O O
suggests O O
that O O
the O O
+ O O
45 O O
region O O
functions O O
as O O
a O O
boundary O O
element O O
that O O
separates O O
the O O
Scl O O
/ O O
Map17 O O
and O O
Cyp O O
transcriptional O O
domains O O
, O O
and O O
raise O O
the O O
possibility O O
that O O
this O O
element O O
may O O
be O O
useful O O
for O O
improving O O
tissue O O
- O O
specific O O
expression O O
of O O
transgenic O O
constructs O O
. O O

Deletion O O
of O O
the O O
Scl O O
+ O O
19 O O
enhancer O O
increases O O
the O O
blood B-CellLine B-CellLine
stem I-CellLine I-CellLine
cell I-CellLine I-CellLine
compartment O O
without O O
affecting O O
the O O
formation O O
of O O
mature O O
blood B-CellLine B-CellLine
lineages I-CellLine I-CellLine
. O O
Deletion O O
of O O
the O O
Scl O O
+ O O
19 O O
enhancer O O
increases O O
the O O
blood B-CellLine B-CellLine
stem I-CellLine I-CellLine
cell I-CellLine I-CellLine
compartment O O
without O O
affecting O O
the O O
formation O O
of O O
mature O O
blood B-CellLine B-CellLine
lineages I-CellLine I-CellLine
. O O

The O O
stem B-CellLine O
cell I-CellLine O
leukemia O O
( O O
Scl O O
) O O
/ O O
Tal1 O O
gene O O
is O O
essential O O
for O O
normal O O
blood B-CellLine B-CellLine
and O O
endothelial O B-CellLine
development O O
, O O
and O O
is O O
expressed O O
in O O
hematopoietic B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
HSCs B-CellLine B-CellLine
) O O
, O O
progenitors O O
, O O
erythroid B-CellLine B-CellLine
, O O
megakaryocytic B-CellLine B-CellLine
, O O
and O O
mast B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

The O O
Scl O O
+ O O
19 O O
enhancer O O
is O O
active O O
in O O
HSCs B-CellLine B-CellLine
and O O
progenitor O O
cells O O
, O O
megakaryocytes B-CellLine B-CellLine
, O O
and O O
mast B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
but O O
not O O
mature O O
erythroid B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
The O O
Scl O O
+ O O
19 O O
enhancer O O
is O O
active O O
in O O
HSCs B-CellLine B-CellLine
and O O
progenitor O O
cells O O
, O O
megakaryocytes B-CellLine B-CellLine
, O O
and O O
mast B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
but O O
not O O
mature O O
erythroid B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Here O O
we O O
demonstrate O O
that O O
in O O
vivo O O
deletion O O
of O O
the O O
Scl O O
+ O O
19 O O
enhancer O O
( O O
Scl O O
( O O
Delta19 O O
/ O O
Delta19 O O
) O O
) O O
results O O
in O O
viable O O
mice O O
with O O
normal O O
Scl O O
expression O O
in O O
mature O O
hematopoietic B-CellLine B-CellLine
lineages I-CellLine I-CellLine
. O O
Here O O
we O O
demonstrate O O
that O O
in O O
vivo O O
deletion O O
of O O
the O O
Scl O O
+ O O
19 O O
enhancer O O
( O O
Scl O O
( O O
Delta19 O O
/ O O
Delta19 O O
) O O
) O O
results O O
in O O
viable O O
mice O O
with O O
normal O O
Scl O O
expression O O
in O O
mature O O
hematopoietic B-CellLine B-CellLine
lineages I-CellLine I-CellLine
. O O

By O O
contrast O O
, O O
Scl O O
expression O O
is O O
reduced O O
in O O
the O O
stem O O
/ O O
progenitor O O
compartment O O
and O O
flow O O
cytometry O O
analysis O O
revealed O O
that O O
the O O
HSC B-CellLine B-CellLine
and O O
megakaryocyte B-CellLine B-CellLine
- O I-CellLine
erythroid B-CellLine I-CellLine
progenitor I-CellLine I-CellLine
populations O O
are O O
enlarged O O
in O O
Scl O O
( O O
Delta19 O O
/ O O
Delta19 O O
) O O
mice O O
. O O
By O O
contrast O O
, O O
Scl O O
expression O O
is O O
reduced O O
in O O
the O O
stem O O
/ O O
progenitor O O
compartment O O
and O O
flow O O
cytometry O O
analysis O O
revealed O O
that O O
the O O
HSC B-CellLine B-CellLine
and O O
megakaryocyte B-CellLine B-CellLine
- O I-CellLine
erythroid B-CellLine I-CellLine
progenitor I-CellLine I-CellLine
populations O O
are O O
enlarged O O
in O O
Scl O O
( O O
Delta19 O O
/ O O
Delta19 O O
) O O
mice O O
. O O

The O O
increase O O
in O O
HSC B-CellLine B-CellLine
numbers O O
contributed O O
to O O
enhanced O O
expansion O O
in O O
bone B-CellLine B-CellLine
marrow I-CellLine I-CellLine
transplantation O O
assays O O
, O O
but O O
did O O
not O O
affect O O
multilineage O O
repopulation O O
or O O
stress O O
responses O O
. O O

These O O
results O O
affirm O O
that O O
the O O
Scl O O
+ O O
19 O O
enhancer O O
plays O O
a O O
key O O
role O O
in O O
the O O
development O O
of O O
hematopoietic B-CellLine B-CellLine
stem I-CellLine I-CellLine
/ I-CellLine I-CellLine
progenitor I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
but O O
is O O
not O O
necessary O O
for O O
mature O O
hematopoietic B-CellLine B-CellLine
lineages I-CellLine I-CellLine
. O O
These O O
results O O
affirm O O
that O O
the O O
Scl O O
+ O O
19 O O
enhancer O O
plays O O
a O O
key O O
role O O
in O O
the O O
development O O
of O O
hematopoietic B-CellLine B-CellLine
stem I-CellLine I-CellLine
/ I-CellLine I-CellLine
progenitor I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
but O O
is O O
not O O
necessary O O
for O O
mature O O
hematopoietic B-CellLine B-CellLine
lineages I-CellLine I-CellLine
. O O

Moreover O O
, O O
active O O
histone O O
marks O O
across O O
the O O
Scl O O
locus O O
were O O
significantly O O
reduced O O
in O O
Scl O O
( O O
Delta19 O O
/ O O
Delta19 O O
) O O
fetal O O
liver B-CellLine B-CellLine
cells I-CellLine I-CellLine
without O O
major O O
changes O O
in O O
steady O O
- O O
state O O
messenger O O
RNA O O
levels O O
, O O
suggesting O O
post O O
- O O
transcriptional O O
compensation O O
for O O
loss O O
of O O
a O O
regulatory O O
element O O
, O O
a O O
result O O
that O O
might O O
be O O
widely O O
relevant O O
given O O
the O O
frequent O O
observation O O
of O O
mild O O
phenotypes O O
after O O
deletion O O
of O O
regulatory O O
elements O O
. O O
Moreover O O
, O O
active O O
histone O O
marks O O
across O O
the O O
Scl O O
locus O O
were O O
significantly O O
reduced O O
in O O
Scl O O
( O O
Delta19 O O
/ O O
Delta19 O O
) O O
fetal O O
liver B-CellLine B-CellLine
cells I-CellLine I-CellLine
without O O
major O O
changes O O
in O O
steady O O
- O O
state O O
messenger O O
RNA O O
levels O O
, O O
suggesting O O
post O O
- O O
transcriptional O O
compensation O O
for O O
loss O O
of O O
a O O
regulatory O O
element O O
, O O
a O O
result O O
that O O
might O O
be O O
widely O O
relevant O O
given O O
the O O
frequent O O
observation O O
of O O
mild O O
phenotypes O O
after O O
deletion O O
of O O
regulatory O O
elements O O
. O O

Regulation O O
of O O
cytotoxic O O
T O O
lymphocyte O O
antigen O O
4 O O
by O O
cyclic O O
AMP O O
. O O

Recent O O
studies O O
indicate O O
that O O
cyclic O O
AMP O O
( O O
cAMP O O
) O O
induces O O
cytotoxic O O
T O O
lymphocyte O O
antigen O O
( O O
CTLA O O
) O O
4 O O
. O O
CTLA4 O O
is O O
expressed O O
in O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
and O O
is O O
a O O
negative O O
regulator O O
of O O
T B-CellLine B-CellLine
cell I-CellLine I-CellLine
activation O O
. O O
CTLA4 O O
expression O O
is O O
regulated O O
by O O
T B-CellLine B-CellLine
cell I-CellLine I-CellLine
receptor O O
plus O O
CD28 O O
( O O
adaptive O O
immune O O
signaling O O
) O O
at O O
both O O
the O O
transcriptional O O
and O O
post O O
- O O
transcriptional O O
level O O
. O O

Here O O
, O O
we O O
examine O O
the O O
pathways O O
by O O
which O O
cAMP O O
regulates O O
CTLA4 O O
expression O O
, O O
focusing O O
on O O
transcriptional O O
activation O O
. O O

Elevating O O
intracellular O O
cAMP O O
levels O O
by O O
cell O O
- O O
permeable O O
cAMP O O
analogs O O
, O O
the O O
adenylyl O O
cyclase O O
activator O O
, O O
forskolin O O
, O O
or O O
phosphodiesterase O O
inhibitors O O
increases O O
CTLA4 O O
mRNA O O
expression O O
in O O
EL4 O B-CellLine
murine O I-CellLine
T B-CellLine I-CellLine
cells I-CellLine I-CellLine
and O O
primary O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Activation O O
of O O
protein O O
kinase O O
A O O
( O O
using O O
the O O
protein O O
kinase O O
A O O
- O O
selective O O
agonist O O
, O O
N6 O O
- O O
phenyladenosine O O
- O O
cAMP O O
) O O
, O O
but O O
not O O
exchange O O
proteins O O
activated O O
by O O
cAMP O O
( O O
using O O
the O O
exchange O O
proteins O O
activated O O
by O O
cAMP O O
- O O
selective O O
8 O O
- O O
pCPT O O
- O O
2Me O O
- O O
cAMP O O
) O O
, O O
increases O O
CTLA4 O O
promoter O O
activity O O
. O O
Activation O O
of O O
protein O O
kinase O O
A O O
( O O
using O O
the O O
protein O O
kinase O O
A O O
- O O
selective O O
agonist O O
, O O
N6 O O
- O O
phenyladenosine O O
- O O
cAMP O O
) O O
, O O
but O O
not O O
exchange O O
proteins O O
activated O O
by O O
cAMP O O
( O O
using O O
the O O
exchange O O
proteins O O
activated O O
by O O
cAMP O O
- O O
selective O O
8 O O
- O O
pCPT O O
- O O
2Me O O
- O O
cAMP O O
) O O
, O O
increases O O
CTLA4 O O
promoter O O
activity O O
. O O

Mutation O O
constructs O O
of O O
the O O
CTLA4 O O
promoter O O
uncover O O
an O O
enhancer O O
binding O O
site O O
located O O
within O O
the O O
- O O
150 O O
to O O
- O O
130 O O
bp O O
region O O
relative O O
to O O
the O O
transcription O O
start O O
site O O
. O O
Mutation O O
constructs O O
of O O
the O O
CTLA4 O O
promoter O O
uncover O O
an O O
enhancer O O
binding O O
site O O
located O O
within O O
the O O
- O O
150 O O
to O O
- O O
130 O O
bp O O
region O O
relative O O
to O O
the O O
transcription O O
start O O
site O O
. O O

Promoter O O
analysis O O
and O O
chromatin O O
immunoprecipitation O O
assays O O
suggest O O
that O O
cAMP O O
response O O
element O O
- O O
binding O O
is O O
a O O
putative O O
transcription O O
factor O O
induced O O
by O O
cAMP O O
. O O

We O O
have O O
previously O O
shown O O
that O O
CTLA4 O O
mediates O O
decreased O O
pulmonary O O
inflammation O O
in O O
an O O
LPS O O
- O O
induced O O
murine O O
model O O
of O O
acute O O
lung O O
injury O O
( O O
ALI O O
) O O
. O O

We O O
observed O O
that O O
LPS O O
can O O
induce O O
CTLA4 O O
transcription O O
via O O
the O O
same O O
cAMP O O
- O O
inducible O O
promoter O O
region O O
. O O

The O O
immunosuppressant O O
, O O
rapamycin O O
, O O
decreases O O
cAMP O O
and O O
LPS O O
- O O
induced O O
CTLA4 O O
transcription O O
in O O
vitro O O
. O O

In O O
vivo O O
, O O
LPS O O
induces O O
cAMP O O
accumulation O O
in O O
bronchoalveolar B-CellLine B-CellLine
lavage I-CellLine I-CellLine
fluid I-CellLine I-CellLine
, O O
bronchoalveolar B-CellLine B-CellLine
lavage I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
and O O
lung B-CellLine B-CellLine
tissues O O
in O O
ALI O O
. O O

We O O
demonstrate O O
that O O
rapamycin O O
decreases O O
cAMP O O
accumulation O O
and O O
CTLA4 O O
expression O O
in O O
ALI O O
. O O

Together O O
, O O
these O O
data O O
suggest O O
that O O
cAMP O O
may O O
negatively O O
regulate O O
pulmonary O O
inflammatory O O
responses O O
in O O
vivo O O
and O O
in O O
vitro O O
by O O
altering O O
CTLA4 O O
expression O O
. O O

Osterix O O
induces O O
Col1a1 O O
gene O O
expression O O
through O O
binding O O
to O O
Sp1 O O
sites O O
in O O
the O O
bone B-CellLine B-CellLine
enhancer O O
and O O
proximal O O
promoter O O
regions O O
. O O
Bone B-CellLine B-CellLine
- O O
specific O O
transcription O O
factors O O
promote O O
differentiation O O
of O O
mesenchymal B-CellLine B-CellLine
precursors I-CellLine I-CellLine
toward O O
the O O
osteoblastic B-CellLine B-CellLine
cell I-CellLine I-CellLine
phenotype O O
. O O
Osterix O O
induces O O
Col1a1 O O
gene O O
expression O O
through O O
binding O O
to O O
Sp1 O O
sites O O
in O O
the O O
bone B-CellLine B-CellLine
enhancer O O
and O O
proximal O O
promoter O O
regions O O
. O O
Bone B-CellLine B-CellLine
- O O
specific O O
transcription O O
factors O O
promote O O
differentiation O O
of O O
mesenchymal B-CellLine B-CellLine
precursors I-CellLine I-CellLine
toward O O
the O O
osteoblastic B-CellLine B-CellLine
cell I-CellLine I-CellLine
phenotype O O
. O O

Among O O
them O O
, O O
Runx2 O O
and O O
Osterix O O
have O O
been O O
widely O O
accepted O O
as O O
master O O
osteogenic O O
factors O O
, O O
since O O
neither O O
Runx2 O O
nor O O
Osterix O O
null O O
mice O O
form O O
mature O O
osteoblasts B-CellLine B-CellLine
. O O

Recruitment O O
of O O
Osterix O O
to O O
a O O
number O O
of O O
promoters O O
of O O
bone B-CellLine B-CellLine
- O O
specific O O
genes O O
has O O
been O O
shown O O
. O O

However O O
, O O
little O O
is O O
known O O
about O O
the O O
functional O O
interactions O O
between O O
Osterix O O
and O O
the O O
Col1a1 O O
promoter O O
. O O
However O O
, O O
little O O
is O O
known O O
about O O
the O O
functional O O
interactions O O
between O O
Osterix O O
and O O
the O O
Col1a1 O O
promoter O O
. O O

In O O
this O O
study O O
we O O
determined O O
in O O
several O O
mesenchymal B-CellLine B-CellLine
and O O
osteoblastic B-CellLine B-CellLine
cell I-CellLine I-CellLine
types O O
that O O
either O O
BMP O O
- O O
2 O O
or O O
Osterix O O
overexpression O O
increased O O
Col1a1 O O
transcription O O
. O O

We O O
identified O O
consensus O O
Sp1 O O
sequences O O
, O O
located O O
in O O
the O O
proximal O O
promoter O O
and O O
in O O
the O O
bone B-CellLine B-CellLine
- O O
enhancer O O
, O O
as O O
Osterix O O
binding O O
regions O O
in O O
the O O
Col1a1 O O
promoter O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O
We O O
identified O O
consensus O O
Sp1 O O
sequences O O
, O O
located O O
in O O
the O O
proximal O O
promoter O O
and O O
in O O
the O O
bone B-CellLine B-CellLine
- O O
enhancer O O
, O O
as O O
Osterix O O
binding O O
regions O O
in O O
the O O
Col1a1 O O
promoter O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

Furthermore O O
, O O
we O O
show O O
that O O
p38 O O
or O O
Erk O O
MAPK O O
signaling O O
is O O
required O O
for O O
maximal O O
transcriptional O O
effects O O
on O O
Col1a1 O O
expression O O
. O O
Runx2 O O
has O O
been O O
shown O O
to O O
activate O O
Col1a1 O O
expression O O
through O O
binding O O
to O O
sites O O
which O O
are O O
located O O
close O O
to O O
the O O
Sp1 O O
sites O O
where O O
Osterix O O
binds O O
. O O
Furthermore O O
, O O
we O O
show O O
that O O
p38 O O
or O O
Erk O O
MAPK O O
signaling O O
is O O
required O O
for O O
maximal O O
transcriptional O O
effects O O
on O O
Col1a1 O O
expression O O
. O O
Runx2 O O
has O O
been O O
shown O O
to O O
activate O O
Col1a1 O O
expression O O
through O O
binding O O
to O O
sites O O
which O O
are O O
located O O
close O O
to O O
the O O
Sp1 O O
sites O O
where O O
Osterix O O
binds O O
. O O

Our O O
data O O
show O O
that O O
overexpression O O
of O O
Runx2 O O
and O O
Osterix O O
leads O O
to O O
a O O
cooperative O O
effect O O
on O O
the O O
expression O O
of O O
the O O
Col1a1 O O
endogenous O O
gene O O
and O O
its O O
promoter O O
reporter O O
construct O O
. O O

These O O
effects O O
mainly O O
affect O O
the O O
long O O
isoform O O
of O O
Osterix O O
which O O
suggest O O
that O O
the O O
two O O
Osterix O O
isoforms O O
might O O
display O O
some O O
differential O O
effects O O
on O O
the O O
transactivation O O
of O O
bone B-CellLine B-CellLine
- O O
specific O O
genes O O
. O O

Bivalent O O
promoter O O
marks O O
and O O
a O O
latent O O
enhancer O O
may O O
prime O O
the O O
leukaemia O O
oncogene O O
LMO1 O O
for O O
ectopic O O
expression O O
in O O
T O O
- O O
cell O O
leukaemia O O
. O O
LMO1 O O
is O O
a O O
transcriptional O O
regulator O O
and O O
a O O
T O O
- O O
acute O O
lymphoblastic O O
leukaemia O O
( O O
T O O
- O O
ALL O O
) O O
oncogene O O
. O O

Although O O
first O O
identified O O
in O O
association O O
with O O
a O O
chromosomal O O
translocation O O
in O O
T O O
- O O
ALL O O
, O O
the O O
ectopic O O
expression O O
of O O
LMO1 O O
occurs O O
far O O
more O O
frequently O O
in O O
the O O
absence O O
of O O
any O O
known O O
mutation O O
involving O O
its O O
locus O O
. O O

Given O O
that O O
LMO1 O O
is O O
barely O O
expressed O O
in O O
any O O
haematopoietic B-CellLine B-CellLine
lineage I-CellLine I-CellLine
, O O
and O O
activation O O
of O O
transcriptional O O
drivers O O
in O O
leukaemic B-CellLine B-CellLine
cells I-CellLine I-CellLine
is O O
not O O
well O O
described O O
, O O
we O O
investigated O O
the O O
regulation O O
of O O
this O O
gene O O
in O O
normal O O
haematopoietic B-CellLine B-CellLine
and O O
leukaemic B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

We O O
show O O
that O O
LMO1 O O
has O O
two O O
promoters O O
that O O
drive O O
reporter O O
gene O O
expression O O
in O O
transgenic O O
mice O O
to O O
neural O O
tissues O O
known O O
to O O
express O O
endogenous O O
LMO1 O O
. O O

The O O
LMO1 O O
promoters O O
display O O
bivalent O O
histone O O
marks O O
in O O
multiple O O
blood B-CellLine B-CellLine
lineages I-CellLine I-CellLine
including O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
and O O
a O O
3 O O
' O O
flanking O O
region O O
at O O
LMO1 O O
+ O O
57 O O
contains O O
a O O
transcriptional O O
enhancer O O
that O O
is O O
active O O
in O O
developing O O
blood B-CellLine B-CellLine
cells O I-CellLine
in O O
transgenic O O
mouse O O
embryos B-CellLine B-CellLine
. O O
The O O
LMO1 O O
promoters O O
display O O
bivalent O O
histone O O
marks O O
in O O
multiple O O
blood B-CellLine B-CellLine
lineages I-CellLine I-CellLine
including O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
and O O
a O O
3 O O
' O O
flanking O O
region O O
at O O
LMO1 O O
+ O O
57 O O
contains O O
a O O
transcriptional O O
enhancer O O
that O O
is O O
active O O
in O O
developing O O
blood B-CellLine B-CellLine
cells O I-CellLine
in O O
transgenic O O
mouse O O
embryos B-CellLine B-CellLine
. O O

The O O
LMO1 O O
promoters O O
become O O
activated O O
in O O
T O O
- O O
ALL O O
together O O
with O O
the O O
3 O O
' O O
enhancer O O
, O O
which O O
is O O
bound O O
in O O
primary O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cells I-CellLine I-CellLine
by O O
SCL O O
/ O O
TAL1 O O
and O O
GATA3 O O
. O O
The O O
LMO1 O O
promoters O O
become O O
activated O O
in O O
T O O
- O O
ALL O O
together O O
with O O
the O O
3 O O
' O O
enhancer O O
, O O
which O O
is O O
bound O O
in O O
primary O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cells I-CellLine I-CellLine
by O O
SCL O O
/ O O
TAL1 O O
and O O
GATA3 O O
. O O

Taken O O
together O O
, O O
our O O
results O O
show O O
that O O
LMO1 O O
is O O
poised O O
for O O
expression O O
in O O
normal O O
progenitors O O
, O O
where O O
activation O O
of O O
SCL O O
/ O O
TAL1 O O
together O O
with O O
a O O
breakdown O O
of O O
epigenetic O O
repression O O
of O O
LMO1 O O
regulatory O O
elements O O
induces O O
ectopic O O
LMO1 O O
expression O O
that O O
contributes O O
to O O
the O O
development O O
and O O
maintenance O O
of O O
T O O
- O O
ALL O O
. O O

Hypoxic O O
adaptation O O
engages O O
the O O
CBP O O
/ O O
CREST O O
- O O
induced O O
coactivator O O
complex O O
of O O
Creb O O
- O O
HIF O O
- O O
1alpha O O
in O O
transactivating O O
murine O O
neuroblastic O O
glucose O O
transporter O O
. O O

We O O
have O O
shown O O
in O O
vitro O O
a O O
hypoxia O O
- O O
induced O O
time O O
- O O
dependent O O
increase O O
in O O
facilitative O O
glucose O O
transporter O O
isoform O O
3 O O
( O O
GLUT3 O O
) O O
expression O O
in O O
N2A B-CellLine B-CellLine
murine I-CellLine I-CellLine
neuroblasts I-CellLine I-CellLine
. O O

This O O
increase O O
in O O
GLUT3 O O
expression O O
is O O
partially O O
reliant O O
on O O
a O O
transcriptional O O
increase O O
noted O O
in O O
actinomycin O O
D O O
and O O
cycloheximide O O
pretreatment O O
experiments O O
. O O

Transient O O
transfection O O
assays O O
in O O
N2A B-CellLine B-CellLine
neuroblasts I-CellLine I-CellLine
using O O
murine O O
glut3 O O
- O O
luciferase O O
reporter O O
constructs O O
mapped O O
the O O
hypoxia O O
- O O
induced O O
enhancer O O
activities O O
to O O
- O O
857 O O
- O O
to O O
- O O
573 O O
- O O
bp O O
and O O
- O O
203 O O
- O O
to O O
- O O
177 O O
- O O
bp O O
regions O O
. O O
Hypoxia O O
- O O
exposed O O
N2A O B-CellLine
nuclear O O
extracts O O
demonstrated O O
an O O
increase O O
in O O
HIF O O
- O O
1alpha O O
and O O
p O O
- O O
Creb O O
binding O O
to O O
HRE O O
( O O
- O O
828 O O
to O O
- O O
824 O O
bp O O
) O O
and O O
AP O O
- O O
1 O O
( O O
- O O
187 O O
to O O
- O O
180 O O
bp O O
) O O
cis O O
- O O
elements O O
, O O
respectively O O
, O O
in O O
electromobility O O
shift O O
and O O
supershift O O
assays O O
, O O
which O O
was O O
confirmed O O
by O O
chromatin O O
immunoprecipitation O O
assays O O
. O O
Transient O O
transfection O O
assays O O
in O O
N2A B-CellLine B-CellLine
neuroblasts I-CellLine I-CellLine
using O O
murine O O
glut3 O O
- O O
luciferase O O
reporter O O
constructs O O
mapped O O
the O O
hypoxia O O
- O O
induced O O
enhancer O O
activities O O
to O O
- O O
857 O O
- O O
to O O
- O O
573 O O
- O O
bp O O
and O O
- O O
203 O O
- O O
to O O
- O O
177 O O
- O O
bp O O
regions O O
. O O
Hypoxia O O
- O O
exposed O O
N2A O B-CellLine
nuclear O O
extracts O O
demonstrated O O
an O O
increase O O
in O O
HIF O O
- O O
1alpha O O
and O O
p O O
- O O
Creb O O
binding O O
to O O
HRE O O
( O O
- O O
828 O O
to O O
- O O
824 O O
bp O O
) O O
and O O
AP O O
- O O
1 O O
( O O
- O O
187 O O
to O O
- O O
180 O O
bp O O
) O O
cis O O
- O O
elements O O
, O O
respectively O O
, O O
in O O
electromobility O O
shift O O
and O O
supershift O O
assays O O
, O O
which O O
was O O
confirmed O O
by O O
chromatin O O
immunoprecipitation O O
assays O O
. O O

In O O
addition O O
, O O
the O O
interaction O O
of O O
CBP O O
with O O
Creb O O
and O O
HIF O O
- O O
1alpha O O
and O O
CREST O O
with O O
CBP O O
in O O
hypoxia O O
was O O
detected O O
by O O
coimmunoprecipitation O O
. O O

Furthermore O O
, O O
small O O
interference O O
( O O
si O O
) O O
RNA O O
targeting O O
Creb O O
in O O
these O O
cells O O
decreased O O
endogenous O O
Creb O O
concentrations O O
that O O
reduced O O
by O O
twofold O O
hypoxia O O
- O O
induced O O
glut3 O O
gene O O
transcription O O
. O O

Thus O O
, O O
in O O
N2A B-CellLine B-CellLine
neuroblasts I-CellLine I-CellLine
, O O
phosphorylated O O
HIF O O
- O O
1alpha O O
and O O
Creb O O
mediated O O
the O O
hypoxia O O
- O O
induced O O
increase O O
in O O
glut3 O O
transcription O O
. O O

Coactivation O O
by O O
the O O
Ca O O
+ O O
+ O O
- O O
dependent O O
CREST O O
and O O
CBP O O
proteins O O
may O O
enhance O O
cross O O
- O O
talk O O
between O O
p O O
- O O
Creb O O
- O O
AP O O
- O O
1 O O
and O O
HIF O O
- O O
1alpha O O
/ O O
HRE O O
of O O
the O O
glut3 O O
gene O O
. O O

Collectively O O
, O O
these O O
processes O O
can O O
facilitate O O
an O O
adaptive O O
response O O
to O O
hypoxic O O
energy O O
depletion O O
targeted O O
at O O
enhancing O O
glucose O O
transport O O
and O O
minimizing O O
injury O O
while O O
fueling O O
the O O
proliferative O O
potential O O
of O O
neuroblasts B-CellLine B-CellLine
. O O

FOXA1 O O
mediates O O
p16 O O
( O O
INK4a O O
) O O
activation O O
during O O
cellular O O
senescence O O
. O O

Mechanisms O O
governing O O
the O O
transcription O O
of O O
p16 O O
( O O
INK4a O O
) O O
, O O
one O O
of O O
the O O
master O O
regulators O O
of O O
cellular O O
senescence O O
, O O
have O O
been O O
extensively O O
studied O O
. O O

However O O
, O O
little O O
is O O
known O O
about O O
chromatin O O
dynamics O O
taking O O
place O O
at O O
its O O
promoter O O
and O O
distal O O
enhancer O O
. O O

Here O O
, O O
we O O
report O O
that O O
Forkhead O O
box O O
A1 O O
protein O O
( O O
FOXA1 O O
) O O
is O O
significantly O O
upregulated O O
in O O
both O O
replicative O O
and O O
oncogene O O
- O O
induced O O
senescence O O
, O O
and O O
in O O
turn O O
activates O O
transcription O O
of O O
p16 O O
( O O
INK4a O O
) O O
through O O
multiple O O
mechanisms O O
. O O

In O O
addition O O
to O O
acting O O
as O O
a O O
classic O O
sequence O O
- O O
specific O O
transcriptional O O
activator O O
, O O
FOXA1 O O
binding O O
leads O O
to O O
a O O
decrease O O
in O O
nucleosome O O
density O O
at O O
the O O
p16 O O
( O O
INK4a O O
) O O
promoter O O
in O O
senescent O O
fibroblasts B-CellLine B-CellLine
. O O
In O O
addition O O
to O O
acting O O
as O O
a O O
classic O O
sequence O O
- O O
specific O O
transcriptional O O
activator O O
, O O
FOXA1 O O
binding O O
leads O O
to O O
a O O
decrease O O
in O O
nucleosome O O
density O O
at O O
the O O
p16 O O
( O O
INK4a O O
) O O
promoter O O
in O O
senescent O O
fibroblasts B-CellLine B-CellLine
. O O

Moreover O O
, O O
FOXA1 O O
, O O
itself O O
a O O
direct O O
target O O
of O O
Polycomb O O
- O O
mediated O O
repression O O
, O O
antagonizes O O
Polycomb O O
function O O
at O O
the O O
p16 O O
( O O
INK4a O O
) O O
locus O O
. O O

Finally O O
, O O
a O O
systematic O O
survey O O
of O O
putative O O
FOXA1 O O
binding O O
sites O O
in O O
the O O
p16 O O
( O O
INK4a O O
) O O
genomic O O
region O O
revealed O O
an O O
~ O O
150 O O
kb O O
distal O O
element O O
that O O
could O O
loop O O
back O O
to O O
the O O
promoter O O
and O O
potentiate O O
p16 O O
( O O
INK4a O O
) O O
expression O O
. O O
Finally O O
, O O
a O O
systematic O O
survey O O
of O O
putative O O
FOXA1 O O
binding O O
sites O O
in O O
the O O
p16 O O
( O O
INK4a O O
) O O
genomic O O
region O O
revealed O O
an O O
~ O O
150 O O
kb O O
distal O O
element O O
that O O
could O O
loop O O
back O O
to O O
the O O
promoter O O
and O O
potentiate O O
p16 O O
( O O
INK4a O O
) O O
expression O O
. O O

Overall O O
, O O
our O O
findings O O
establish O O
several O O
mechanisms O O
by O O
which O O
FOXA1 O O
controls O O
p16 O O
( O O
INK4a O O
) O O
expression O O
during O O
cellular O O
senescence O O
. O O

Establishment O O
of O O
active O O
chromatin O O
structure O O
at O O
enhancer O O
elements O O
by O O
mixed O O
- O O
lineage O O
leukemia O O
1 O O
to O O
initiate O O
estrogen O O
- O O
dependent O O
gene O O
expression O O
. O O

A O O
number O O
of O O
genome O O
- O O
wide O O
analyses O O
have O O
revealed O O
that O O
estrogen O O
receptor O O
alpha O O
binding O O
to O O
and O O
regulation O O
of O O
its O O
target O O
genes O O
correlate O O
with O O
binding O O
of O O
FOXA1 O O
, O O
a O O
pioneer O O
factor O O
, O O
to O O
nearby O O
DNA O O
sites O O
in O O
MCF B-CellLine B-CellLine
- I-CellLine I-CellLine
7 I-CellLine I-CellLine
breast I-CellLine I-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

The O O
enhancer O O
element O O
- O O
specific O O
histone O O
H3K4me1 O O
/ O O
2 O O
mark O O
is O O
enriched O O
at O O
the O O
specific O O
FOXA1 O O
/ O O
ERalpha O O
recruitment O O
sites O O
in O O
chromatin O O
, O O
but O O
the O O
mechanism O O
by O O
which O O
these O O
enhancer O O
marks O O
are O O
established O O
in O O
chromatin O O
before O O
hormone O O
treatment O O
is O O
unclear O O
. O O

Here O O
, O O
we O O
show O O
that O O
mixed O O
- O O
lineage O O
leukemia O O
1 O O
( O O
MLL1 O O
) O O
protein O O
is O O
a O O
key O O
determinant O O
that O O
maintains O O
permissive O O
chromatin O O
structure O O
of O O
the O O
TFF1 O O
enhancer O O
region O O
. O O
MLL1 O O
occupies O O
the O O
TFF1 O O
enhancer O O
region O O
and O O
methylates O O
H3K4 O O
before O O
hormone O O
stimulation O O
. O O
Here O O
, O O
we O O
show O O
that O O
mixed O O
- O O
lineage O O
leukemia O O
1 O O
( O O
MLL1 O O
) O O
protein O O
is O O
a O O
key O O
determinant O O
that O O
maintains O O
permissive O O
chromatin O O
structure O O
of O O
the O O
TFF1 O O
enhancer O O
region O O
. O O
MLL1 O O
occupies O O
the O O
TFF1 O O
enhancer O O
region O O
and O O
methylates O O
H3K4 O O
before O O
hormone O O
stimulation O O
. O O

In O O
vitro O O
, O O
MLL1 O O
binds O O
directly O O
to O O
the O O
CpG O O
- O O
rich O O
region O O
of O O
the O O
TFF1 O O
enhancer O O
, O O
and O O
its O O
binding O O
is O O
dependent O O
on O O
hypomethylation O O
of O O
DNA O O
. O O
In O O
vitro O O
, O O
MLL1 O O
binds O O
directly O O
to O O
the O O
CpG O O
- O O
rich O O
region O O
of O O
the O O
TFF1 O O
enhancer O O
, O O
and O O
its O O
binding O O
is O O
dependent O O
on O O
hypomethylation O O
of O O
DNA O O
. O O

Furthermore O O
, O O
the O O
depletion O O
of O O
MLL1 O O
in O O
MCF B-CellLine B-CellLine
- I-CellLine I-CellLine
7 I-CellLine I-CellLine
cells I-CellLine I-CellLine
results O O
in O O
a O O
dramatic O O
decrease O O
of O O
chromatin O O
accessibility O O
and O O
recruitment O O
of O O
FOXA1 O O
and O O
ERalpha O O
to O O
the O O
enhancer O O
element O O
. O O

Our O O
study O O
defines O O
the O O
mechanism O O
by O O
which O O
MLL1 O O
nucleates O O
histone O O
H3K4 O O
methylation O O
marks O O
in O O
CpG O O
- O O
enriched O O
regions O O
to O O
maintain O O
permissive O O
chromatin O O
architecture O O
and O O
allow O O
FOXA1 O O
and O O
estrogen O O
receptor O O
alpha O O
binding O O
to O O
transcriptional O O
regulatory O O
sites O O
in O O
breast B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Discovery O O
and O O
characterization O O
of O O
super O O
- O O
enhancer O O
- O O
associated O O
dependencies O O
in O O
diffuse O O
large O O
B O O
cell O O
lymphoma O O
. O O
Diffuse O O
large O O
B O O
cell O O
lymphoma O O
( O O
DLBCL O O
) O O
is O O
a O O
biologically O O
heterogeneous O O
and O O
clinically O O
aggressive O O
disease O O
. O O

Here O O
, O O
we O O
explore O O
the O O
role O O
of O O
bromodomain O O
and O O
extra O O
- O O
terminal O O
domain O O
( O O
BET O O
) O O
proteins O O
in O O
DLBCL O O
, O O
using O O
integrative O O
chemical O O
genetics O O
and O O
functional O O
epigenomics O O
. O O

We O O
observe O O
highly O O
asymmetric O O
loading O O
of O O
bromodomain O O
4 O O
( O O
BRD4 O O
) O O
at O O
enhancers O O
, O O
with O O
approximately O O
33 O O
% O O
of O O
all O O
BRD4 O O
localizing O O
to O O
enhancers O O
at O O
1 O O
. O O
6 O O
% O O
of O O
occupied O O
genes O O
. O O

These O O
super O O
- O O
enhancers O O
prove O O
particularly O O
sensitive O O
to O O
bromodomain O O
inhibition O O
, O O
explaining O O
the O O
selective O O
effect O O
of O O
BET O O
inhibitors O O
on O O
oncogenic O O
and O O
lineage O O
- O O
specific O O
transcriptional O O
circuits O O
. O O

Functional O O
study O O
of O O
genes O O
marked O O
by O O
super O O
- O O
enhancers O O
identifies O O
DLBCLs O O
dependent O O
on O O
OCA O O
- O O
B O O
and O O
suggests O O
a O O
strategy O O
for O O
discovering O O
unrecognized O O
cancer O O
dependencies O O
. O O

Translational O O
studies O O
performed O O
on O O
a O O
comprehensive O O
panel O O
of O O
DLBCLs O O
establish O O
a O O
therapeutic O O
rationale O O
for O O
evaluating O O
BET O O
inhibitors O O
in O O
this O O
disease O O
. O O

Evolution O O
of O O
Alu O O
elements O O
toward O O
enhancers O O
. O O

The O O
human O O
genome O O
contains O O
approximately O O
one O O
million O O
Alu O O
repetitive O O
elements O O
comprising O O
10 O O
% O O
of O O
the O O
genome O O
, O O
yet O O
their O O
functions O O
are O O
not O O
well O O
understood O O
. O O

Here O O
, O O
we O O
show O O
that O O
Alu O O
elements O O
resemble O O
enhancers O O
. O O

Alu O O
elements O O
are O O
bound O O
by O O
two O O
well O O
- O O
phased O O
nucleosomes O O
that O O
contain O O
histones O O
bearing O O
marks O O
of O O
active O O
chromatin O O
, O O
and O O
they O O
show O O
tissue O O
- O O
specific O O
enrichment O O
for O O
the O O
enhancer O O
mark O O
H3K4me1 O O
. O O

A O O
proportion O O
of O O
Alu O O
elements O O
were O O
experimentally O O
validated O O
as O O
bona O O
fide O O
active O O
enhancers O O
with O O
an O O
in O O
vitro O O
reporter O O
assay O O
. O O

In O O
addition O O
, O O
Hi O O
- O O
C O O
data O O
indicate O O
that O O
Alus O O
show O O
long O O
- O O
range O O
interactions O O
with O O
gene O O
promoters O O
. O O

We O O
also O O
find O O
that O O
Alus O O
are O O
generally O O
more O O
conserved O O
when O O
located O O
in O O
the O O
proximal O O
upstream O O
region O O
of O O
genes O O
. O O

Their O O
similarity O O
to O O
enhancers O O
becomes O O
more O O
prominent O O
with O O
their O O
age O O
in O O
the O O
human O O
genome O O
, O O
following O O
a O O
clear O O
evolutionary O O
continuum O O
reminiscent O O
of O O
the O O
evolutionary O O
pattern O O
of O O
proto O O
- O O
genes O O
. O O

Therefore O O
, O O
we O O
conclude O O
that O O
some O O
Alu O O
elements O O
can O O
function O O
as O O
enhancers O O
and O O
propose O O
that O O
many O O
more O O
may O O
be O O
proto O O
- O O
enhancers O O
that O O
serve O O
as O O
a O O
repertoire O O
for O O
the O O
de O O
novo O O
birth O O
of O O
enhancers O O
. O O

YY1 O O
acts O O
as O O
a O O
transcriptional O O
activator O O
of O O
Hoxa5 O O
gene O O
expression O O
in O O
mouse O O
organogenesis O O
. O O

The O O
Hox O O
gene O O
family O O
encodes O O
homeodomain O O
- O O
containing O O
transcriptional O O
regulators O O
that O O
confer O O
positional O O
information O O
to O O
axial O O
and O O
paraxial O O
tissues O O
in O O
the O O
developing O O
embryo O B-CellLine
. O O

The O O
dynamic O O
Hox O O
gene O O
expression O O
pattern O O
requires O O
mechanisms O O
that O O
differentially O O
control O O
Hox O O
transcription O O
in O O
a O O
precise O O
spatio O O
- O O
temporal O O
fashion O O
. O O

This O O
implies O O
an O O
integrated O O
regulation O O
of O O
neighbouring O O
Hox O O
genes O O
achieved O O
through O O
the O O
sharing O O
and O O
the O O
selective O O
use O O
of O O
defined O O
enhancer O O
sequences O O
. O O

The O O
Hoxa5 O O
gene O O
plays O O
a O O
crucial O O
role O O
in O O
lung B-CellLine B-CellLine
and O O
gut B-CellLine B-CellLine
organogenesis O O
. O O

To O O
position O O
Hoxa5 O O
in O O
the O O
regulatory O O
hierarchy O O
that O O
drives O O
organ O B-CellLine
morphogenesis O O
, O O
we O O
searched O O
for O O
cis O O
- O O
acting O O
regulatory O O
sequences O O
and O O
associated O O
trans O O
- O O
acting O O
factors O O
required O O
for O O
Hoxa5 O O
expression O O
in O O
the O O
developing O O
lung B-CellLine B-CellLine
and O O
gut B-CellLine B-CellLine
. O O

Using O O
mouse O O
transgenesis O O
, O O
we O O
identified O O
two O O
DNA O O
regions O O
included O O
in O O
a O O
1 O O
. O O
5 O O
- O O
kb O O
XbaI O O
- O O
XbaI O O
fragment O O
located O O
in O O
the O O
Hoxa4 O O
- O O
Hoxa5 O O
intergenic O O
domain O O
and O O
known O O
to O O
control O O
Hoxa4 O O
organ O O
expression O O
. O O
Using O O
mouse O O
transgenesis O O
, O O
we O O
identified O O
two O O
DNA O O
regions O O
included O O
in O O
a O O
1 O O
. O O
5 O O
- O O
kb O O
XbaI O O
- O O
XbaI O O
fragment O O
located O O
in O O
the O O
Hoxa4 O O
- O O
Hoxa5 O O
intergenic O O
domain O O
and O O
known O O
to O O
control O O
Hoxa4 O O
organ O O
expression O O
. O O

The O O
multifunctional O O
YY1 O O
transcription O O
factor O O
binds O O
the O O
two O O
regulatory O O
sequences O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O
The O O
multifunctional O O
YY1 O O
transcription O O
factor O O
binds O O
the O O
two O O
regulatory O O
sequences O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

Moreover O O
, O O
the O O
mesenchymal O O
deletion O O
of O O
the O O
Yy1 O O
gene O O
function O O
in O O
mice O O
results O O
in O O
a O O
Hoxa5 O O
- O O
like O O
lung B-CellLine O
phenotype O O
with O O
decreased O O
Hoxa5 O O
and O O
Hoxa4 O O
gene O O
expression O O
. O O

Thus O O
, O O
YY1 O O
acts O O
as O O
a O O
positive O O
regulator O O
of O O
Hoxa5 O O
expression O O
in O O
the O O
developing O O
lung B-CellLine B-CellLine
and O O
gut B-CellLine B-CellLine
. O O

Our O O
data O O
also O O
support O O
a O O
role O O
for O O
YY1 O O
in O O
the O O
coordinated O O
expression O O
of O O
Hox O O
genes O O
for O O
correct O O
organogenesis O O
. O O

Two O O
deletions O O
overlapping O O
a O O
distant O O
FOXF1 O O
enhancer O O
unravel O O
the O O
role O O
of O O
lncRNA O O
LINC01081 O O
in O O
etiology O O
of O O
alveolar O O
capillary O O
dysplasia O O
with O O
misalignment O O
of O O
pulmonary O B-CellLine
veins O I-CellLine
. O O
Two O O
deletions O O
overlapping O O
a O O
distant O O
FOXF1 O O
enhancer O O
unravel O O
the O O
role O O
of O O
lncRNA O O
LINC01081 O O
in O O
etiology O O
of O O
alveolar O O
capillary O O
dysplasia O O
with O O
misalignment O O
of O O
pulmonary O B-CellLine
veins O I-CellLine
. O O

Position O O
effects O O
due O O
to O O
disruption O O
of O O
distant O O
cis O O
- O O
regulatory O O
regions O O
have O O
been O O
reported O O
for O O
over O O
40 O O
human O O
gene O O
loci O O
; O O
however O O
, O O
the O O
underlying O O
mechanisms O O
of O O
long O O
- O O
range O O
gene O O
regulation O O
remain O O
largely O O
unknown O O
. O O

We O O
report O O
on O O
two O O
patients O O
with O O
alveolar O O
capillary O O
dysplasia O O
with O O
misalignment O O
of O O
pulmonary O O
veins O O
( O O
ACDMPV O O
) O O
caused O O
by O O
overlapping O O
genomic O O
deletions O O
that O O
included O O
a O O
distant O O
FOXF1 O O
transcriptional O O
enhancer O O
mapping O O
0 O O
. O O
3 O O
Mb O O
upstream O O
to O O
FOXF1 O O
on O O
16q24 O O
. O O
1 O O
. O O
We O O
report O O
on O O
two O O
patients O O
with O O
alveolar O O
capillary O O
dysplasia O O
with O O
misalignment O O
of O O
pulmonary O O
veins O O
( O O
ACDMPV O O
) O O
caused O O
by O O
overlapping O O
genomic O O
deletions O O
that O O
included O O
a O O
distant O O
FOXF1 O O
transcriptional O O
enhancer O O
mapping O O
0 O O
. O O
3 O O
Mb O O
upstream O O
to O O
FOXF1 O O
on O O
16q24 O O
. O O
1 O O
. O O

In O O
one O O
patient O O
with O O
atypical O O
late O O
- O O
onset O O
ACDMPV O O
, O O
a O O
~ O O
1 O O
. O O
5 O O
Mb O O
deletion O O
removed O O
the O O
proximal O O
43 O O
% O O
of O O
this O O
enhancer O O
, O O
leaving O O
the O O
lung B-CellLine O
- O O
specific O O
long O O
non O O
- O O
coding O O
RNA O O
( O O
lncRNA O O
) O O
gene O O
LINC01081 O O
intact O O
. O O

In O O
the O O
second O O
patient O O
with O O
severe O O
neonatal O O
- O O
onset O O
ACDMPV O O
, O O
an O O
overlapping O O
~ O O
194 O O
kb O O
deletion O O
disrupted O O
LINC01081 O O
. O O

Both O O
deletions O O
arose O O
de O O
novo O O
on O O
maternal O O
copy O O
of O O
the O O
chromosome O O
16 O O
, O O
supporting O O
the O O
notion O O
that O O
FOXF1 O O
is O O
paternally O O
imprinted O O
in O O
the O O
human O O
lungs B-CellLine B-CellLine
. O O

RNAi O O
- O O
mediated O O
knock O O
- O O
down O O
of O O
LINC01081 O O
in O O
normal O O
fetal O O
lung B-CellLine B-CellLine
fibroblasts I-CellLine I-CellLine
showed O O
that O O
this O O
lncRNA O O
positively O O
regulates O O
FOXF1 O O
transcript O O
level O O
, O O
further O O
indicating O O
that O O
decrease O O
in O O
LINC01081 O O
expression O O
can O O
contribute O O
to O O
development O O
of O O
ACDMPV O O
. O O

Epigenomic O O
analysis O O
of O O
primary O O
human O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
reveals O O
enhancers O O
associated O O
with O O
TH2 B-CellLine B-CellLine
memory I-CellLine I-CellLine
cell I-CellLine I-CellLine
differentiation O O
and O O
asthma O O
susceptibility O O
. O O

A O O
characteristic O O
feature O O
of O O
asthma O O
is O O
the O O
aberrant O O
accumulation O O
, O O
differentiation O O
or O O
function O O
of O O
memory B-CellLine O
CD4 I-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
that I-CellLine O
produce I-CellLine O
type I-CellLine O
2 I-CellLine O
cytokines I-CellLine O
( O O
TH2 B-CellLine B-CellLine
cells I-CellLine I-CellLine
) O O
. O O

By O O
mapping O O
genome O O
- O O
wide O O
histone O O
modification O O
profiles O O
for O O
subsets O O
of O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
isolated O O
from O O
peripheral B-CellLine B-CellLine
blood I-CellLine I-CellLine
of O O
healthy O O
and O O
asthmatic O O
individuals O O
, O O
we O O
identified O O
enhancers O O
with O O
known O O
and O O
potential O O
roles O O
in O O
the O O
normal O O
differentiation O O
of O O
human O O
TH1 B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
TH2 B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

We O O
discovered O O
disease O O
- O O
specific O O
enhancers O O
in O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
that O O
differ O O
between O O
healthy O O
and O O
asthmatic O O
individuals O O
. O O

Enhancers O O
that O O
gained O O
the O O
histone O O
H3 O O
Lys4 O O
dimethyl O O
( O O
H3K4me2 O O
) O O
mark O O
during O O
TH2 B-CellLine B-CellLine
cell I-CellLine I-CellLine
development O O
showed O O
the O O
highest O O
enrichment O O
for O O
asthma O O
- O O
associated O O
single O O
nucleotide O O
polymorphisms O O
( O O
SNPs O O
) O O
, O O
which O O
supported O O
a O O
pathogenic O O
role O O
for O O
TH2 B-CellLine B-CellLine
cells I-CellLine I-CellLine
in O O
asthma O O
. O O

In O O
silico O O
analysis O O
of O O
cell O O
- O O
specific O O
enhancers O O
revealed O O
transcription O O
factors O O
, O O
microRNAs O O
and O O
genes O O
potentially O O
linked O O
to O O
human O O
TH2 B-CellLine B-CellLine
cell I-CellLine I-CellLine
differentiation O O
. O O

Our O O
results O O
establish O O
the O O
feasibility O O
and O O
utility O O
of O O
enhancer O O
profiling O O
in O O
well O O
- O O
defined O O
populations O O
of O O
specialized O O
cell O O
types O O
involved O O
in O O
disease O O
pathogenesis O O
. O O

The O O
active O O
enhancer O O
network O O
operated O O
by O O
liganded O O
RXR O O
supports O O
angiogenic O O
activity O O
in O O
macrophages B-CellLine B-CellLine
. O O

RXR O O
signaling O O
is O O
predicted O O
to O O
have O O
a O O
major O O
impact O O
in O O
macrophages B-CellLine B-CellLine
, O O
but O O
neither O O
the O O
biological O O
consequence O O
nor O O
the O O
genomic O O
basis O O
of O O
its O O
ligand O O
activation O O
is O O
known O O
. O O

Comprehensive O O
genome O O
- O O
wide O O
studies O O
were O O
carried O O
out O O
to O O
map O O
liganded O O
RXR O O
- O O
mediated O O
transcriptional O O
changes O O
, O O
active O O
binding O O
sites O O
, O O
and O O
cistromic O O
interactions O O
in O O
the O O
context O O
of O O
the O O
macrophage B-CellLine B-CellLine
genome O O
architecture O O
. O O

The O O
macrophage B-CellLine B-CellLine
RXR O O
cistrome O O
has O O
5200 O O
genomic O O
binding O O
sites O O
, O O
which O O
are O O
not O O
impacted O O
by O O
ligand O O
. O O

Active O O
enhancers O O
are O O
characterized O O
by O O
PU O O
. O O
1 O O
binding O O
, O O
an O O
increase O O
of O O
enhancer O O
RNA O O
, O O
and O O
P300 O O
recruitment O O
. O O

Using O O
these O O
features O O
, O O
387 O O
liganded O O
RXR O O
- O O
bound O O
enhancers O O
were O O
linked O O
to O O
226 O O
genes O O
, O O
which O O
predominantly O O
reside O O
in O O
CTCF O O
/ O O
cohesin O O
- O O
limited O O
functional O O
domains O O
. O O

These O O
findings O O
were O O
molecularly O O
validated O O
using O O
chromosome O O
conformation O O
capture O O
( O O
3C O O
) O O
and O O
3C O O
combined O O
with O O
sequencing O O
( O O
3C O O
- O O
seq O O
) O O
, O O
and O O
we O O
show O O
that O O
selected O O
long O O
- O O
range O O
enhancers O O
communicate O O
with O O
promoters O O
via O O
stable O O
or O O
RXR O O
- O O
induced O O
loops O O
and O O
that O O
some O O
of O O
the O O
enhancers O O
interact O O
with O O
each O O
other O O
, O O
forming O O
an O O
interchromosomal O O
network O O
. O O

A O O
set O O
of O O
angiogenic O O
genes O O
, O O
including O O
Vegfa O O
, O O
has O O
liganded O O
RXR O O
- O O
controlled O O
enhancers O O
and O O
provides O O
the O O
macrophage B-CellLine B-CellLine
with O O
a O O
novel O O
inducible O O
program O O
. O O

Comparison O O
of O O
TALE O O
designer O O
transcription O O
factors O O
and O O
the O O
CRISPR O O
/ O O
dCas9 O O
in O O
regulation O O
of O O
gene O O
expression O O
by O O
targeting O O
enhancers O O
. O O

The O O
transcription O O
activator O O
- O O
like O O
effectors O O
( O O
TALEs O O
) O O
and O O
the O O
RNA O O
- O O
guided O O
clustered O O
regularly O O
interspaced O O
short O O
palindromic O O
repeat O O
( O O
CRISPR O O
) O O
associated O O
protein O O
( O O
Cas9 O O
) O O
utlilize O O
distinct O O
molecular O O
mechanisms O O
in O O
targeting O O
site O O
recognition O O
. O O

The O O
two O O
proteins O O
can O O
be O O
modified O O
to O O
carry O O
additional O O
functional O O
domains O O
to O O
regulate O O
expression O O
of O O
genomic O O
loci O O
in O O
mammalian O O
cells O O
. O O

In O O
this O O
study O O
, O O
we O O
have O O
compared O O
the O O
two O O
systems O O
in O O
activation O O
and O O
suppression O O
of O O
the O O
Oct4 O O
and O O
Nanog O O
loci O O
by O O
targeting O O
their O O
enhancers O O
. O O

Although O O
both O O
are O O
able O O
to O O
efficiently O O
activate O O
the O O
luciferase O O
reporters O O
, O O
the O O
CRISPR O O
/ O O
dCas9 O O
system O O
is O O
much O O
less O O
potent O O
in O O
activating O O
the O O
endogenous O O
loci O O
and O O
in O O
the O O
application O O
of O O
reprogramming O O
somatic B-CellLine B-CellLine
cells I-CellLine I-CellLine
to O O
iPS B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Nevertheless O O
, O O
repression O O
by O O
CRISPR O O
/ O O
dCas9 O O
is O O
comparable O O
to O O
or O O
even O O
better O O
than O O
TALE O O
repressors O O
. O O

We O O
demonstrated O O
that O O
dCas9 O O
protein O O
binding O O
results O O
in O O
significant O O
physical O O
interference O O
to O O
binding O O
of O O
native O O
transcription O O
factors O O
at O O
enhancer O O
, O O
less O O
efficient O O
active O O
histone O O
markers O O
induction O O
or O O
recruitment O O
of O O
activating O O
complexes O O
in O O
gene O O
activation O O
. O O

This O O
study O O
thus O O
highlighted O O
the O O
merits O O
and O O
drawbacks O O
of O O
transcription O O
regulation O O
by O O
each O O
system O O
. O O

A O O
combined O O
approach O O
of O O
TALEs O O
and O O
CRISPR O O
/ O O
dCas9 O O
should O O
provide O O
an O O
optimized O O
solution O O
to O O
regulate O O
genomic O O
loci O O
and O O
to O O
study O O
genetic O O
elements O O
such O O
as O O
enhancers O O
in O O
biological O O
processes O O
including O O
somatic O B-CellLine
cell O I-CellLine
reprogramming O O
and O O
guided O O
differentiation O O
. O O

Pi3kcb O O
links O O
Hippo O O
- O O
YAP O O
and O O
PI3K O O
- O O
AKT O O
signaling O O
pathways O O
to O O
promote O O
cardiomyocyte B-CellLine B-CellLine
proliferation O O
and O O
survival O O
. O O

RATIONALE O O
: O O
Yes O O
- O O
associated O O
protein O O
( O O
YAP O O
) O O
, O O
the O O
nuclear O O
effector O O
of O O
Hippo O O
signaling O O
, O O
regulates O O
cellular O O
growth O O
and O O
survival O O
in O O
multiple O O
organs O O
, O O
including O O
the O O
heart B-CellLine B-CellLine
, O O
by O O
interacting O O
with O O
TEA O O
( O O
transcriptional O O
enhancer O O
activator O O
) O O
- O O
domain O O
sequence O O
- O O
specific O O
DNA O O
- O O
binding O O
proteins O O
. O O

Recent O O
studies O O
showed O O
that O O
YAP O O
stimulates O O
cardiomyocyte B-CellLine B-CellLine
proliferation O O
and O O
survival O O
. O O

However O O
, O O
the O O
direct O O
transcriptional O O
targets O O
through O O
which O O
YAP O O
exerts O O
its O O
effects O O
are O O
poorly O O
defined O O
. O O

OBJECTIVE O O
: O O
To O O
identify O O
direct O O
YAP O O
targets O O
that O O
mediate O O
its O O
mitogenic O O
and O O
antiapoptotic O O
effects O O
in O O
the O O
heart B-CellLine B-CellLine
. O O

METHODS O O
AND O O
RESULTS O O
: O O
We O O
identified O O
direct O O
YAP O O
targets O O
by O O
combining O O
differential O O
gene O O
expression O O
analysis O O
in O O
YAP O O
gain O O
- O O
and O O
loss O O
- O O
of O O
- O O
function O O
with O O
genome O O
- O O
wide O O
identification O O
of O O
YAP O O
- O O
bound O O
loci O O
using O O
chromatin O O
immunoprecipitation O O
and O O
high O O
throughput O O
sequencing O O
. O O

This O O
screen O O
identified O O
Pik3cb O O
, O O
encoding O O
p110beta O O
, O O
a O O
catalytic O O
subunit O O
of O O
phosphoinositol O O
- O O
3 O O
- O O
kinase O O
, O O
as O O
a O O
candidate O O
YAP O O
effector O O
that O O
promotes O O
cardiomyocyte B-CellLine B-CellLine
proliferation O O
and O O
survival O O
. O O
YAP O O
and O O
TEA O O
- O O
domain O O
occupied O O
a O O
conserved O O
enhancer O O
within O O
the O O
first O O
intron O O
of O O
Pik3cb O O
, O O
and O O
this O O
enhancer O O
drove O O
YAP O O
- O O
dependent O O
reporter O O
gene O O
expression O O
. O O
Yap O O
gain O O
- O O
and O O
loss O O
- O O
of O O
- O O
function O O
studies O O
indicated O O
that O O
YAP O O
is O O
necessary O O
and O O
sufficient O O
to O O
activate O O
the O O
phosphoinositol O O
- O O
3 O O
- O O
kinase O O
- O O
Akt O O
pathway O O
. O O
This O O
screen O O
identified O O
Pik3cb O O
, O O
encoding O O
p110beta O O
, O O
a O O
catalytic O O
subunit O O
of O O
phosphoinositol O O
- O O
3 O O
- O O
kinase O O
, O O
as O O
a O O
candidate O O
YAP O O
effector O O
that O O
promotes O O
cardiomyocyte B-CellLine B-CellLine
proliferation O O
and O O
survival O O
. O O
YAP O O
and O O
TEA O O
- O O
domain O O
occupied O O
a O O
conserved O O
enhancer O O
within O O
the O O
first O O
intron O O
of O O
Pik3cb O O
, O O
and O O
this O O
enhancer O O
drove O O
YAP O O
- O O
dependent O O
reporter O O
gene O O
expression O O
. O O
Yap O O
gain O O
- O O
and O O
loss O O
- O O
of O O
- O O
function O O
studies O O
indicated O O
that O O
YAP O O
is O O
necessary O O
and O O
sufficient O O
to O O
activate O O
the O O
phosphoinositol O O
- O O
3 O O
- O O
kinase O O
- O O
Akt O O
pathway O O
. O O

Like O O
Yap O O
, O O
Pik3cb O O
gain O O
- O O
of O O
- O O
function O O
stimulated O O
cardiomyocyte B-CellLine B-CellLine
proliferation O O
, O O
and O O
Pik3cb O O
knockdown O O
dampened O O
YAP O O
mitogenic O O
activity O O
. O O

Reciprocally O O
, O O
impaired O O
heart B-CellLine B-CellLine
function O O
in O O
Yap O O
loss O O
- O O
of O O
- O O
function O O
was O O
significantly O O
rescued O O
by O O
adeno O O
- O O
associated O O
virus O O
- O O
mediated O O
Pik3cb O O
expression O O
. O O

CONCLUSIONS O O
: O O
Pik3cb O O
is O O
a O O
crucial O O
direct O O
target O O
of O O
YAP O O
, O O
through O O
which O O
the O O
YAP O O
activates O O
phosphoinositol O O
- O O
3 O O
- O O
kinase O O
- O O
AKT O O
pathway O O
and O O
regulates O O
cardiomyocyte B-CellLine B-CellLine
proliferation O O
and O O
survival O O
. O O

5mC O O
oxidation O O
by O O
Tet2 O O
modulates O O
enhancer O O
activity O O
and O O
timing O O
of O O
transcriptome O O
reprogramming O O
during O O
differentiation O O
. O O

In O O
mammals O O
, O O
cytosine O O
methylation O O
( O O
5mC O O
) O O
is O O
widely O O
distributed O O
throughout O O
the O O
genome O O
but O O
is O O
notably O O
depleted O O
from O O
active O O
promoters O O
and O O
enhancers O O
. O O

While O O
the O O
role O O
of O O
DNA O O
methylation O O
in O O
promoter O O
silencing O O
has O O
been O O
well O O
documented O O
, O O
the O O
function O O
of O O
this O O
epigenetic O O
mark O O
at O O
enhancers O O
remains O O
unclear O O
. O O

Recent O O
experiments O O
have O O
demonstrated O O
that O O
enhancers O O
are O O
enriched O O
for O O
5 O O
- O O
hydroxymethylcytosine O O
( O O
5hmC O O
) O O
, O O
an O O
oxidization O O
product O O
of O O
the O O
Tet O O
family O O
of O O
5mC O O
dioxygenases O O
and O O
an O O
intermediate O O
of O O
DNA O O
demethylation O O
. O O

These O O
results O O
support O O
the O O
involvement O O
of O O
Tet O O
proteins O O
in O O
the O O
regulation O O
of O O
dynamic O O
DNA O O
methylation O O
at O O
enhancers O O
. O O

By O O
mapping O O
DNA O O
methylation O O
and O O
hydroxymethylation O O
at O O
base O O
resolution O O
, O O
we O O
find O O
that O O
deletion O O
of O O
Tet2 O O
causes O O
extensive O O
loss O O
of O O
5hmC O O
at O O
enhancers O O
, O O
accompanied O O
by O O
enhancer O O
hypermethylation O O
, O O
reduction O O
of O O
enhancer O O
activity O O
, O O
and O O
delayed O O
gene O O
induction O O
in O O
the O O
early O O
steps O O
of O O
differentiation O O
. O O

Our O O
results O O
reveal O O
that O O
DNA O O
demethylation O O
modulates O O
enhancer O O
activity O O
, O O
and O O
its O O
disruption O O
influences O O
the O O
timing O O
of O O
transcriptome O O
reprogramming O O
during O O
cellular O O
differentiation O O
. O O

MUNC O O
, O O
a O O
long O O
noncoding O O
RNA O O
that O O
facilitates O O
the O O
function O O
of O O
MyoD O O
in O O
skeletal O O
myogenesis O O
. O O

An O O
in O O
silico O O
screen O O
for O O
myogenic O O
long O O
noncoding O O
RNAs O O
( O O
lncRNAs O O
) O O
revealed O O
nine O O
lncRNAs O O
that O O
are O O
upregulated O O
more O O
than O O
10 O O
- O O
fold O O
in O O
myotubes O B-CellLine
versus O O
levels O O
in O O
myoblasts B-CellLine B-CellLine
. O O

One O O
of O O
these O O
lncRNAs O O
, O O
MyoD O O
upstream O O
noncoding O O
( O O
MUNC O O
, O O
also O O
known O O
as O O
DRR O O
( O O
eRNA O O
) O O
) O O
, O O
is O O
encoded O O
5 O O
kb O O
upstream O O
of O O
the O O
transcription O O
start O O
site O O
of O O
MyoD O O
, O O
a O O
myogenic O O
transcription O O
factor O O
gene O O
. O O

MUNC O O
is O O
specifically O O
expressed O O
in O O
skeletal B-CellLine B-CellLine
muscle I-CellLine I-CellLine
and O O
exists O O
as O O
in O O
unspliced O O
and O O
spliced O O
isoforms O O
, O O
and O O
its O O
5 O O
' O O
end O O
overlaps O O
with O O
the O O
cis O O
- O O
acting O O
distal O O
regulatory O O
region O O
( O O
DRR O O
) O O
of O O
MyoD O O
. O O

Small O O
interfering O O
RNA O O
( O O
siRNA O O
) O O
of O O
MUNC O O
reduced O O
myoblast O B-CellLine
differentiation O O
and O O
specifically O O
reduced O O
the O O
association O O
of O O
MyoD O O
to O O
the O O
DRR O O
enhancer O O
and O O
myogenin O O
promoter O O
but O O
not O O
to O O
another O O
MyoD O O
- O O
dependent O O
enhancer O O
. O O
Small O O
interfering O O
RNA O O
( O O
siRNA O O
) O O
of O O
MUNC O O
reduced O O
myoblast O B-CellLine
differentiation O O
and O O
specifically O O
reduced O O
the O O
association O O
of O O
MyoD O O
to O O
the O O
DRR O O
enhancer O O
and O O
myogenin O O
promoter O O
but O O
not O O
to O O
another O O
MyoD O O
- O O
dependent O O
enhancer O O
. O O

Stable O O
overexpression O O
of O O
MUNC O O
from O O
a O O
heterologous O O
promoter O O
increased O O
endogenous O O
MyoD O O
, O O
Myogenin O O
, O O
and O O
Myh3 O O
( O O
myosin O O
heavy O O
chain O O
, O O
[ O O
MHC O O
] O O
gene O O
) O O
mRNAs O O
but O O
not O O
the O O
cognate O O
proteins O O
, O O
suggesting O O
that O O
MUNC O O
can O O
act O O
in O O
trans O O
to O O
promote O O
gene O O
expression O O
but O O
that O O
this O O
activity O O
does O O
not O O
require O O
an O O
induction O O
of O O
MyoD O O
protein O O
. O O

MUNC O O
also O O
stimulates O O
the O O
transcription O O
of O O
other O O
genes O O
that O O
are O O
not O O
recognized O O
as O O
MyoD O O
- O O
inducible O O
genes O O
. O O

Knockdown O O
of O O
MUNC O O
in O O
vivo O O
impaired O O
murine O O
muscle B-CellLine B-CellLine
regeneration O O
, O O
implicating O O
MUNC O O
in O O
primary O O
satellite O B-CellLine
cell O I-CellLine
differentiation O O
in O O
the O O
animal O O
. O O

We O O
also O O
discovered O O
a O O
human O O
MUNC O O
that O O
is O O
induced O O
during O O
differentiation O O
of O O
myoblasts B-CellLine B-CellLine
and O O
whose O O
knockdown O O
decreases O O
differentiation O O
, O O
suggesting O O
an O O
evolutionarily O O
conserved O O
role O O
of O O
MUNC O O
lncRNA O O
in O O
myogenesis O O
. O O

Although O O
MUNC O O
overlaps O O
with O O
the O O
DRR O O
enhancer O O
, O O
our O O
results O O
suggest O O
that O O
MUNC O O
is O O
not O O
a O O
classic O O
cis O O
- O O
acting O O
enhancer O O
RNA O O
( O O
e O O
- O O
RNA O O
) O O
acting O O
exclusively O O
by O O
stimulating O O
the O O
neighboring O O
MyoD O O
gene O O
but O O
more O O
like O O
a O O
promyogenic O O
lncRNA O O
that O O
acts O O
directly O O
or O O
indirectly O O
on O O
multiple O O
promoters O O
to O O
increase O O
myogenic O O
gene O O
expression O O
. O O

A O O
novel O O
Cd8 O O
- O O
cis O O
- O O
regulatory O O
element O O
preferentially O O
directs O O
expression O O
in O O
CD44hiCD62L B-CellLine O
+ I-CellLine O
CD8 I-CellLine B-CellLine
+ I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
and O O
in O O
CD8alphaalpha B-CellLine B-CellLine
+ I-CellLine I-CellLine
dendritic I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O
CD8 O O
coreceptor O O
expression O O
is O O
dynamically O O
regulated O O
during O O
thymocyte B-CellLine B-CellLine
development O O
and O O
is O O
tightly O O
controlled O O
by O O
the O O
activity O O
of O O
at O O
least O O
5 O O
different O O
cis O O
- O O
regulatory O O
elements O O
. O O

Despite O O
the O O
detailed O O
characterization O O
of O O
the O O
Cd8 O O
loci O O
, O O
the O O
regulation O O
of O O
the O O
complex O O
expression O O
pattern O O
of O O
CD8 O O
cannot O O
be O O
fully O O
explained O O
by O O
the O O
activity O O
of O O
the O O
known O O
Cd8 O O
enhancers O O
. O O
Despite O O
the O O
detailed O O
characterization O O
of O O
the O O
Cd8 O O
loci O O
, O O
the O O
regulation O O
of O O
the O O
complex O O
expression O O
pattern O O
of O O
CD8 O O
cannot O O
be O O
fully O O
explained O O
by O O
the O O
activity O O
of O O
the O O
known O O
Cd8 O O
enhancers O O
. O O

In O O
this O O
study O O
, O O
we O O
revisited O O
the O O
Cd8ab O O
gene O O
complex O O
with O O
bioinformatics O O
and O O
transgenic O O
reporter O O
gene O O
expression O O
approaches O O
to O O
search O O
for O O
additional O O
Cd8 O O
cis O O
- O O
regulatory O O
elements O O
. O O

This O O
led O O
to O O
the O O
identification O O
of O O
an O O
ECR O O
( O O
ECR O O
- O O
4 O O
) O O
, O O
which O O
in O O
transgenic O O
reporter O O
gene O O
expression O O
assays O O
, O O
directed O O
expression O O
preferentially O O
in O O
CD44 B-CellLine B-CellLine
( I-CellLine I-CellLine
hi I-CellLine I-CellLine
) I-CellLine I-CellLine
CD62L I-CellLine I-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
CD8 I-CellLine I-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
including O O
innate O O
- O O
like O O
CD8 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

ECR O O
- O O
4 O O
, O O
designated O O
as O O
Cd8 O O
enhancer O O
E8VI O O
, O O
was O O
bound O O
by O O
Runx O O
/ O O
CBFbeta O O
complexes O O
and O O
Bcl11b O O
, O O
indicating O O
that O O
E8VI O O
is O O
part O O
of O O
the O O
cis O O
- O O
regulatory O O
network O O
that O O
recruits O O
transcription O O
factors O O
to O O
the O O
Cd8ab O O
gene O O
complex O O
in O O
CD8 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Transgenic O O
reporter O O
expression O O
was O O
maintained O O
in O O
LCMV O O
- O O
specific O O
CD8 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
upon O O
infection O O
, O O
although O O
short O O
- O O
term O O
, O O
in O O
vitro O O
activation O O
led O O
to O O
a O O
down O O
- O O
regulation O O
of O O
E8VI O O
activity O O
. O O

Finally O O
, O O
E8VI O O
directed O O
transgene O O
expression O O
also O O
in O O
CD8alphaalpha B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
DCs I-CellLine I-CellLine
but O O
not O O
in O O
CD8alphaalpha B-CellLine B-CellLine
- I-CellLine I-CellLine
expressing I-CellLine I-CellLine
IELs I-CellLine I-CellLine
. O O

Taken O O
together O O
, O O
we O O
have O O
identified O O
a O O
novel O O
Cd8 O O
enhancer O O
that O O
directs O O
expression O O
in O O
CD44 B-CellLine B-CellLine
( I-CellLine I-CellLine
hi I-CellLine I-CellLine
) I-CellLine I-CellLine
CD62L I-CellLine I-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
CD8 I-CellLine I-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
including O O
innate O O
- O O
like O O
and O O
antigen O O
- O O
specific O O
effector O O
/ O O
memory O O
CD8 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
and O O
in O O
CD8alphaalpha B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
DCs I-CellLine I-CellLine
, O O
and O O
thus O O
, O O
our O O
data O O
provide O O
further O O
insight O O
into O O
the O O
cis O O
- O O
regulatory O O
networks O O
that O O
control O O
CD8 O O
expression O O
. O O
Taken O O
together O O
, O O
we O O
have O O
identified O O
a O O
novel O O
Cd8 O O
enhancer O O
that O O
directs O O
expression O O
in O O
CD44 B-CellLine B-CellLine
( I-CellLine I-CellLine
hi I-CellLine I-CellLine
) I-CellLine I-CellLine
CD62L I-CellLine I-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
CD8 I-CellLine I-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
including O O
innate O O
- O O
like O O
and O O
antigen O O
- O O
specific O O
effector O O
/ O O
memory O O
CD8 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
and O O
in O O
CD8alphaalpha B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
DCs I-CellLine I-CellLine
, O O
and O O
thus O O
, O O
our O O
data O O
provide O O
further O O
insight O O
into O O
the O O
cis O O
- O O
regulatory O O
networks O O
that O O
control O O
CD8 O O
expression O O
. O O

Histone O O
Deacetylase O O
Inhibitors O O
Repress O O
Tumoral O O
Expression O O
of O O
the O O
Proinvasive O O
Factor O O
RUNX2 O O
. O O

Aberrant O O
reactivation O O
of O O
embryonic O O
pathways O O
occurs O O
commonly O O
in O O
cancer O O
. O O

The O O
transcription O O
factor O O
RUNX2 O O
plays O O
a O O
fundamental O O
role O O
during O O
embryogenesis O O
and O O
is O O
aberrantly O O
reactivated O O
during O O
progression O O
and O O
metastasization O O
of O O
different O O
types O O
of O O
human O O
tumors O O
. O O

In O O
this O O
study O O
, O O
we O O
attempted O O
to O O
dissect O O
the O O
molecular O O
mechanisms O O
governing O O
RUNX2 O O
expression O O
and O O
its O O
aberrant O O
reactivation O O
. O O

We O O
identified O O
a O O
new O O
regulatory O O
enhancer O O
element O O
, O O
located O O
within O O
the O O
RUNX2 O O
gene O O
, O O
which O O
is O O
responsible O O
for O O
the O O
activation O O
of O O
the O O
RUNX2 O O
promoter O O
and O O
for O O
the O O
regulation O O
of O O
its O O
expression O O
in O O
cancer B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
We O O
identified O O
a O O
new O O
regulatory O O
enhancer O O
element O O
, O O
located O O
within O O
the O O
RUNX2 O O
gene O O
, O O
which O O
is O O
responsible O O
for O O
the O O
activation O O
of O O
the O O
RUNX2 O O
promoter O O
and O O
for O O
the O O
regulation O O
of O O
its O O
expression O O
in O O
cancer B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Furthermore O O
, O O
we O O
have O O
shown O O
that O O
treatment O O
with O O
the O O
anticancer O O
compounds O O
histone O O
deacetylase O O
inhibitor O O
( O O
HDACi O O
) O O
results O O
in O O
a O O
profound O O
inhibition O O
of O O
RUNX2 O O
expression O O
, O O
which O O
is O O
determined O O
by O O
the O O
disruption O O
of O O
the O O
transcription O O
- O O
activating O O
complex O O
on O O
the O O
identified O O
enhancer O O
. O O

These O O
data O O
envisage O O
a O O
possible O O
targeting O O
strategy O O
to O O
counteract O O
the O O
oncongenic O O
function O O
of O O
RUNX2 O O
in O O
cancer B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
provide O O
evidence O O
that O O
the O O
cytotoxic O O
activity O O
of O O
HDACi O O
in O O
cancer O O
is O O
not O O
only O O
dependent O O
on O O
the O O
reactivation O O
of O O
silenced O O
oncosuppressors O O
but O O
also O O
on O O
the O O
repression O O
of O O
oncogenic O O
factors O O
that O O
are O O
necessary O O
for O O
survival O O
and O O
progression O O
. O O

An O O
insulator O O
element O O
located O O
at O O
the O O
cyclin O O
B1 O O
interacting O O
protein O O
1 O O
gene O O
locus O O
is O O
highly O O
conserved O O
among O O
mammalian O O
species O O
. O O

Insulators O O
are O O
cis O O
- O O
elements O O
that O O
control O O
the O O
direction O O
of O O
enhancer O O
and O O
silencer O O
activities O O
( O O
enhancer O O
- O O
blocking O O
) O O
and O O
protect O O
genes O O
from O O
silencing O O
by O O
heterochromatinization O O
( O O
barrier O O
activity O O
) O O
. O O

Understanding O O
insulators O O
is O O
critical O O
to O O
elucidate O O
gene O O
regulatory O O
mechanisms O O
at O O
chromosomal O O
domain O O
levels O O
. O O

Here O O
, O O
we O O
focused O O
on O O
a O O
genomic O O
region O O
upstream O O
of O O
the O O
mouse O O
Ccnb1ip1 O O
( O O
cyclin O O
B1 O O
interacting O O
protein O O
1 O O
) O O
gene O O
that O O
was O O
methylated O O
in O O
E9 O O
. O O
5 O O
embryos B-CellLine B-CellLine
of O O
the O O
C57BL O O
/ O O
6 O O
strain O O
, O O
but O O
unmethylated O O
in O O
those O O
of O O
the O O
129X1 O O
/ O O
SvJ O O
and O O
JF1 O O
/ O O
Ms O O
strains O O
. O O

We O O
hypothesized O O
the O O
existence O O
of O O
an O O
insulator O O
- O O
type O O
element O O
that O O
prevents O O
the O O
spread O O
of O O
DNA O O
methylation O O
within O O
the O O
1 O O
. O O
8 O O
kbp O O
segment O O
, O O
and O O
actually O O
identified O O
a O O
242 O O
- O O
bp O O
and O O
a O O
185 O O
- O O
bp O O
fragments O O
that O O
were O O
located O O
adjacent O O
to O O
each O O
other O O
and O O
showed O O
insulator O O
and O O
enhancer O O
activities O O
, O O
respectively O O
, O O
in O O
reporter O O
assays O O
. O O

We O O
designated O O
these O O
genomic O O
regions O O
as O O
the O O
Ccnb1ip1 O O
insulator O O
and O O
the O O
Ccnb1ip1 O O
enhancer O O
. O O
We O O
designated O O
these O O
genomic O O
regions O O
as O O
the O O
Ccnb1ip1 O O
insulator O O
and O O
the O O
Ccnb1ip1 O O
enhancer O O
. O O

The O O
Ccnb1ip1 O O
insulator O O
showed O O
enhancer O O
- O O
blocking O O
activity O O
in O O
the O O
luciferase O O
assays O O
and O O
barrier O O
activity O O
in O O
the O O
colony O O
formation O O
assays O O
. O O

Further O O
examination O O
of O O
the O O
Ccnb1ip1 O O
locus O O
in O O
other O O
mammalian O O
species O O
revealed O O
that O O
the O O
insulator O O
and O O
enhancer O O
are O O
highly O O
conserved O O
among O O
a O O
wide O O
variety O O
of O O
species O O
, O O
and O O
are O O
located O O
immediately O O
upstream O O
of O O
the O O
transcriptional O O
start O O
site O O
of O O
Ccnb1ip1 O O
. O O
Further O O
examination O O
of O O
the O O
Ccnb1ip1 O O
locus O O
in O O
other O O
mammalian O O
species O O
revealed O O
that O O
the O O
insulator O O
and O O
enhancer O O
are O O
highly O O
conserved O O
among O O
a O O
wide O O
variety O O
of O O
species O O
, O O
and O O
are O O
located O O
immediately O O
upstream O O
of O O
the O O
transcriptional O O
start O O
site O O
of O O
Ccnb1ip1 O O
. O O

These O O
newly O O
identified O O
cis O O
- O O
elements O O
may O O
be O O
involved O O
in O O
transcriptional O O
regulation O O
of O O
Ccnb1ip1 O O
, O O
which O O
is O O
important O O
in O O
meiotic O O
crossing O O
- O O
over O O
and O O
G2 O O
/ O O
M O O
transition O O
of O O
the O O
mitotic O O
cell O O
cycle O O
. O O

Detection O O
of O O
Enhancer O O
- O O
Associated O O
Rearrangements O O
Reveals O O
Mechanisms O O
of O O
Oncogene O O
Dysregulation O O
in O O
B O O
- O O
cell O O
Lymphoma O O
. O O

UNLABELLED O O
: O O
B O O
- O O
cell O O
lymphomas O O
frequently O O
contain O O
genomic O O
rearrangements O O
that O O
lead O O
to O O
oncogene O O
activation O O
by O O
heterologous O O
distal O O
regulatory O O
elements O O
. O O

We O O
used O O
a O O
novel O O
approach O O
called O O
" O O
pinpointing O O
enhancer O O
- O O
associated O O
rearrangements O O
by O O
chromatin O O
immunoprecipitation O O
, O O
" O O
or O O
PEAR O O
- O O
ChIP O O
, O O
to O O
simultaneously O O
map O O
enhancer O O
activity O O
and O O
proximal O O
rearrangements O O
in O O
lymphoma B-CellLine B-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
and O O
patient O O
biopsies O O
. O O

This O O
method O O
detects O O
rearrangements O O
involving O O
known O O
cancer O O
genes O O
, O O
including O O
CCND1 O O
, O O
BCL2 O O
, O O
MYC O O
, O O
PDCD1LG2 O O
, O O
NOTCH1 O O
, O O
CIITA O O
, O O
and O O
SGK1 O O
, O O
as O O
well O O
as O O
novel O O
enhancer O O
duplication O O
events O O
of O O
likely O O
oncogenic O O
significance O O
. O O

We O O
identify O O
lymphoma O O
subtype O O
- O O
specific O O
enhancers O O
in O O
the O O
MYC O O
locus O O
that O O
are O O
silenced O O
in O O
lymphomas O O
with O O
MYC O O
- O O
activating O O
rearrangements O O
and O O
are O O
associated O O
with O O
germline O O
polymorphisms O O
that O O
alter O O
lymphoma O O
risk O O
. O O
We O O
identify O O
lymphoma O O
subtype O O
- O O
specific O O
enhancers O O
in O O
the O O
MYC O O
locus O O
that O O
are O O
silenced O O
in O O
lymphomas O O
with O O
MYC O O
- O O
activating O O
rearrangements O O
and O O
are O O
associated O O
with O O
germline O O
polymorphisms O O
that O O
alter O O
lymphoma O O
risk O O
. O O

We O O
show O O
that O O
BCL6 O O
- O O
locus O O
enhancers O O
are O O
acetylated O O
by O O
the O O
BCL6 O O
- O O
activating O O
transcription O O
factor O O
MEF2B O O
, O O
and O O
can O O
undergo O O
genomic O O
duplication O O
, O O
or O O
target O O
the O O
MYC O O
promoter O O
for O O
activation O O
in O O
the O O
context O O
of O O
a O O
" O O
pseudo O O
- O O
double O O
- O O
hit O O
" O O
t O O
( O O
3 O O
; O O
8 O O
) O O
( O O
q27 O O
; O O
q24 O O
) O O
rearrangement O O
linking O O
the O O
BCL6 O O
and O O
MYC O O
loci O O
. O O
We O O
show O O
that O O
BCL6 O O
- O O
locus O O
enhancers O O
are O O
acetylated O O
by O O
the O O
BCL6 O O
- O O
activating O O
transcription O O
factor O O
MEF2B O O
, O O
and O O
can O O
undergo O O
genomic O O
duplication O O
, O O
or O O
target O O
the O O
MYC O O
promoter O O
for O O
activation O O
in O O
the O O
context O O
of O O
a O O
" O O
pseudo O O
- O O
double O O
- O O
hit O O
" O O
t O O
( O O
3 O O
; O O
8 O O
) O O
( O O
q27 O O
; O O
q24 O O
) O O
rearrangement O O
linking O O
the O O
BCL6 O O
and O O
MYC O O
loci O O
. O O

Our O O
work O O
provides O O
novel O O
insights O O
regarding O O
enhancer O O
- O O
driven O O
oncogene O O
activation O O
in O O
lymphoma O O
. O O

SIGNIFICANCE O O
: O O
We O O
demonstrate O O
a O O
novel O O
approach O O
for O O
simultaneous O O
detection O O
of O O
genomic O O
rearrangements O O
and O O
enhancer O O
activity O O
in O O
tumor O O
biopsies O O
. O O

We O O
identify O O
novel O O
mechanisms O O
of O O
enhancer O O
- O O
driven O O
regulation O O
of O O
the O O
oncogenes O O
MYC O O
and O O
BCL6 O O
, O O
and O O
show O O
that O O
the O O
BCL6 O O
locus O O
can O O
serve O O
as O O
an O O
enhancer O O
donor O O
in O O
an O O
" O O
enhancer O O
hijacking O O
" O O
translocation O O
. O O
We O O
identify O O
novel O O
mechanisms O O
of O O
enhancer O O
- O O
driven O O
regulation O O
of O O
the O O
oncogenes O O
MYC O O
and O O
BCL6 O O
, O O
and O O
show O O
that O O
the O O
BCL6 O O
locus O O
can O O
serve O O
as O O
an O O
enhancer O O
donor O O
in O O
an O O
" O O
enhancer O O
hijacking O O
" O O
translocation O O
. O O

Tip60 O O
complex O O
binds O O
to O O
active O O
Pol O O
II O O
promoters O O
and O O
a O O
subset O O
of O O
enhancers O O
and O O
co O O
- O O
regulates O O
the O O
c O O
- O O
Myc O O
network O O
in O O
mouse O O
embryonic B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

BACKGROUND O O
: O O
Tip60 O O
( O O
KAT5 O O
) O O
is O O
the O O
histone O O
acetyltransferase O O
( O O
HAT O O
) O O
of O O
the O O
mammalian O O
Tip60 O O
/ O O
NuA4 O O
complex O O
. O O

While O O
Tip60 O O
is O O
important O O
for O O
early O O
mouse O O
development O O
and O O
mouse B-CellLine O
embryonic I-CellLine B-CellLine
stem I-CellLine I-CellLine
cell I-CellLine I-CellLine
( O O
mESC B-CellLine B-CellLine
) O O
pluripotency O O
, O O
the O O
function O O
of O O
Tip60 O O
as O O
reflected O O
in O O
a O O
genome O O
- O O
wide O O
context O O
is O O
not O O
yet O O
well O O
understood O O
. O O

RESULTS O O
: O O
Gel O O
filtration O O
of O O
nuclear O O
mESCs B-CellLine B-CellLine
extracts O O
indicate O O
incorporation O O
of O O
Tip60 O O
into O O
large O O
molecular O O
complexes O O
and O O
exclude O O
the O O
existence O O
of O O
large O O
quantities O O
of O O
" O O
free O O
" O O
Tip60 O O
within O O
the O O
nuclei O O
of O O
ESCs B-CellLine B-CellLine
. O O

Thus O O
, O O
monitoring O O
of O O
Tip60 O O
binding O O
to O O
the O O
genome O O
should O O
reflect O O
the O O
behaviour O O
of O O
Tip60 O O
- O O
containing O O
complexes O O
. O O

The O O
genome O O
- O O
wide O O
mapping O O
of O O
Tip60 O O
binding O O
in O O
mESCs B-CellLine B-CellLine
by O O
chromatin O O
immunoprecipitation O O
( O O
ChIP O O
) O O
coupled O O
with O O
high O O
- O O
throughput O O
sequencing O O
( O O
ChIP O O
- O O
seq O O
) O O
shows O O
that O O
the O O
Tip60 O O
complex O O
is O O
present O O
at O O
promoter O O
regions O O
of O O
predominantly O O
active O O
genes O O
that O O
are O O
bound O O
by O O
RNA O O
polymerase O O
II O O
( O O
Pol O O
II O O
) O O
and O O
contain O O
the O O
H3K4me3 O O
histone O O
mark O O
. O O

The O O
coactivator O O
HAT O O
complexes O O
, O O
Tip60 O O
- O O
and O O
Mof O O
( O O
KAT8 O O
) O O
- O O
containing O O
( O O
NSL O O
and O O
MSL O O
) O O
, O O
show O O
a O O
global O O
overlap O O
at O O
promoters O O
, O O
whereas O O
distinct O O
binding O O
profiles O O
at O O
enhancers O O
suggest O O
different O O
regulatory O O
functions O O
of O O
each O O
essential O O
HAT O O
complex O O
. O O

Interestingly O O
, O O
Tip60 O O
enrichment O O
peaks O O
at O O
about O O
200 O O
bp O O
downstream O O
of O O
the O O
transcription O O
start O O
sites O O
suggesting O O
a O O
function O O
for O O
the O O
Tip60 O O
complexes O O
in O O
addition O O
to O O
histone O O
acetylation O O
. O O

The O O
comparison O O
of O O
genome O O
- O O
wide O O
binding O O
profiles O O
of O O
Tip60 O O
and O O
c O O
- O O
Myc O O
, O O
a O O
somatic O O
cell O O
reprogramming O O
factor O O
that O O
binds O O
predominantly O O
to O O
active O O
genes O O
in O O
mESCs B-CellLine B-CellLine
, O O
demonstrate O O
that O O
Tip60 O O
and O O
c O O
- O O
Myc O O
co O O
- O O
bind O O
at O O
50 O O
- O O
60 O O
% O O
of O O
their O O
binding O O
sites O O
. O O
The O O
comparison O O
of O O
genome O O
- O O
wide O O
binding O O
profiles O O
of O O
Tip60 O O
and O O
c O O
- O O
Myc O O
, O O
a O O
somatic O O
cell O O
reprogramming O O
factor O O
that O O
binds O O
predominantly O O
to O O
active O O
genes O O
in O O
mESCs B-CellLine B-CellLine
, O O
demonstrate O O
that O O
Tip60 O O
and O O
c O O
- O O
Myc O O
co O O
- O O
bind O O
at O O
50 O O
- O O
60 O O
% O O
of O O
their O O
binding O O
sites O O
. O O

We O O
also O O
show O O
that O O
the O O
Tip60 O O
complex O O
binds O O
to O O
a O O
subset O O
of O O
bivalent O O
developmental O O
genes O O
and O O
defines O O
a O O
set O O
of O O
mESC B-CellLine B-CellLine
- O O
specific O O
enhancer O O
as O O
well O O
as O O
super O O
- O O
enhancer O O
regions O O
. O O

CONCLUSIONS O O
: O O
Our O O
study O O
suggests O O
that O O
the O O
Tip60 O O
complex O O
functions O O
as O O
a O O
global O O
transcriptional O O
co O O
- O O
activator O O
at O O
most O O
active O O
Pol O O
II O O
promoters O O
, O O
co O O
- O O
regulates O O
the O O
ESC B-CellLine B-CellLine
- O O
specific O O
c O O
- O O
Myc O O
network O O
, O O
important O O
for O O
ESC B-CellLine B-CellLine
self O O
- O O
renewal O O
and O O
cell O O
metabolism O O
and O O
acts O O
at O O
a O O
subset O O
of O O
active O O
distal O O
regulatory O O
elements O O
, O O
or O O
super O O
enhancers O O
, O O
in O O
mESCs B-CellLine B-CellLine
. O O

Enhancer O O
Turnover O O
Is O O
Associated O O
with O O
a O O
Divergent O O
Transcriptional O O
Response O O
to O O
Glucocorticoid O O
in O O
Mouse O O
and O O
Human O O
Macrophages B-CellLine B-CellLine
. O O

Phenotypic O O
differences O O
between O O
individuals O O
and O O
species O O
are O O
controlled O O
in O O
part O O
through O O
differences O O
in O O
expression O O
of O O
a O O
relatively O O
conserved O O
set O O
of O O
genes O O
. O O

Genes O O
expressed O O
in O O
the O O
immune B-CellLine B-CellLine
system I-CellLine I-CellLine
are O O
subject O O
to O O
especially O O
powerful O O
selection O O
. O O

We O O
have O O
investigated O O
the O O
evolution O O
of O O
both O O
gene O O
expression O O
and O O
candidate O O
enhancers O O
in O O
human O O
and O O
mouse O O
macrophages B-CellLine B-CellLine
exposed O O
to O O
glucocorticoid O O
( O O
GC O O
) O O
, O O
a O O
regulator O O
of O O
innate O O
immunity O O
and O O
an O O
important O O
therapeutic O O
agent O O
. O O

Our O O
analyses O O
revealed O O
a O O
very O O
limited O O
overlap O O
in O O
the O O
repertoire O O
of O O
genes O O
responsive O O
to O O
GC O O
in O O
human O O
and O O
mouse O O
macrophages B-CellLine B-CellLine
. O O

Peaks O O
of O O
inducible O O
binding O O
of O O
the O O
GC O O
receptor O O
( O O
GR O O
) O O
detected O O
by O O
chromatin O O
immunoprecipitation O O
- O O
Seq O O
correlated O O
with O O
induction O O
, O O
but O O
not O O
repression O O
, O O
of O O
target O O
genes O O
in O O
both O O
species O O
, O O
occurred O O
at O O
distal O O
regulatory O O
sites O O
not O O
promoters O O
, O O
and O O
were O O
strongly O O
enriched O O
for O O
the O O
consensus O O
GR O O
- O O
binding O O
motif O O
. O O

Turnover O O
of O O
GR O O
binding O O
between O O
mice O O
and O O
humans O O
was O O
associated O O
with O O
gain O O
and O O
loss O O
of O O
the O O
motif O O
. O O

There O O
was O O
no O O
detectable O O
signal O O
of O O
positive O O
selection O O
at O O
species O O
- O O
specific O O
GR O O
binding O O
sites O O
, O O
but O O
clear O O
evidence O O
of O O
purifying O O
selection O O
at O O
the O O
small O O
number O O
of O O
conserved O O
sites O O
. O O

We O O
conclude O O
that O O
enhancer O O
divergence O O
underlies O O
the O O
difference O O
in O O
transcriptional O O
activation O O
after O O
GC O O
treatment O O
between O O
mouse O O
and O O
human O O
macrophages B-CellLine B-CellLine
. O O

Only O O
the O O
shared O O
inducible O O
loci O O
show O O
evidence O O
of O O
selection O O
, O O
and O O
therefore O O
these O O
loci O O
may O O
be O O
important O O
for O O
the O O
subset O O
of O O
responses O O
to O O
GC O O
that O O
is O O
shared O O
between O O
species O O
. O O

Dynamic O O
recruitment O O
of O O
Ets1 O O
to O O
both O O
nucleosome O O
- O O
occupied O O
and O O
- O O
depleted O O
enhancer O O
regions O O
mediates O O
a O O
transcriptional O O
program O O
switch O O
during O O
early O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
differentiation O O
. O O
Ets1 O O
is O O
a O O
sequence O O
- O O
specific O O
transcription O O
factor O O
that O O
plays O O
an O O
important O O
role O O
during O O
hematopoiesis O O
, O O
and O O
is O O
essential O O
for O O
the O O
transition O O
of O O
CD4 B-CellLine B-CellLine
( I-CellLine O
- I-CellLine O
) I-CellLine O
/ I-CellLine O
CD8 I-CellLine O
( I-CellLine O
- I-CellLine O
) I-CellLine O
double I-CellLine O
negative I-CellLine O
( O O
DN B-CellLine O
) O O
to O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
/ I-CellLine I-CellLine
CD8 I-CellLine I-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
double I-CellLine I-CellLine
positive I-CellLine I-CellLine
( I-CellLine I-CellLine
DP I-CellLine I-CellLine
) I-CellLine I-CellLine
thymocytes I-CellLine I-CellLine
. O O

Using O O
genome O O
- O O
wide O O
and O O
functional O O
approaches O O
, O O
we O O
investigated O O
the O O
binding O O
properties O O
, O O
transcriptional O O
role O O
and O O
chromatin O O
environment O O
of O O
Ets1 O O
during O O
this O O
transition O O
. O O

We O O
found O O
that O O
while O O
Ets1 O O
binding O O
at O O
distal O O
sites O O
was O O
associated O O
with O O
active O O
genes O O
at O O
both O O
DN B-CellLine O
and O O
DP B-CellLine O
stages O O
, O O
its O O
enhancer O O
activity O O
was O O
attained O O
at O O
the O O
DP B-CellLine O
stage O O
, O O
as O O
reflected O O
by O O
levels O O
of O O
the O O
core O O
transcriptional O O
hallmarks O O
H3K4me1 O O
/ O O
3 O O
, O O
RNA O O
Polymerase O O
II O O
and O O
eRNA O O
. O O

This O O
dual O O
, O O
stage O O
- O O
specific O O
ability O O
reflected O O
a O O
switch O O
from O O
non O O
- O O
T O O
hematopoietic O O
toward O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
specific O O
gene O O
expression O O
programs O O
during O O
the O O
DN B-CellLine O
- O O
to O O
- O O
DP B-CellLine O
transition O O
, O O
as O O
indicated O O
by O O
transcriptome O O
analyses O O
of O O
Ets1 B-CellLine B-CellLine
( I-CellLine I-CellLine
- I-CellLine I-CellLine
/ I-CellLine I-CellLine
- I-CellLine I-CellLine
) I-CellLine I-CellLine
thymic I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Coincidentally O O
, O O
Ets1 O O
associates O O
more O O
specifically O O
with O O
Runx1 O O
in O O
DN O O
and O O
with O O
TCF1 O O
in O O
DP B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

We O O
also O O
provide O O
evidence O O
that O O
Ets1 O O
predominantly O O
binds O O
distal O O
nucleosome O O
- O O
occupied O O
regions O O
in O O
DN B-CellLine O
and O O
nucleosome O O
- O O
depleted O O
regions O O
in O O
DP B-CellLine O
. O O

Finally O O
and O O
importantly O O
, O O
we O O
demonstrate O O
that O O
Ets1 O O
induces O O
chromatin O O
remodeling O O
by O O
displacing O O
H3K4me1 O O
- O O
marked O O
nucleosomes O O
. O O

Our O O
results O O
thus O O
provide O O
an O O
original O O
model O O
whereby O O
the O O
ability O O
of O O
a O O
transcription O O
factor O O
to O O
bind O O
nucleosomal O O
DNA O O
changes O O
during O O
differentiation O O
with O O
consequences O O
on O O
its O O
cognate O O
enhancer O O
activity O O
. O O

Deposition O O
of O O
5 O O
- O O
Methylcytosine O O
on O O
Enhancer O O
RNAs O O
Enables O O
the O O
Coactivator O O
Function O O
of O O
PGC O O
- O O
1alpha O O
. O O

The O O
Peroxisome O O
proliferator O O
- O O
activated O O
receptor O O
- O O
gamma O O
coactivator O O
1 O O
alpha O O
( O O
PGC O O
- O O
1alpha O O
) O O
is O O
a O O
transcriptional O O
co O O
- O O
activator O O
that O O
plays O O
a O O
central O O
role O O
in O O
adapted O O
metabolic O O
responses O O
. O O
PGC O O
- O O
1alpha O O
is O O
dynamically O O
methylated O O
and O O
unmethylated O O
at O O
the O O
residue O O
K779 O O
by O O
the O O
methyltransferase O O
SET7 O O
/ O O
9 O O
and O O
the O O
Lysine O O
Specific O O
Demethylase O O
1A O O
( O O
LSD1 O O
) O O
, O O
respectively O O
. O O

Interactions O O
of O O
methylated O O
PGC O O
- O O
1alpha O O
[ O O
K779me O O
] O O
with O O
the O O
Spt O O
- O O
Ada O O
- O O
Gcn5 O O
- O O
acetyltransferase O O
( O O
SAGA O O
) O O
complex O O
, O O
the O O
Mediator O O
members O O
MED1 O O
and O O
MED17 O O
, O O
and O O
the O O
NOP2 O O
/ O O
Sun O O
RNA O O
methytransferase O O
7 O O
( O O
NSUN7 O O
) O O
reinforce O O
transcription O O
, O O
and O O
are O O
concomitant O O
with O O
the O O
m O O
( O O
5 O O
) O O
C O O
mark O O
on O O
enhancer O O
RNAs O O
( O O
eRNAs O O
) O O
. O O

Consistently O O
, O O
loss O O
of O O
Set7 O O
/ O O
9 O O
and O O
NSun7 O O
in O O
liver B-CellLine B-CellLine
cell I-CellLine I-CellLine
model O O
systems O O
resulted O O
in O O
depletion O O
of O O
the O O
PGC O O
- O O
1alpha O O
target O O
genes O O
Pfkl O O
, O O
Sirt5 O O
, O O
Idh3b O O
, O O
and O O
Hmox2 O O
, O O
which O O
was O O
accompanied O O
by O O
a O O
decrease O O
in O O
the O O
eRNAs O O
levels O O
associated O O
with O O
these O O
loci O O
. O O

Enrichment O O
of O O
m O O
( O O
5 O O
) O O
C O O
within O O
eRNA O O
species O O
coincides O O
with O O
metabolic O O
stress O O
of O O
fasting O O
in O O
vivo O O
. O O

Collectively O O
, O O
these O O
findings O O
illustrate O O
the O O
complex O O
epigenetic O O
circuitry O O
imposed O O
by O O
PGC O O
- O O
1alpha O O
at O O
the O O
eRNA O O
level O O
to O O
fine O O
- O O
tune O O
energy O O
metabolism O O
. O O

A O O
p53 O O
- O O
bound O O
enhancer O O
region O O
controls O O
a O O
long O O
intergenic O O
noncoding O O
RNA O O
required O O
for O O
p53 O O
stress O O
response O O
. O O
A O O
p53 O O
- O O
bound O O
enhancer O O
region O O
controls O O
a O O
long O O
intergenic O O
noncoding O O
RNA O O
required O O
for O O
p53 O O
stress O O
response O O
. O O

Genome O O
- O O
wide O O
chromatin O O
studies O O
identified O O
the O O
tumor O O
suppressor O O
p53 O O
as O O
both O O
a O O
promoter O O
and O O
an O O
enhancer O O
- O O
binding O O
transcription O O
factor O O
. O O

As O O
an O O
enhancer O O
factor O O
, O O
p53 O O
can O O
induce O O
local O O
production O O
of O O
enhancer O O
RNAs O O
, O O
as O O
well O O
as O O
transcriptional O O
activation O O
of O O
distal O O
neighboring O O
genes O O
. O O

Beyond O O
the O O
regulation O O
of O O
protein O O
- O O
coding O O
genes O O
, O O
p53 O O
has O O
the O O
capacity O O
to O O
regulate O O
long O O
intergenic O O
noncoding O O
RNA O O
molecules O O
( O O
lincRNAs O O
) O O
; O O
however O O
, O O
their O O
importance O O
to O O
the O O
p53 O O
tumor O O
suppressive O O
function O O
remains O O
poorly O O
characterized O O
. O O

Here O O
, O O
we O O
identified O O
and O O
characterized O O
a O O
novel O O
p53 O O
- O O
bound O O
intronic O O
enhancer O O
that O O
controls O O
the O O
expression O O
of O O
its O O
host O O
, O O
the O O
lincRNA00475 O O
( O O
linc O O
- O O
475 O O
) O O
. O O
Here O O
, O O
we O O
identified O O
and O O
characterized O O
a O O
novel O O
p53 O O
- O O
bound O O
intronic O O
enhancer O O
that O O
controls O O
the O O
expression O O
of O O
its O O
host O O
, O O
the O O
lincRNA00475 O O
( O O
linc O O
- O O
475 O O
) O O
. O O

We O O
demonstrate O O
the O O
requirement O O
of O O
linc O O
- O O
475 O O
for O O
the O O
proper O O
induction O O
of O O
a O O
p53 O O
- O O
dependent O O
cell O O
cycle O O
inhibitory O O
response O O
. O O

We O O
further O O
confirm O O
the O O
functional O O
importance O O
of O O
linc O O
- O O
475 O O
in O O
the O O
maintenance O O
of O O
CDKN1A O O
/ O O
p21 O O
levels O O
, O O
a O O
cell O O
cycle O O
inhibitor O O
and O O
a O O
major O O
p53 O O
target O O
gene O O
, O O
following O O
p53 O O
activation O O
. O O

Interestingly O O
, O O
loss O O
of O O
linc O O
- O O
475 O O
reduced O O
the O O
binding O O
of O O
both O O
p53 O O
and O O
RNA O O
polymerase O O
II O O
( O O
RNAPII O O
) O O
to O O
the O O
promoter O O
of O O
p21 O O
, O O
attenuating O O
its O O
transcription O O
rate O O
following O O
p53 O O
activation O O
. O O
Interestingly O O
, O O
loss O O
of O O
linc O O
- O O
475 O O
reduced O O
the O O
binding O O
of O O
both O O
p53 O O
and O O
RNA O O
polymerase O O
II O O
( O O
RNAPII O O
) O O
to O O
the O O
promoter O O
of O O
p21 O O
, O O
attenuating O O
its O O
transcription O O
rate O O
following O O
p53 O O
activation O O
. O O

Altogether O O
, O O
our O O
data O O
suggest O O
a O O
direct O O
role O O
of O O
p53 O O
- O O
bound O O
enhancer O O
domains O O
in O O
the O O
activation O O
of O O
lincRNAs O O
required O O
for O O
an O O
efficient O O
p53 O O
transcriptional O O
response O O
. O O
Altogether O O
, O O
our O O
data O O
suggest O O
a O O
direct O O
role O O
of O O
p53 O O
- O O
bound O O
enhancer O O
domains O O
in O O
the O O
activation O O
of O O
lincRNAs O O
required O O
for O O
an O O
efficient O O
p53 O O
transcriptional O O
response O O
. O O

Enhanced O O
Identification O O
of O O
Transcriptional O O
Enhancers O O
Provides O O
Mechanistic O O
Insights O O
into O O
Diseases O O
. O O

Enhancers O O
are O O
distal O O
cis O O
- O O
regulatory O O
DNA O O
elements O O
that O O
increase O O
the O O
expression O O
of O O
target O O
genes O O
. O O

Various O O
experimental O O
and O O
computational O O
approaches O O
including O O
chromatin O O
signature O O
profiling O O
have O O
been O O
developed O O
to O O
predict O O
enhancers O O
on O O
a O O
genome O O
- O O
wide O O
scale O O
, O O
although O O
each O O
method O O
has O O
its O O
advantages O O
and O O
disadvantages O O
. O O

Here O O
we O O
overview O O
an O O
emerging O O
method O O
to O O
identify O O
transcribed O O
enhancers O O
at O O
exceedingly O O
high O O
nucleotide O O
resolution O O
based O O
on O O
enhancer O O
RNA O O
transcripts O O
captured O O
by O O
Cap O O
Analysis O O
of O O
Gene O O
Expression O O
( O O
CAGE O O
) O O
technology O O
. O O

We O O
further O O
argue O O
that O O
disease O O
- O O
causative O O
regulatory O O
mutations O O
at O O
enhancers O O
are O O
increasingly O O
recognized O O
, O O
emphasizing O O
the O O
importance O O
of O O
enhancer O O
identification O O
in O O
functional O O
and O O
clinical O O
genomics O O
including O O
, O O
but O O
not O O
limited O O
to O O
, O O
genome O O
- O O
wide O O
association O O
studies O O
( O O
GWASs O O
) O O
and O O
cancer O O
genomics O O
studies O O
. O O

E2F O O
/ O O
Rb O O
Family O O
Proteins O O
Mediate O O
Interferon O O
Induced O O
Repression O O
of O O
Adenovirus O O
Immediate O O
Early O O
Transcription O O
to O O
Promote O O
Persistent O O
Viral O O
Infection O O
. O O

Interferons O O
( O O
IFNs O O
) O O
are O O
cytokines O O
that O O
have O O
pleiotropic O O
effects O O
and O O
play O O
important O O
roles O O
in O O
innate O O
and O O
adaptive O O
immunity O O
. O O

IFNs O O
have O O
broad O O
antiviral O O
properties O O
and O O
function O O
by O O
different O O
mechanisms O O
. O O

IFNs O O
fail O O
to O O
inhibit O O
wild O O
- O O
type O O
Adenovirus O O
( O O
Ad O O
) O O
replication O O
in O O
established O O
cancer B-CellLine B-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
. O O

In O O
this O O
study O O
, O O
we O O
analyzed O O
the O O
effects O O
of O O
IFNs O O
on O O
Ad O O
replication O O
in O O
normal O O
human O O
cells O O
. O O

Our O O
data O O
demonstrate O O
that O O
both O O
IFNalpha O O
and O O
IFNgamma O O
blocked O O
wild O O
- O O
type O O
Ad5 O O
replication O O
in O O
primary B-CellLine O
human I-CellLine O
bronchial I-CellLine B-CellLine
epithelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
NHBEC B-CellLine B-CellLine
) O O
and O O
TERT B-CellLine O
- I-CellLine O
immortalized I-CellLine O
normal I-CellLine O
human I-CellLine O
diploid I-CellLine O
fibroblasts I-CellLine B-CellLine
( O O
HDF B-CellLine B-CellLine
- I-CellLine O
TERT I-CellLine O
) O O
. O O
Our O O
data O O
demonstrate O O
that O O
both O O
IFNalpha O O
and O O
IFNgamma O O
blocked O O
wild O O
- O O
type O O
Ad5 O O
replication O O
in O O
primary B-CellLine O
human I-CellLine O
bronchial I-CellLine B-CellLine
epithelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
NHBEC B-CellLine B-CellLine
) O O
and O O
TERT B-CellLine O
- I-CellLine O
immortalized I-CellLine O
normal I-CellLine O
human I-CellLine O
diploid I-CellLine O
fibroblasts I-CellLine B-CellLine
( O O
HDF B-CellLine B-CellLine
- I-CellLine O
TERT I-CellLine O
) O O
. O O

IFNs O O
inhibited O O
the O O
replication O O
of O O
divergent O O
adenoviruses O O
. O O

The O O
inhibition O O
of O O
Ad5 O O
replication O O
by O O
IFNalpha O O
and O O
IFNgamma O O
is O O
the O O
consequence O O
of O O
repression O O
of O O
transcription O O
of O O
the O O
E1A O O
immediate O O
early O O
gene O O
product O O
. O O

Both O O
IFNalpha O O
and O O
IFNgamma O O
impede O O
the O O
association O O
of O O
the O O
transactivator O O
GABP O O
with O O
the O O
E1A O O
enhancer O O
region O O
during O O
the O O
early O O
phase O O
of O O
infection O O
. O O

The O O
repression O O
of O O
E1A O O
expression O O
by O O
IFNs O O
requires O O
a O O
conserved O O
E2F O O
binding O O
site O O
in O O
the O O
E1A O O
enhancer O O
, O O
and O O
IFNs O O
increased O O
the O O
enrichment O O
of O O
the O O
E2F O O
- O O
associated O O
pocket O O
proteins O O
, O O
Rb O O
and O O
p107 O O
, O O
at O O
the O O
E1A O O
enhancer O O
in O O
vivo O O
. O O
The O O
repression O O
of O O
E1A O O
expression O O
by O O
IFNs O O
requires O O
a O O
conserved O O
E2F O O
binding O O
site O O
in O O
the O O
E1A O O
enhancer O O
, O O
and O O
IFNs O O
increased O O
the O O
enrichment O O
of O O
the O O
E2F O O
- O O
associated O O
pocket O O
proteins O O
, O O
Rb O O
and O O
p107 O O
, O O
at O O
the O O
E1A O O
enhancer O O
in O O
vivo O O
. O O

PD0332991 O O
( O O
Pabociclib O O
) O O
, O O
a O O
specific O O
CDK4 O O
/ O O
6 O O
inhibitor O O
, O O
dephosphoryles O O
pocket O O
proteins O O
to O O
promote O O
their O O
interaction O O
with O O
E2Fs O O
and O O
inhibited O O
wild O O
- O O
type O O
Ad5 O O
replication O O
dependent O O
on O O
the O O
conserved O O
E2F O O
binding O O
site O O
. O O

Consistent O O
with O O
this O O
result O O
, O O
expression O O
of O O
the O O
small O O
E1A O O
oncoprotein O O
, O O
which O O
abrogates O O
E2F O O
/ O O
pocket O O
protein O O
interactions O O
, O O
rescued O O
Ad O O
replication O O
in O O
the O O
presence O O
of O O
IFNalpha O O
or O O
IFNgamma O O
. O O

Finally O O
, O O
we O O
established O O
a O O
persistent O O
Ad O O
infection O O
model O O
in O O
vitro O O
and O O
demonstrated O O
that O O
IFNgamma O O
suppresses O O
productive O O
Ad O O
replication O O
in O O
a O O
manner O O
dependent O O
on O O
the O O
E2F O O
binding O O
site O O
in O O
the O O
E1A O O
enhancer O O
. O O
Finally O O
, O O
we O O
established O O
a O O
persistent O O
Ad O O
infection O O
model O O
in O O
vitro O O
and O O
demonstrated O O
that O O
IFNgamma O O
suppresses O O
productive O O
Ad O O
replication O O
in O O
a O O
manner O O
dependent O O
on O O
the O O
E2F O O
binding O O
site O O
in O O
the O O
E1A O O
enhancer O O
. O O

This O O
is O O
the O O
first O O
study O O
that O O
probes O O
the O O
molecular O O
basis O O
of O O
persistent O O
adenovirus O O
infection O O
and O O
reveals O O
a O O
novel O O
mechanism O O
by O O
which O O
adenoviruses O O
utilize O O
IFN O O
signaling O O
to O O
suppress O O
lytic O O
virus O O
replication O O
and O O
to O O
promote O O
persistent O O
infection O O
. O O

Looking O O
beyond O O
GWAS O O
: O O
allele O O
- O O
specific O O
transcription O O
factor O O
binding O O
drives O O
the O O
association O O
of O O
GALNT2 O O
to O O
HDL O O
- O O
C O O
plasma O O
levels O O
. O O

BACKGROUND O O
: O O
Plasma O O
levels O O
of O O
high O O
- O O
density O O
lipoprotein O O
cholesterol O O
( O O
HDL O O
- O O
C O O
) O O
have O O
been O O
associated O O
to O O
cardiovascular O O
disease O O
. O O

The O O
high O O
heritability O O
of O O
HDL O O
- O O
C O O
plasma O O
levels O O
has O O
been O O
an O O
incentive O O
for O O
several O O
genome O O
wide O O
association O O
studies O O
( O O
GWASs O O
) O O
which O O
identified O O
, O O
among O O
others O O
, O O
variants O O
in O O
the O O
first O O
intron O O
of O O
the O O
GALNT2 O O
gene O O
strongly O O
associated O O
to O O
HDL O O
- O O
C O O
levels O O
. O O

However O O
, O O
the O O
lead O O
GWAS O O
SNP O O
associated O O
to O O
HDL O O
- O O
C O O
levels O O
in O O
this O O
genomic O O
region O O
, O O
rs4846914 O O
, O O
is O O
located O O
outside O O
of O O
transcription O O
factor O O
( O O
TF O O
) O O
binding O O
sites O O
defined O O
by O O
chromatin O O
immunoprecipitation O O
followed O O
by O O
DNA O O
sequencing O O
( O O
ChIP O O
- O O
seq O O
) O O
experiments O O
in O O
the O O
ENCODE O O
project O O
and O O
is O O
therefore O O
unlikely O O
to O O
be O O
functional O O
. O O

In O O
this O O
study O O
we O O
apply O O
a O O
bioinformatics O O
approach O O
which O O
rely O O
on O O
the O O
premise O O
that O O
ChIP O O
- O O
seq O O
reads O O
can O O
identify O O
allele O O
specific O O
binding O O
of O O
a O O
TF O O
at O O
cell O O
specific O O
regulatory O O
elements O O
harboring O O
allele O O
specific O O
SNPs O O
( O O
AS O O
- O O
SNPs O O
) O O
. O O

EMSA O O
and O O
luciferase O O
assays O O
were O O
used O O
to O O
validate O O
the O O
allele O O
specific O O
binding O O
and O O
to O O
test O O
the O O
enhancer O O
activity O O
of O O
the O O
regulatory O O
element O O
harboring O O
the O O
AS O O
- O O
SNP O O
rs4846913 O O
as O O
well O O
as O O
the O O
neighboring O O
rs2144300 O O
which O O
are O O
in O O
high O O
LD O O
with O O
rs4846914 O O
. O O
EMSA O O
and O O
luciferase O O
assays O O
were O O
used O O
to O O
validate O O
the O O
allele O O
specific O O
binding O O
and O O
to O O
test O O
the O O
enhancer O O
activity O O
of O O
the O O
regulatory O O
element O O
harboring O O
the O O
AS O O
- O O
SNP O O
rs4846913 O O
as O O
well O O
as O O
the O O
neighboring O O
rs2144300 O O
which O O
are O O
in O O
high O O
LD O O
with O O
rs4846914 O O
. O O

FINDINGS O O
: O O
Using O O
luciferase O O
assays O O
we O O
found O O
that O O
rs4846913 O O
and O O
the O O
neighboring O O
rs2144300 O O
displayed O O
allele O O
specific O O
enhancer O O
activity O O
. O O
FINDINGS O O
: O O
Using O O
luciferase O O
assays O O
we O O
found O O
that O O
rs4846913 O O
and O O
the O O
neighboring O O
rs2144300 O O
displayed O O
allele O O
specific O O
enhancer O O
activity O O
. O O

We O O
propose O O
that O O
an O O
inhibitor O O
binds O O
preferentially O O
to O O
the O O
rs4846913 O O
- O O
C O O
allele O O
with O O
an O O
inhibitory O O
boost O O
from O O
the O O
synergistic O O
binding O O
of O O
other O O
TFs O O
at O O
the O O
neighboring O O
SNP O O
rs2144300 O O
. O O

These O O
events O O
influence O O
the O O
transcription O O
level O O
of O O
GALNT2 O O
. O O

CONCLUSIONS O O
: O O
The O O
results O O
suggest O O
that O O
rs4846913 O O
and O O
rs2144300 O O
drive O O
the O O
association O O
to O O
HDL O O
- O O
C O O
plasma O O
levels O O
through O O
an O O
inhibitory O O
regulation O O
of O O
GALNT2 O O
rather O O
than O O
the O O
reported O O
lead O O
GWAS O O
SNP O O
rs4846914 O O
. O O

Super O O
enhancers O O
at O O
the O O
miR O O
- O O
146a O O
and O O
miR O O
- O O
155 O O
genes O O
contribute O O
to O O
self O O
- O O
regulation O O
of O O
inflammation O O
. O O
Super O O
enhancers O O
at O O
the O O
miR O O
- O O
146a O O
and O O
miR O O
- O O
155 O O
genes O O
contribute O O
to O O
self O O
- O O
regulation O O
of O O
inflammation O O
. O O

Inflammatory O O
response O O
is O O
essential O O
to O O
host O O
defense O O
and O O
repair O O
, O O
and O O
requires O O
tight O O
regulation O O
as O O
excessive O O
and O O
constant O O
inflammatory O O
response O O
is O O
deleterious O O
. O O

We O O
recently O O
identified O O
that O O
one O O
of O O
the O O
general O O
but O O
key O O
mechanisms O O
for O O
inflammatory O O
gene O O
transcription O O
regulation O O
is O O
controlled O O
by O O
the O O
formation O O
of O O
super O O
enhancers O O
mediated O O
by O O
NF O O
- O O
kappaB O O
, O O
and O O
bromodomain O O
and O O
extraterminal O O
( O O
BET O O
) O O
proteins O O
. O O

Given O O
that O O
microRNA O O
transcription O O
shares O O
a O O
similar O O
mechanism O O
to O O
mRNA O O
, O O
we O O
assume O O
that O O
the O O
inflammatory O O
microRNAs O O
transcription O O
could O O
be O O
NF O O
- O O
kappaB O O
and O O
BET O O
bromodomain O O
dependent O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
confirmed O O
that O O
inflammatory O O
stimuli O O
changed O O
human B-CellLine O
umbilical I-CellLine B-CellLine
vein I-CellLine I-CellLine
endothelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
HUVEC B-CellLine B-CellLine
) O O
microRNA O O
profile O O
. O O

Among O O
these O O
microRNAs O O
, O O
miR O O
- O O
146a O O
and O O
miR O O
- O O
155 O O
, O O
two O O
well O O
- O O
established O O
inflammatory O O
microRNAs O O
, O O
are O O
both O O
downregulated O O
at O O
transcriptional O O
level O O
by O O
NF O O
- O O
kappaB O O
and O O
BET O O
bromodomain O O
inhibition O O
. O O

To O O
pursue O O
this O O
mechanism O O
, O O
we O O
analyzed O O
the O O
ChIP O O
- O O
seq O O
data O O
and O O
found O O
that O O
NF O O
- O O
kappaB O O
, O O
BRD4 O O
and O O
RNA O O
POL O O
II O O
were O O
rapidly O O
distributed O O
at O O
the O O
upstream O O
regions O O
of O O
miR O O
- O O
146a O O
and O O
miR O O
- O O
155 O O
, O O
and O O
more O O
importantly O O
mediated O O
the O O
formation O O
of O O
the O O
super O O
enhancers O O
that O O
drive O O
miR O O
- O O
146a O O
and O O
miR O O
- O O
155 O O
transcription O O
. O O
To O O
pursue O O
this O O
mechanism O O
, O O
we O O
analyzed O O
the O O
ChIP O O
- O O
seq O O
data O O
and O O
found O O
that O O
NF O O
- O O
kappaB O O
, O O
BRD4 O O
and O O
RNA O O
POL O O
II O O
were O O
rapidly O O
distributed O O
at O O
the O O
upstream O O
regions O O
of O O
miR O O
- O O
146a O O
and O O
miR O O
- O O
155 O O
, O O
and O O
more O O
importantly O O
mediated O O
the O O
formation O O
of O O
the O O
super O O
enhancers O O
that O O
drive O O
miR O O
- O O
146a O O
and O O
miR O O
- O O
155 O O
transcription O O
. O O

These O O
microRNAs O O
transcription O O
driven O O
by O O
super O O
enhancers O O
in O O
turn O O
downregulate O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
canonical O O
inflammatory O O
genes O O
expression O O
through O O
targeting O O
inflammatory O O
mediators O O
. O O

This O O
novel O O
finding O O
demonstrated O O
how O O
the O O
host O O
self O O
- O O
regulates O O
inflammatory O O
genes O O
expression O O
at O O
both O O
transcriptional O O
and O O
post O O
- O O
transcriptional O O
level O O
to O O
ensure O O
the O O
appropriate O O
level O O
of O O
the O O
host O O
inflammatory O O
response O O
. O O

Deciphering O O
the O O
importance O O
of O O
the O O
palindromic O O
architecture O O
of O O
the O O
immunoglobulin O O
heavy O O
- O O
chain O O
3 O O
' O O
regulatory O O
region O O
. O O

The O O
IgH O O
3 O O
' O O
regulatory O O
region O O
( O O
3 O O
' O O
RR O O
) O O
controls O O
class O O
switch O O
recombination O O
( O O
CSR O O
) O O
and O O
somatic O O
hypermutation O O
( O O
SHM O O
) O O
in O O
B B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

The O O
mouse O O
3 O O
' O O
RR O O
contains O O
four O O
enhancer O O
elements O O
with O O
hs1 O O
, O O
2 O O
flanked O O
by O O
inverted O O
repeated O O
sequences O O
and O O
the O O
centre O O
of O O
a O O
25 O O
- O O
kb O O
palindrome O O
bounded O O
by O O
two O O
hs3 O O
enhancer O O
inverted O O
copies O O
( O O
hs3a O O
and O O
hs3b O O
) O O
. O O
hs4 O O
lies O O
downstream O O
of O O
the O O
palindrome O O
. O O

In O O
mammals O O
, O O
evolution O O
maintained O O
this O O
unique O O
palindromic O O
arrangement O O
, O O
suggesting O O
that O O
it O O
is O O
functionally O O
significant O O
. O O

Here O O
we O O
report O O
that O O
deconstructing O O
the O O
palindromic O O
IgH O O
3 O O
' O O
RR O O
strongly O O
affects O O
its O O
function O O
even O O
when O O
enhancers O O
are O O
preserved O O
. O O

CSR O O
and O O
IgH O O
transcription O O
appear O O
to O O
be O O
poorly O O
dependent O O
on O O
the O O
3 O O
' O O
RR O O
architecture O O
and O O
it O O
is O O
more O O
or O O
less O O
preserved O O
, O O
provided O O
3 O O
' O O
RR O O
enhancers O O
are O O
present O O
. O O

By O O
contrast O O
, O O
a O O
' O O
palindromic O O
effect O O
' O O
significantly O O
lowers O O
VH O O
germline O O
transcription O O
, O O
AID O O
recruitment O O
and O O
SHM O O
. O O

In O O
conclusion O O
, O O
this O O
work O O
indicates O O
that O O
the O O
IgH O O
3 O O
' O O
RR O O
does O O
not O O
simply O O
pile O O
up O O
enhancer O O
units O O
but O O
also O O
optimally O O
exposes O O
them O O
into O O
a O O
functional O O
architecture O O
of O O
crucial O O
importance O O
. O O

An O O
ankylosing O O
spondylitis O O
- O O
associated O O
genetic O O
variant O O
in O O
the O O
IL23R O O
- O O
IL12RB2 O O
intergenic O O
region O O
modulates O O
enhancer O O
activity O O
and O O
is O O
associated O O
with O O
increased O O
Th1 B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
differentiation O O
. O O

OBJECTIVES O O
: O O
To O O
explore O O
the O O
functional O O
basis O O
for O O
the O O
association O O
between O O
ankylosing O O
spondylitis O O
( O O
AS O O
) O O
and O O
single O O
- O O
nucleotide O O
polymorphisms O O
( O O
SNPs O O
) O O
in O O
the O O
IL23R O O
- O O
IL12RB2 O O
intergenic O O
region O O
. O O

METHODS O O
: O O
We O O
performed O O
conditional O O
analysis O O
on O O
genetic O O
association O O
data O O
and O O
used O O
epigenetic O O
data O O
on O O
chromatin O O
remodelling O O
and O O
transcription O O
factor O O
( O O
TF O O
) O O
binding O O
to O O
identify O O
the O O
primary O O
AS O O
- O O
associated O O
IL23R O O
- O O
IL12RB2 O O
intergenic O O
SNP O O
. O O

Functional O O
effects O O
were O O
tested O O
in O O
luciferase O O
reporter O O
assays O O
in O O
HEK293T B-CellLine B-CellLine
cells O I-CellLine
and O O
allele O O
- O O
specific O O
TF O O
binding O O
was O O
investigated O O
by O O
electrophoretic O O
mobility O O
gel O O
shift O O
assays O O
. O O
IL23R O O
and O O
IL12RB2 O O
mRNA O O
levels O O
in O O
CD4 B-CellLine B-CellLine
+ I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
were O O
compared O O
between O O
cases O O
homozygous O O
for O O
the O O
AS O O
- O O
risk O O
' O O
A O O
' O O
allele O O
and O O
the O O
protective O O
' O O
G O O
' O O
allele O O
. O O

The O O
proportions O O
of O O
interleukin O O
( O O
IL O O
) O O
- O O
17A O O
+ O O
and O O
interferon O O
( O O
IFN O O
) O O
- O O
gamma O O
+ O O
CD4 B-CellLine B-CellLine
+ I-CellLine I-CellLine
T I-CellLine I-CellLine
- I-CellLine I-CellLine
cells I-CellLine I-CellLine
were O O
measured O O
by O O
fluorescence O O
- O O
activated O O
cell O O
sorting O O
and O O
compared O O
between O O
these O O
AS O O
- O O
risk O O
and O O
protective O O
genotypes O O
. O O

RESULTS O O
: O O
Conditional O O
analysis O O
identified O O
rs11209032 O O
as O O
the O O
probable O O
causal O O
SNP O O
within O O
a O O
1 O O
. O O
14 O O
kb O O
putative O O
enhancer O O
between O O
IL23R O O
and O O
IL12RB2 O O
. O O
RESULTS O O
: O O
Conditional O O
analysis O O
identified O O
rs11209032 O O
as O O
the O O
probable O O
causal O O
SNP O O
within O O
a O O
1 O O
. O O
14 O O
kb O O
putative O O
enhancer O O
between O O
IL23R O O
and O O
IL12RB2 O O
. O O

Reduced O O
luciferase O O
activity O O
was O O
seen O O
for O O
the O O
risk O O
allele O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
and O O
reduced O O
H3K4me1 O O
methylation O O
observed O O
in O O
CD4 B-CellLine B-CellLine
+ I-CellLine I-CellLine
T I-CellLine I-CellLine
- I-CellLine I-CellLine
cells I-CellLine I-CellLine
from O O
' O O
A O O
/ O O
A O O
' O O
homozygotes O O
( O O
p O O
= O O
0 O O
. O O
02 O O
) O O
. O O

The O O
binding O O
of O O
nuclear O O
extract O O
to O O
the O O
risk O O
allele O O
was O O
decreased O O
~ O O
3 O O
. O O
5 O O
- O O
fold O O
compared O O
with O O
the O O
protective O O
allele O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O

The O O
proportion O O
of O O
IFN O O
- O O
gamma O O
+ O O
CD4 B-CellLine B-CellLine
+ I-CellLine I-CellLine
T I-CellLine I-CellLine
- I-CellLine I-CellLine
cells I-CellLine I-CellLine
was O O
increased O O
in O O
' O O
A O O
/ O O
A O O
' O O
homozygotes O O
( O O
p O O
= O O
0 O O
. O O
004 O O
) O O
, O O
but O O
neither O O
IL23R O O
nor O O
IL12RB2 O O
mRNA O O
was O O
affected O O
. O O

CONCLUSIONS O O
: O O
The O O
rs11209032 O O
SNP O O
downstream O O
of O O
IL23R O O
forms O O
part O O
of O O
an O O
enhancer O O
, O O
allelic O O
variation O O
of O O
which O O
may O O
influence O O
Th1 B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
numbers O O
. O O

Homozygosity O O
for O O
the O O
risk O O
' O O
A O O
' O O
allele O O
is O O
associated O O
with O O
more O O
IFN O B-CellLine
- O I-CellLine
gamma O I-CellLine
- O I-CellLine
secreting O I-CellLine
( B-CellLine I-CellLine
Th1 I-CellLine I-CellLine
) I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Further O O
work O O
is O O
necessary O O
to O O
explain O O
the O O
mechanisms O O
for O O
these O O
important O O
observations O O
. O O

Stilbenoids O O
remodel O O
the O O
DNA O O
methylation O O
patterns O O
in O O
breast B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
and O O
inhibit O O
oncogenic O O
NOTCH O O
signaling O O
through O O
epigenetic O O
regulation O O
of O O
MAML2 O O
transcriptional O O
activity O O
. O O

DNA O O
hypomethylation O O
was O O
previously O O
implicated O O
in O O
cancer O O
progression O O
and O O
metastasis O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
examine O O
whether O O
stilbenoids O O
, O O
resveratrol O O
and O O
pterostilbene O O
thought O O
to O O
exert O O
anticancer O O
effects O O
, O O
target O O
genes O O
with O O
oncogenic O O
function O O
for O O
de O O
novo O O
methylation O O
and O O
silencing O O
, O O
leading O O
to O O
inactivation O O
of O O
related O O
signaling O O
pathways O O
. O O

Following O O
Illumina O O
450K O O
, O O
genome O O
- O O
wide O O
DNA O O
methylation O O
analysis O O
reveals O O
that O O
stilbenoids O O
alter O O
DNA O O
methylation O O
patterns O O
in O O
breast B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

On O O
average O O
, O O
75 O O
% O O
of O O
differentially O O
methylated O O
genes O O
have O O
increased O O
methylation O O
, O O
and O O
these O O
genes O O
are O O
enriched O O
for O O
oncogenic O O
functions O O
, O O
including O O
NOTCH O O
signaling O O
pathway O O
. O O
MAML2 O O
, O O
a O O
coactivator O O
of O O
NOTCH O O
targets O O
, O O
is O O
methylated O O
at O O
the O O
enhancer O O
region O O
and O O
transcriptionally O O
silenced O O
in O O
response O O
to O O
stilbenoids O O
, O O
possibly O O
explaining O O
the O O
downregulation O O
of O O
NOTCH O O
target O O
genes O O
. O O

The O O
increased O O
DNA O O
methylation O O
at O O
MAML2 O O
enhancer O O
coincides O O
with O O
increased O O
occupancy O O
of O O
repressive O O
histone O O
marks O O
and O O
decrease O O
in O O
activating O O
marks O O
. O O
The O O
increased O O
DNA O O
methylation O O
at O O
MAML2 O O
enhancer O O
coincides O O
with O O
increased O O
occupancy O O
of O O
repressive O O
histone O O
marks O O
and O O
decrease O O
in O O
activating O O
marks O O
. O O

This O O
condensed O O
chromatin O O
structure O O
is O O
associated O O
with O O
binding O O
of O O
DNMT3B O O
and O O
decreased O O
occupancy O O
of O O
OCT1 O O
transcription O O
factor O O
at O O
MAML2 O O
enhancer O O
, O O
suggesting O O
a O O
role O O
of O O
DNMT3B O O
in O O
increasing O O
methylation O O
of O O
MAML2 O O
after O O
stilbenoid O O
treatment O O
. O O
This O O
condensed O O
chromatin O O
structure O O
is O O
associated O O
with O O
binding O O
of O O
DNMT3B O O
and O O
decreased O O
occupancy O O
of O O
OCT1 O O
transcription O O
factor O O
at O O
MAML2 O O
enhancer O O
, O O
suggesting O O
a O O
role O O
of O O
DNMT3B O O
in O O
increasing O O
methylation O O
of O O
MAML2 O O
after O O
stilbenoid O O
treatment O O
. O O

Our O O
results O O
deliver O O
a O O
novel O O
insight O O
into O O
epigenetic O O
regulation O O
of O O
oncogenic O O
signals O O
in O O
cancer O O
and O O
provide O O
support O O
for O O
epigenetic O O
- O O
targeting O O
strategies O O
as O O
an O O
effective O O
anticancer O O
approach O O
. O O

Enhancers O O
and O O
super O O
- O O
enhancers O O
have O O
an O O
equivalent O O
regulatory O O
role O O
in O O
embryonic B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
through O O
regulation O O
of O O
single O O
or O O
multiple O O
genes O O
. O O

Transcriptional O O
enhancers O O
are O O
critical O O
for O O
maintaining O O
cell O O
- O O
type O O
- O O
specific O O
gene O O
expression O O
and O O
driving O O
cell O O
fate O O
changes O O
during O O
development O O
. O O

Highly O O
transcribed O O
genes O O
are O O
often O O
associated O O
with O O
a O O
cluster O O
of O O
individual O O
enhancers O O
such O O
as O O
those O O
found O O
in O O
locus O O
control O O
regions O O
. O O

Recently O O
, O O
these O O
have O O
been O O
termed O O
stretch O O
enhancers O O
or O O
super O O
- O O
enhancers O O
, O O
which O O
have O O
been O O
predicted O O
to O O
regulate O O
critical O O
cell O O
identity O O
genes O O
. O O

We O O
employed O O
a O O
CRISPR O O
/ O O
Cas9 O O
- O O
mediated O O
deletion O O
approach O O
to O O
study O O
the O O
function O O
of O O
several O O
enhancer O O
clusters O O
( O O
ECs O B-CellLine
) O O
and O O
isolated O O
enhancers O O
in O O
mouse O O
embryonic B-CellLine B-CellLine
stem I-CellLine I-CellLine
( I-CellLine I-CellLine
ES I-CellLine I-CellLine
) I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Our O O
results O O
reveal O O
that O O
the O O
effect O O
of O O
deleting O O
ECs O B-CellLine
, O O
also O O
classified O O
as O O
ES B-CellLine B-CellLine
cell I-CellLine I-CellLine
super O O
- O O
enhancers O O
, O O
is O O
highly O O
variable O O
, O O
resulting O O
in O O
target O O
gene O O
expression O O
reductions O O
ranging O O
from O O
12 O O
% O O
to O O
as O O
much O O
as O O
92 O O
% O O
. O O

Partial O O
deletions O O
of O O
these O O
ECs O B-CellLine
which O O
removed O O
only O O
one O O
enhancer O O
or O O
a O O
subcluster O O
of O O
enhancers O O
revealed O O
partially O O
redundant O O
control O O
of O O
the O O
regulated O O
gene O O
by O O
multiple O O
enhancers O O
within O O
the O O
larger O O
cluster O O
. O O

Many O O
highly O O
transcribed O O
genes O O
in O O
ES B-CellLine B-CellLine
cells I-CellLine I-CellLine
are O O
not O O
associated O O
with O O
a O O
super O O
- O O
enhancer O O
; O O
furthermore O O
, O O
super O O
- O O
enhancer O O
predictions O O
ignore O O
81 O O
% O O
of O O
the O O
potentially O O
active O O
regulatory O O
elements O O
predicted O O
by O O
cobinding O O
of O O
five O O
or O O
more O O
pluripotency O O
- O O
associated O O
transcription O O
factors O O
. O O

Deletion O O
of O O
these O O
additional O O
enhancer O O
regions O O
revealed O O
their O O
robust O O
regulatory O O
role O O
in O O
gene O O
transcription O O
. O O

In O O
addition O O
, O O
select O O
super O O
- O O
enhancers O O
and O O
enhancers O O
were O O
identified O O
that O O
regulated O O
clusters O O
of O O
paralogous O O
genes O O
. O O

We O O
conclude O O
that O O
, O O
whereas O O
robust O O
transcriptional O O
output O O
can O O
be O O
achieved O O
by O O
an O O
isolated O O
enhancer O O
, O O
clusters O O
of O O
enhancers O O
acting O O
on O O
a O O
common O O
target O O
gene O O
act O O
in O O
a O O
partially O O
redundant O O
manner O O
to O O
fine O O
tune O O
transcriptional O O
output O O
of O O
their O O
target O O
genes O O
. O O

The O O
transcription O O
factor O O
GATA1 O O
regulates O O
NBEAL2 O O
expression O O
through O O
a O O
long O O
- O O
distance O O
enhancer O O
. O O
Gray O O
platelet O O
syndrome O O
is O O
named O O
after O O
the O O
gray O O
appearance O O
of O O
platelets B-CellLine B-CellLine
due O O
to O O
the O O
absence O O
of O O
alpha O O
- O O
granules O O
. O O

It O O
is O O
caused O O
by O O
recessive O O
mutations O O
in O O
NBEAL2 O O
, O O
resulting O O
in O O
macrothrombocytopenia O O
and O O
myelofibrosis O O
. O O

Though O O
using O O
the O O
term O O
gray O O
platelets O B-CellLine
for O O
GATA1 O O
deficiency O O
has O O
been O O
debated O O
, O O
a O O
reduced O O
number O O
of O O
alpha O B-CellLine
- O I-CellLine
granules O I-CellLine
has O O
been O O
described O O
for O O
macrothrombocytopenia O O
due O O
to O O
GATA1 O O
mutations O O
. O O

We O O
compared O O
platelet B-CellLine O
size O O
and O O
number O O
of O O
alpha O O
- O O
granules O O
for O O
two O O
NBEAL2 O O
and O O
two O O
GATA1 O O
- O O
deficient O O
patients O O
and O O
found O O
reduced O O
numbers O O
of O O
alpha O B-CellLine
- O I-CellLine
granules O I-CellLine
for O O
all O O
, O O
with O O
the O O
defect O O
being O O
more O O
pronounced O O
for O O
NBEAL2 O O
deficiency O O
. O O

We O O
further O O
hypothesized O O
that O O
the O O
granule O O
defect O O
for O O
GATA1 O O
is O O
due O O
to O O
a O O
defective O O
control O O
of O O
NBEAL2 O O
expression O O
. O O

Remarkably O O
, O O
platelets O B-CellLine
from O O
two O O
patients O O
, O O
and O O
Gata1 O O
- O O
deficient O O
mice O O
, O O
expressed O O
almost O O
no O O
NBEAL2 O O
. O O

The O O
differentiation O O
of O O
GATA1 O O
patient O O
- O O
derived O O
CD34 B-CellLine B-CellLine
+ I-CellLine I-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
to O O
megakaryocytes B-CellLine B-CellLine
showed O O
defective O O
proplatelet O B-CellLine
and O O
alpha O B-CellLine
- O I-CellLine
granule O I-CellLine
formation O O
with O O
strongly O O
reduced O O
NBEAL2 O O
protein O O
and O O
ribonucleic O O
acid O O
expression O O
. O O

Chromatin O O
immunoprecipitation O O
sequencing O O
revealed O O
5 O O
GATA O O
binding O O
sites O O
in O O
a O O
regulatory O O
region O O
31 O O
kb O O
upstream O O
of O O
NBEAL2 O O
covered O O
by O O
a O O
H3K4Me1 O O
mark O O
indicative O O
of O O
an O O
enhancer O O
locus O O
. O O

Luciferase O O
reporter O O
constructs O O
containing O O
this O O
region O O
confirmed O O
its O O
enhancer O O
activity O O
in O O
K562 B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
and O O
mutagenesis O O
of O O
the O O
GATA1 O O
binding O O
sites O O
resulted O O
in O O
significantly O O
reduced O O
enhancer O O
activity O O
. O O
Luciferase O O
reporter O O
constructs O O
containing O O
this O O
region O O
confirmed O O
its O O
enhancer O O
activity O O
in O O
K562 B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
and O O
mutagenesis O O
of O O
the O O
GATA1 O O
binding O O
sites O O
resulted O O
in O O
significantly O O
reduced O O
enhancer O O
activity O O
. O O

Moreover O O
, O O
DNA O O
binding O O
studies O O
showed O O
that O O
GATA1 O O
and O O
GATA2 O O
physically O O
interact O O
with O O
this O O
enhancer O O
region O O
. O O
GATA1 O O
depletion O O
using O O
small O O
interfering O O
ribonucleic O O
acid O O
in O O
K562 B-CellLine B-CellLine
cells I-CellLine I-CellLine
also O O
resulted O O
in O O
reduced O O
NBEAL2 O O
expression O O
. O O

In O O
conclusion O O
, O O
we O O
herein O O
show O O
a O O
long O O
- O O
distance O O
regulatory O O
region O O
with O O
GATA1 O O
binding O O
sites O O
as O O
being O O
a O O
strong O O
enhancer O O
for O O
NBEAL2 O O
expression O O
. O O
In O O
conclusion O O
, O O
we O O
herein O O
show O O
a O O
long O O
- O O
distance O O
regulatory O O
region O O
with O O
GATA1 O O
binding O O
sites O O
as O O
being O O
a O O
strong O O
enhancer O O
for O O
NBEAL2 O O
expression O O
. O O

Genome O O
- O O
wide O O
identification O O
of O O
regulatory O O
elements O O
in O O
Sertoli B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

A O O
current O O
goal O O
of O O
molecular O O
biology O O
is O O
to O O
identify O O
transcriptional O O
networks O O
that O O
regulate O O
cell O O
differentiation O O
. O O

However O O
, O O
identifying O O
functional O O
gene O O
regulatory O O
elements O O
has O O
been O O
challenging O O
in O O
the O O
context O O
of O O
developing O O
tissues O O
where O O
material O O
is O O
limited O O
and O O
cell O O
types O O
are O O
mixed O O
. O O

To O O
identify O O
regulatory O O
sites O O
during O O
sex O O
determination O O
, O O
we O O
subjected O O
Sertoli B-CellLine B-CellLine
cells I-CellLine I-CellLine
from O O
mouse O O
fetal O O
testes B-CellLine B-CellLine
to O O
DNaseI O O
- O O
seq O O
and O O
ChIP O O
- O O
seq O O
for O O
H3K27ac O O
. O O

DNaseI O O
- O O
seq O O
identified O O
putative O O
regulatory O O
sites O O
around O O
genes O O
enriched O O
in O O
Sertoli B-CellLine B-CellLine
and O O
pregranulosa B-CellLine B-CellLine
cells I-CellLine I-CellLine
; O O
however O O
, O O
active O O
enhancers O O
marked O O
by O O
H3K27ac O O
were O O
enriched O O
proximal O O
to O O
only O O
Sertoli O B-CellLine
- O O
enriched O O
genes O O
. O O

Sequence O O
analysis O O
identified O O
putative O O
binding O O
sites O O
of O O
known O O
and O O
novel O O
transcription O O
factors O O
likely O O
controlling O O
Sertoli B-CellLine B-CellLine
cell I-CellLine I-CellLine
differentiation O O
. O O

As O O
a O O
validation O O
of O O
this O O
approach O O
, O O
we O O
identified O O
a O O
novel O O
Sertoli B-CellLine B-CellLine
cell I-CellLine I-CellLine
enhancer O O
upstream O O
of O O
Wt1 O O
, O O
and O O
used O O
it O O
to O O
drive O O
expression O O
of O O
a O O
transgenic O O
reporter O O
in O O
Sertoli B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
As O O
a O O
validation O O
of O O
this O O
approach O O
, O O
we O O
identified O O
a O O
novel O O
Sertoli B-CellLine B-CellLine
cell I-CellLine I-CellLine
enhancer O O
upstream O O
of O O
Wt1 O O
, O O
and O O
used O O
it O O
to O O
drive O O
expression O O
of O O
a O O
transgenic O O
reporter O O
in O O
Sertoli B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

This O O
work O O
furthers O O
our O O
understanding O O
of O O
the O O
complex O O
genetic O O
network O O
that O O
underlies O O
sex O O
determination O O
and O O
identifies O O
regions O O
that O O
potentially O O
harbor O O
non O O
- O O
coding O O
mutations O O
underlying O O
disorders O O
of O O
sexual O O
development O O
. O O

Constitutively O O
active O O
RAS O O
signaling O O
reduces O O
1 O O
, O O
25 O O
dihydroxyvitamin O O
D O O
- O O
mediated O O
gene O O
transcription O O
in O O
intestinal B-CellLine B-CellLine
epithelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
by O O
reducing O O
vitamin O O
D O O
receptor O O
expression O O
. O O

High O O
vitamin O O
D O O
status O O
is O O
associated O O
with O O
reduced O O
colon O O
cancer O O
risk O O
but O O
these O O
studies O O
ignore O O
the O O
diversity O O
in O O
the O O
molecular O O
etiology O O
of O O
colon O O
cancer O O
. O O

RAS O O
activating O O
mutations O O
are O O
common O O
in O O
colon O O
cancer O O
and O O
they O O
activate O O
pro O O
- O O
proliferative O O
signaling O O
pathways O O
. O O

We O O
examined O O
the O O
impact O O
of O O
RAS O O
activating O O
mutations O O
on O O
1 O O
, O O
25 O O
dihydroxyvitamin O O
D O O
( O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D O O
) O O
- O O
mediated O O
gene O O
expression O O
in O O
cultured O O
colon B-CellLine B-CellLine
and O O
intestinal B-CellLine B-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
. O O

Transient O O
transfection O O
of O O
Caco B-CellLine B-CellLine
- I-CellLine I-CellLine
2 I-CellLine I-CellLine
cells I-CellLine I-CellLine
with O O
a O O
constitutively O O
active O O
mutant O O
K O O
- O O
RAS O O
( O O
G12 O O
V O O
) O O
significantly O O
reduced O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D O O
- O O
induced O O
activity O O
of O O
both O O
a O O
human O O
25 O O
- O O
hydroxyvitamin O O
D O O
, O O
24 O O
hydroxyase O O
( O O
CYP24A1 O O
) O O
promoter O O
- O O
luciferase O O
and O O
an O O
artificial O O
3X O O
vitamin O O
D O O
response O O
element O O
( O O
VDRE O O
) O O
promoter O O
- O O
luciferase O O
reporter O O
gene O O
. O O
Young B-CellLine O
Adult I-CellLine O
Mouse I-CellLine O
Colon I-CellLine B-CellLine
( O O
YAMC B-CellLine B-CellLine
) O O
and O O
Rat B-CellLine O
Intestinal I-CellLine B-CellLine
Epithelial I-CellLine I-CellLine
( I-CellLine I-CellLine
RIE I-CellLine I-CellLine
) I-CellLine I-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
with O O
stable O O
expression O O
of O O
mutant O O
H O O
- O O
RAS O O
had O O
suppressed O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D O O
- O O
mediated O O
induction O O
of O O
CYP24A1 O O
mRNA O O
. O O
Transient O O
transfection O O
of O O
Caco B-CellLine B-CellLine
- I-CellLine I-CellLine
2 I-CellLine I-CellLine
cells I-CellLine I-CellLine
with O O
a O O
constitutively O O
active O O
mutant O O
K O O
- O O
RAS O O
( O O
G12 O O
V O O
) O O
significantly O O
reduced O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D O O
- O O
induced O O
activity O O
of O O
both O O
a O O
human O O
25 O O
- O O
hydroxyvitamin O O
D O O
, O O
24 O O
hydroxyase O O
( O O
CYP24A1 O O
) O O
promoter O O
- O O
luciferase O O
and O O
an O O
artificial O O
3X O O
vitamin O O
D O O
response O O
element O O
( O O
VDRE O O
) O O
promoter O O
- O O
luciferase O O
reporter O O
gene O O
. O O
Young B-CellLine O
Adult I-CellLine O
Mouse I-CellLine O
Colon I-CellLine B-CellLine
( O O
YAMC B-CellLine B-CellLine
) O O
and O O
Rat B-CellLine O
Intestinal I-CellLine B-CellLine
Epithelial I-CellLine I-CellLine
( I-CellLine I-CellLine
RIE I-CellLine I-CellLine
) I-CellLine I-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
with O O
stable O O
expression O O
of O O
mutant O O
H O O
- O O
RAS O O
had O O
suppressed O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D O O
- O O
mediated O O
induction O O
of O O
CYP24A1 O O
mRNA O O
. O O

The O O
RAS O O
effects O O
were O O
associated O O
with O O
lower O O
Vitamin O O
D O O
receptor O O
( O O
VDR O O
) O O
mRNA O O
and O O
protein O O
levels O O
in O O
YAMC B-CellLine B-CellLine
and O O
RIE B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
they O O
could O O
be O O
partially O O
reversed O O
by O O
VDR O O
overexpression O O
. O O

RAS O O
- O O
mediated O O
suppression O O
of O O
VDR O O
levels O O
was O O
not O O
due O O
to O O
either O O
reduced O O
VDR O O
mRNA O O
stability O O
or O O
increased O O
VDR O O
gene O O
methylation O O
. O O

However O O
, O O
chromatin O O
accessibility O O
to O O
the O O
VDR O O
gene O O
at O O
the O O
proximal O O
promoter O O
( O O
- O O
300bp O O
) O O
, O O
an O O
enhancer O O
region O O
at O O
- O O
6kb O O
, O O
and O O
an O O
enhancer O O
region O O
located O O
in O O
exon O O
3 O O
was O O
significantly O O
reduced O O
in O O
RAS O O
transformed O O
YAMC B-CellLine B-CellLine
cells I-CellLine I-CellLine
( O O
YAMC B-CellLine O
- O O
RAS O O
) O O
. O O

These O O
data O O
show O O
that O O
constitutively O O
active O O
RAS O O
signaling O O
suppresses O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D O O
- O O
mediated O O
gene O O
transcription O O
in O O
colon B-CellLine B-CellLine
epithelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
by O O
reducing O O
VDR O O
gene O O
transcription O O
but O O
the O O
mechanism O O
for O O
this O O
suppression O O
is O O
not O O
yet O O
known O O
. O O

These O O
data O O
suggest O O
that O O
cancers O O
with O O
RAS O O
- O O
activating O O
mutations O O
may O O
be O O
less O O
responsive O O
to O O
vitamin O O
D O O
mediated O O
treatment O O
or O O
chemoprevention O O
. O O

Inhibition O O
of O O
Inflammatory O O
Gene O O
Transcription O O
by O O
IL O O
- O O
10 O O
Is O O
Associated O O
with O O
Rapid O O
Suppression O O
of O O
Lipopolysaccharide O O
- O O
Induced O O
Enhancer O O
Activation O O
. O O
IL O O
- O O
10 O O
limits O O
the O O
magnitude O O
of O O
inflammatory O O
gene O O
expression O O
following O O
microbial O O
stimuli O O
and O O
is O O
essential O O
to O O
prevent O O
inflammatory O O
disease O O
; O O
however O O
, O O
the O O
molecular O O
basis O O
for O O
IL O O
- O O
10 O O
- O O
mediated O O
inhibition O O
remains O O
elusive O O
. O O

Using O O
a O O
genome O O
- O O
wide O O
approach O O
, O O
we O O
demonstrate O O
that O O
inhibition O O
of O O
transcription O O
is O O
the O O
primary O O
mechanism O O
for O O
IL O O
- O O
10 O O
- O O
mediated O O
suppression O O
in O O
LPS B-CellLine O
- I-CellLine O
stimulated I-CellLine O
macrophages I-CellLine B-CellLine
and O O
that O O
inhibited O O
genes O O
can O O
be O O
divided O O
into O O
two O O
clusters O O
. O O

Genes O O
in O O
the O O
first O O
cluster O O
are O O
inhibited O O
only O O
if O O
IL O O
- O O
10 O O
is O O
included O O
early O O
in O O
the O O
course O O
of O O
LPS O O
stimulation O O
and O O
is O O
strongly O O
enriched O O
for O O
IFN O O
- O O
inducible O O
genes O O
. O O

Genes O O
in O O
the O O
second O O
cluster O O
can O O
be O O
rapidly O O
suppressed O O
by O O
IL O O
- O O
10 O O
even O O
after O O
transcription O O
is O O
initiated O O
, O O
and O O
this O O
is O O
associated O O
with O O
suppression O O
of O O
LPS O O
- O O
induced O O
enhancer O O
activation O O
. O O

Interestingly O O
, O O
the O O
ability O O
of O O
IL O O
- O O
10 O O
to O O
rapidly O O
suppress O O
active O O
transcription O O
exhibits O O
a O O
delay O O
following O O
LPS O O
stimulation O O
. O O

Thus O O
, O O
a O O
key O O
pathway O O
for O O
IL O O
- O O
10 O O
- O O
mediated O O
suppression O O
involves O O
rapid O O
inhibition O O
of O O
enhancer O O
function O O
during O O
the O O
secondary O O
phase O O
of O O
the O O
response O O
to O O
LPS O O
. O O

The O O
SWI O O
/ O O
SNF O O
chromatin O O
remodelling O O
complex O O
is O O
required O O
for O O
maintenance O O
of O O
lineage O O
specific O O
enhancers O O
. O O

Genes O O
encoding O O
subunits O O
of O O
SWI O O
/ O O
SNF O O
( O O
BAF O O
) O O
chromatin O O
remodelling O O
complexes O O
are O O
collectively O O
altered O O
in O O
over O O
20 O O
% O O
of O O
human O O
malignancies O O
, O O
but O O
the O O
mechanisms O O
by O O
which O O
these O O
complexes O O
alter O O
chromatin O O
to O O
modulate O O
transcription O O
and O O
cell O O
fate O O
are O O
poorly O O
understood O O
. O O

Utilizing O O
mouse O O
embryonic O B-CellLine
fibroblast B-CellLine I-CellLine
and O O
cancer B-CellLine B-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
models O O
, O O
here O O
we O O
show O O
via O O
ChIP O O
- O O
seq O O
and O O
biochemical O O
assays O O
that O O
SWI O O
/ O O
SNF O O
complexes O O
are O O
preferentially O O
targeted O O
to O O
distal O O
lineage O O
specific O O
enhancers O O
and O O
interact O O
with O O
p300 O O
to O O
modulate O O
histone O O
H3 O O
lysine O O
27 O O
acetylation O O
. O O

We O O
identify O O
a O O
greater O O
requirement O O
for O O
SWI O O
/ O O
SNF O O
at O O
typical O O
enhancers O O
than O O
at O O
most O O
super O O
- O O
enhancers O O
and O O
at O O
enhancers O O
in O O
untranscribed O O
regions O O
than O O
in O O
transcribed O O
regions O O
. O O

Our O O
data O O
further O O
demonstrate O O
that O O
SWI O O
/ O O
SNF O O
- O O
dependent O O
distal O O
enhancers O O
are O O
essential O O
for O O
controlling O O
expression O O
of O O
genes O O
linked O O
to O O
developmental O O
processes O O
. O O

Our O O
findings O O
thus O O
establish O O
SWI O O
/ O O
SNF O O
complexes O O
as O O
regulators O O
of O O
the O O
enhancer O O
landscape O O
and O O
provide O O
insight O O
into O O
the O O
roles O O
of O O
SWI O O
/ O O
SNF O O
in O O
cellular O O
fate O O
control O O
. O O

Inhibiting O O
histone O O
deacetylases O O
suppresses O O
glucose O O
metabolism O O
and O O
hepatocellular O O
carcinoma O O
growth O O
by O O
restoring O O
FBP1 O O
expression O O
. O O
Hepatocellular O O
carcinoma O O
( O O
HCC O O
) O O
is O O
one O O
of O O
the O O
most O O
commonly O O
diagnosed O O
cancers O O
in O O
the O O
world O O
. O O

Elevated O O
glucose O O
metabolism O O
in O O
the O O
availability O O
of O O
oxygen O O
, O O
a O O
phenomenon O O
called O O
the O O
Warburg O O
effect O O
, O O
is O O
important O O
for O O
cancer B-CellLine B-CellLine
cell I-CellLine I-CellLine
growth O O
. O O
Fructose O O
- O O
1 O O
, O O
6 O O
- O O
bisphosphatase O O
( O O
FBP1 O O
) O O
is O O
a O O
rate O O
- O O
limiting O O
enzyme O O
in O O
gluconeogenesis O O
and O O
is O O
frequently O O
lost O O
in O O
various O O
types O O
of O O
cancer O O
. O O

Here O O
, O O
we O O
demonstrated O O
that O O
expression O O
of O O
FBP1 O O
was O O
downregulated O O
in O O
HCC O O
patient O O
specimens O O
and O O
decreased O O
expression O O
of O O
FBP1 O O
associated O O
with O O
poor O O
prognosis O O
. O O

Low O O
expression O O
of O O
FBP1 O O
correlated O O
with O O
high O O
levels O O
of O O
histone O O
deacetylase O O
1 O O
( O O
HDAC1 O O
) O O
and O O
HDAC2 O O
proteins O O
in O O
HCC O O
patient O O
tissues O O
. O O

Treatment O O
of O O
HCC B-CellLine B-CellLine
cells I-CellLine I-CellLine
with O O
HDAC O O
inhibitors O O
or O O
knockdown O O
of O O
HDAC1 O O
and O O
/ O O
or O O
HDAC2 O O
restored O O
FBP1 O O
expression O O
and O O
inhibited O O
HCC B-CellLine B-CellLine
cell I-CellLine I-CellLine
growth O O
. O O

HDAC O O
- O O
mediated O O
suppression O O
of O O
FBP1 O O
expression O O
correlated O O
with O O
decreased O O
histone O O
H3 O O
lysine O O
27 O O
acetylation O O
( O O
H3K27Ac O O
) O O
in O O
the O O
FBP1 O O
enhancer O O
. O O
HDAC O O
- O O
mediated O O
suppression O O
of O O
FBP1 O O
expression O O
correlated O O
with O O
decreased O O
histone O O
H3 O O
lysine O O
27 O O
acetylation O O
( O O
H3K27Ac O O
) O O
in O O
the O O
FBP1 O O
enhancer O O
. O O

Restored O O
expression O O
of O O
FBP1 O O
decreased O O
glucose O O
reduction O O
and O O
lactate O O
secretion O O
and O O
inhibited O O
HCC B-CellLine B-CellLine
cell I-CellLine I-CellLine
growth O O
in O O
vitro O O
and O O
tumor O O
growth O O
in O O
mice O O
. O O

Our O O
data O O
reveal O O
that O O
loss O O
of O O
FBP1 O O
due O O
to O O
histone O O
deacetylation O O
associates O O
with O O
poor O O
prognosis O O
of O O
HCC O O
and O O
restored O O
FBP1 O O
expression O O
by O O
HDAC O O
inhibitors O O
suppresses O O
HCC O O
growth O O
. O O

Our O O
findings O O
suggest O O
that O O
repression O O
of O O
FBP1 O O
by O O
HDACs O O
has O O
important O O
implications O O
for O O
HCC O O
prognosis O O
and O O
treatment O O
. O O

A O O
class O O
of O O
circadian O O
long O O
non O O
- O O
coding O O
RNAs O O
mark O O
enhancers O O
modulating O O
long O O
- O O
range O O
circadian O O
gene O O
regulation O O
. O O

Circadian O O
rhythm O O
exerts O O
its O O
influence O O
on O O
animal O O
physiology O O
and O O
behavior O O
by O O
regulating O O
gene O O
expression O O
at O O
various O O
levels O O
. O O

Here O O
we O O
systematically O O
explored O O
circadian O O
long O O
non O O
- O O
coding O O
RNAs O O
( O O
lncRNAs O O
) O O
in O O
mouse O O
liver B-CellLine B-CellLine
and O O
examined O O
their O O
circadian O O
regulation O O
. O O

We O O
found O O
that O O
a O O
significant O O
proportion O O
of O O
circadian O O
lncRNAs O O
are O O
expressed O O
at O O
enhancer O O
regions O O
, O O
mostly O O
bound O O
by O O
two O O
key O O
circadian O O
transcription O O
factors O O
, O O
BMAL1 O O
and O O
REV O O
- O O
ERBalpha O O
. O O

These O O
circadian O O
lncRNAs O O
showed O O
similar O O
circadian O O
phases O O
with O O
their O O
nearby O O
genes O O
. O O

The O O
extent O O
of O O
their O O
nuclear O O
localization O O
is O O
higher O O
than O O
protein O O
coding O O
genes O O
but O O
less O O
than O O
enhancer O O
RNAs O O
. O O

The O O
association O O
between O O
enhancer O O
and O O
circadian O O
lncRNAs O O
is O O
also O O
observed O O
in O O
tissues O O
other O O
than O O
liver B-CellLine B-CellLine
. O O

Comparative O O
analysis O O
between O O
mouse O O
and O O
rat O O
circadian O O
liver B-CellLine B-CellLine
transcriptomes O O
showed O O
that O O
circadian O O
transcription O O
at O O
lncRNA O O
loci O O
tends O O
to O O
be O O
conserved O O
despite O O
of O O
low O O
sequence O O
conservation O O
of O O
lncRNAs O O
. O O

One O O
such O O
circadian O O
lncRNA O O
termed O O
lnc O O
- O O
Crot O O
led O O
us O O
to O O
identify O O
a O O
super O O
- O O
enhancer O O
region O O
interacting O O
with O O
a O O
cluster O O
of O O
genes O O
involved O O
in O O
circadian O O
regulation O O
of O O
metabolism O O
through O O
long O O
- O O
range O O
interactions O O
. O O

Further O O
experiments O O
showed O O
that O O
lnc O O
- O O
Crot O O
locus O O
has O O
enhancer O O
function O O
independent O O
of O O
lnc O O
- O O
Crot O O
' O O
s O O
transcription O O
. O O

Our O O
results O O
suggest O O
that O O
the O O
enhancer O O
- O O
associated O O
circadian O O
lncRNAs O O
mark O O
the O O
genomic O O
loci O O
modulating O O
long O O
- O O
range O O
circadian O O
gene O O
regulation O O
and O O
shed O O
new O O
lights O O
on O O
the O O
evolutionary O O
origin O O
of O O
lncRNAs O O
. O O

Myeloid O O
Zinc O O
Finger O O
1 O O
and O O
GA O O
Binding O O
Protein O O
Co O O
- O O
Operate O O
with O O
Sox2 O O
in O O
Regulating O O
the O O
Expression O O
of O O
Yes O O
- O O
Associated O O
Protein O O
1 O O
in O O
Cancer B-CellLine B-CellLine
Cells I-CellLine I-CellLine
. O O

The O O
transcription O O
factor O O
( O O
TF O O
) O O
yes O O
- O O
associated O O
protein O O
1 O O
( O O
YAP1 O O
) O O
is O O
a O O
major O O
effector O O
of O O
the O O
tumor O O
suppressive O O
Hippo O O
signaling O O
pathway O O
and O O
is O O
also O O
necessary O O
to O O
maintain O O
pluripotency O O
in O O
embryonic B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Elevated O O
levels O O
of O O
YAP1 O O
expression O O
antagonize O O
the O O
tumor O O
suppressive O O
effects O O
of O O
the O O
Hippo O O
pathway O O
that O O
normally O O
represses O O
YAP1 O O
function O O
. O O

High O O
YAP1 O O
expression O O
is O O
observed O O
in O O
several O O
types O O
of O O
human O O
cancers O O
and O O
is O O
particularly O O
prominent O O
in O O
cancer B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
CSCs B-CellLine B-CellLine
) O O
. O O

The O O
stem B-CellLine B-CellLine
cell I-CellLine I-CellLine
TF O O
Sox2 O O
, O O
which O O
marks O O
and O O
maintains O O
CSCs B-CellLine O
in O O
osteosarcomas O O
( O O
OSs O O
) O O
, O O
promotes O O
YAP1 O O
expression O O
by O O
binding O O
to O O
an O O
intronic O O
enhancer O O
element O O
and O O
YAP1 O O
expression O O
is O O
also O O
crucial O O
for O O
the O O
maintainance O O
of O O
OS B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

To O O
further O O
understand O O
the O O
regulation O O
of O O
YAP1 O O
expression O O
in O O
OSs O O
, O O
we O O
subjected O O
the O O
YAP1 O O
intronic O O
enhancer O O
to O O
scanning O O
mutagenesis O O
to O O
identify O O
all O O
DNA O O
cis O O
- O O
elements O O
critical O O
for O O
enhancer O O
function O O
. O O
To O O
further O O
understand O O
the O O
regulation O O
of O O
YAP1 O O
expression O O
in O O
OSs O O
, O O
we O O
subjected O O
the O O
YAP1 O O
intronic O O
enhancer O O
to O O
scanning O O
mutagenesis O O
to O O
identify O O
all O O
DNA O O
cis O O
- O O
elements O O
critical O O
for O O
enhancer O O
function O O
. O O

Through O O
this O O
approach O O
, O O
we O O
identified O O
two O O
novel O O
TFs O O
, O O
GA O O
binding O O
protein O O
( O O
GABP O O
) O O
and O O
myeloid O O
zinc O O
finger O O
1 O O
( O O
MZF1 O O
) O O
, O O
which O O
are O O
essential O O
for O O
basal O O
YAP1 O O
transcription O O
. O O

These O O
factors O O
are O O
highly O O
expressed O O
in O O
OSs O O
and O O
bind O O
to O O
distinct O O
sites O O
in O O
the O O
YAP1 O O
enhancer O O
. O O
These O O
factors O O
are O O
highly O O
expressed O O
in O O
OSs O B-CellLine
and O O
bind O O
to O O
distinct O O
sites O O
in O O
the O O
YAP1 O O
enhancer O O
. O O

Depletion O O
of O O
either O O
factor O O
leads O O
to O O
drastically O O
reduced O O
YAP1 O O
expression O O
and O O
thus O O
a O O
reversal O O
of O O
stem B-CellLine B-CellLine
cell I-CellLine I-CellLine
properties O O
. O O

We O O
also O O
found O O
that O O
YAP1 O O
can O O
regulate O O
the O O
expression O O
of O O
Sox2 O O
by O O
binding O O
to O O
two O O
distinct O O
DNA O O
binding O O
sites O O
upstream O O
and O O
downstream O O
of O O
the O O
Sox2 O O
gene O O
. O O
We O O
also O O
found O O
that O O
YAP1 O O
can O O
regulate O O
the O O
expression O O
of O O
Sox2 O O
by O O
binding O O
to O O
two O O
distinct O O
DNA O O
binding O O
sites O O
upstream O O
and O O
downstream O O
of O O
the O O
Sox2 O O
gene O O
. O O

Thus O O
, O O
Sox2 O O
and O O
YAP1 O O
reinforce O O
each O O
others O O
expression O O
to O O
maintain O O
stemness O O
and O O
tumorigenicity O O
in O O
OSs O O
, O O
but O O
the O O
activity O O
of O O
MZF1 O O
and O O
GABP O O
is O O
essential O O
for O O
YAP1 O O
transcription O O
. O O

Stem O B-CellLine
Cells O I-CellLine
2017 O O
; O O
35 O O
: O O
2340 O O
- O O
2350 O O
. O O

Multiple O O
enhancer O O
regions O O
govern O O
the O O
transcription O O
of O O
CCN2 O O
during O O
embryonic O O
development O O
. O O
CCN2 O O
is O O
a O O
critical O O
matricellular O O
protein O O
that O O
is O O
expressed O O
in O O
several O O
cells O O
with O O
major O O
implications O O
in O O
physiology O O
and O O
different O O
pathologies O O
. O O

However O O
, O O
the O O
transcriptional O O
regulation O O
of O O
this O O
gene O O
remains O O
obscure O O
. O O

We O O
used O O
the O O
Encyclopaedia O O
of O O
DNA O O
Elements O O
browser O O
( O O
ENCODE O O
) O O
to O O
visualise O O
the O O
region O O
spanning O O
from O O
300 O O
kb O O
upstream O O
to O O
the O O
CCN2 O O
start O O
site O O
in O O
silico O O
in O O
order O O
to O O
identify O O
enhancer O O
regions O O
that O O
regulate O O
transcription O O
of O O
this O O
gene O O
. O O

Selection O O
was O O
based O O
on O O
three O O
criteria O O
associated O O
with O O
enhancer O O
regions O O
: O O
1 O O
) O O
H3K4me1 O O
and O O
H3K27ac O O
histone O O
modifications O O
, O O
2 O O
) O O
DNase O O
I O O
hypersensitivity O O
of O O
chromatin O O
and O O
3 O O
) O O
inter O O
- O O
species O O
conservation O O
. O O

Reporter O O
constructs O O
were O O
created O O
with O O
sequences O O
spanning O O
each O O
of O O
the O O
regions O O
of O O
interest O O
placed O O
upstream O O
of O O
an O O
Hsp68 O O
silent O O
proximal O O
promoter O O
sequence O O
in O O
order O O
to O O
drive O O
the O O
expression O O
of O O
beta O O
- O O
galactosidase O O
transgene O O
. O O

Each O O
of O O
these O O
constructs O O
was O O
subsequently O O
used O O
to O O
create O O
transgenic O O
mice O O
in O O
which O O
reporter O O
gene O O
production O O
was O O
assessed O O
at O O
the O O
E15 O O
. O O
5 O O
developmental O O
stage O O
. O O
Four O O
functional O O
enhancers O O
were O O
identified O O
, O O
with O O
each O O
driving O O
distinct O O
, O O
tissue O O
- O O
specific O O
patterns O O
of O O
transgene O O
expression O O
. O O

An O O
enhancer O O
located O O
- O O
100 O O
kb O O
from O O
the O O
CCN2 O O
transcription O O
start O O
site O O
facilitated O O
expression O O
within O O
vascular O O
tissue O O
. O O
An O O
enhancer O O
located O O
- O O
100 O O
kb O O
from O O
the O O
CCN2 O O
transcription O O
start O O
site O O
facilitated O O
expression O O
within O O
vascular O O
tissue O O
. O O

An O O
enhancer O O
- O O
135 O O
kb O O
upstream O O
of O O
CCN2 O O
drove O O
expression O O
within O O
the O O
articular O B-CellLine
chondrocytes B-CellLine I-CellLine
of O O
synovial O O
joints O B-CellLine
. O O
An O O
enhancer O O
- O O
135 O O
kb O O
upstream O O
of O O
CCN2 O O
drove O O
expression O O
within O O
the O O
articular O B-CellLine
chondrocytes B-CellLine I-CellLine
of O O
synovial O O
joints O B-CellLine
. O O

The O O
other O O
two O O
enhancers O O
, O O
located O O
at O O
- O O
198 O O
kb O O
and O O
- O O
229 O O
kb O O
, O O
mediated O O
transgene O O
expression O O
within O O
dermal O B-CellLine
fibroblasts B-CellLine I-CellLine
, O O
however O O
the O O
most O O
prevalent O O
activity O O
was O O
found O O
within O O
hypertrophic O O
chondrocytes B-CellLine B-CellLine
and O O
periosteal O O
tissue O O
, O O
respectively O O
. O O

These O O
findings O O
suggest O O
that O O
the O O
global O O
expression O O
of O O
CCN2 O O
during O O
development O O
results O O
from O O
the O O
activity O O
of O O
several O O
tissue O O
- O O
specific O O
enhancer O O
regions O O
in O O
addition O O
to O O
proximal O O
regulatory O O
elements O O
that O O
have O O
previously O O
been O O
demonstrated O O
to O O
drive O O
transcription O O
of O O
the O O
gene O O
during O O
development O O
. O O

ARID5B O O
as O O
a O O
critical O O
downstream O O
target O O
of O O
the O O
TAL1 O O
complex O O
that O O
activates O O
the O O
oncogenic O O
transcriptional O O
program O O
and O O
promotes O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
leukemogenesis O O
. O O

The O O
oncogenic O O
transcription O O
factor O O
TAL1 O O
/ O O
SCL O O
induces O O
an O O
aberrant O O
transcriptional O O
program O O
in O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
acute I-CellLine I-CellLine
lymphoblastic I-CellLine I-CellLine
leukemia I-CellLine I-CellLine
( I-CellLine I-CellLine
T I-CellLine I-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
) I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

However O O
, O O
the O O
critical O O
factors O O
that O O
are O O
directly O O
activated O O
by O O
TAL1 O O
and O O
contribute O O
to O O
T O O
- O O
ALL O O
pathogenesis O O
are O O
largely O O
unknown O O
. O O

Here O O
, O O
we O O
identified O O
AT O O
- O O
rich O O
interactive O O
domain O O
5B O O
( O O
ARID5B O O
) O O
as O O
a O O
collaborating O O
oncogenic O O
factor O O
involved O O
in O O
the O O
transcriptional O O
program O O
in O O
T O O
- O O
ALL O O
. O O
ARID5B O O
expression O O
is O O
down O O
- O O
regulated O O
at O O
the O O
double O O
- O O
negative O O
2 O O
- O O
4 O O
stages O O
in O O
normal O O
thymocytes B-CellLine B-CellLine
, O O
while O O
it O O
is O O
induced O O
by O O
the O O
TAL1 O O
complex O O
in O O
human O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

The O O
enhancer O O
located O O
135 O O
kb O O
upstream O O
of O O
the O O
ARID5B O O
gene O O
locus O O
is O O
activated O O
under O O
a O O
superenhancer O O
in O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cells I-CellLine I-CellLine
but O O
not O O
in O O
normal O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
The O O
enhancer O O
located O O
135 O O
kb O O
upstream O O
of O O
the O O
ARID5B O O
gene O O
locus O O
is O O
activated O O
under O O
a O O
superenhancer O O
in O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cells I-CellLine I-CellLine
but O O
not O O
in O O
normal O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Notably O O
, O O
ARID5B O O
- O O
bound O O
regions O O
are O O
associated O O
predominantly O O
with O O
active O O
transcription O O
. O O
ARID5B O O
and O O
TAL1 O O
frequently O O
co O O
- O O
occupy O O
target O O
genes O O
and O O
coordinately O O
control O O
their O O
expression O O
. O O
ARID5B O O
positively O O
regulates O O
the O O
expression O O
of O O
TAL1 O O
and O O
its O O
regulatory O O
partners O O
. O O
ARID5B O O
also O O
activates O O
the O O
expression O O
of O O
the O O
oncogene O O
MYC O O
Importantly O O
, O O
ARID5B O O
is O O
required O O
for O O
the O O
survival O O
and O O
growth O O
of O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
and O O
forced O O
expression O O
of O O
ARID5B O O
in O O
immature O O
thymocytes B-CellLine B-CellLine
results O O
in O O
thymus B-CellLine B-CellLine
retention O O
, O O
differentiation O O
arrest O O
, O O
radioresistance O O
, O O
and O O
tumor O O
formation O O
in O O
zebrafish O O
. O O

Our O O
results O O
indicate O O
that O O
ARID5B O O
reinforces O O
the O O
oncogenic O O
transcriptional O O
program O O
by O O
positively O O
regulating O O
the O O
TAL1 O O
- O O
induced O O
regulatory O O
circuit O O
and O O
MYC O O
in O O
T O O
- O O
ALL O O
, O O
thereby O O
contributing O O
to O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
leukemogenesis O O
. O O

High O O
MITF O O
Expression O O
Is O O
Associated O O
with O O
Super O O
- O O
Enhancers O O
and O O
Suppressed O O
by O O
CDK7 O O
Inhibition O O
in O O
Melanoma O O
. O O
Cutaneous O O
melanoma O O
is O O
an O O
aggressive O O
tumor O O
that O O
accounts O O
for O O
most O O
skin O O
cancer O O
deaths O O
. O O

Among O O
the O O
physiological O O
barriers O O
against O O
therapeutic O O
success O O
is O O
a O O
strong O O
survival O O
program O O
driven O O
by O O
genes O O
such O O
as O O
MITF O O
that O O
specify O O
melanocyte B-CellLine B-CellLine
identity O O
, O O
a O O
phenomenon O O
known O O
in O O
melanoma O O
biology O O
as O O
lineage O O
dependency O O
. O O
MITF O O
overexpression O O
is O O
occasionally O O
explained O O
by O O
gene O O
amplification O O
, O O
but O O
here O O
we O O
show O O
that O O
super O O
- O O
enhancers O O
are O O
also O O
important O O
determinants O O
of O O
MITF O O
overexpression O O
in O O
some O O
melanoma B-CellLine B-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
and O O
tumors O O
. O O

Although O O
compounds O O
that O O
directly O O
inhibit O O
MITF O O
are O O
unavailable O O
, O O
a O O
covalent O O
CDK7 O O
inhibitor O O
, O O
THZ1 O O
, O O
has O O
recently O O
been O O
shown O O
to O O
potently O O
suppress O O
the O O
growth O O
of O O
various O O
cancers O O
through O O
the O O
depletion O O
of O O
master O O
transcription O O
- O O
regulating O O
oncogenes O O
and O O
the O O
disruption O O
of O O
their O O
attendant O O
super O O
- O O
enhancers O O
. O O

We O O
also O O
show O O
that O O
melanoma B-CellLine B-CellLine
cells I-CellLine I-CellLine
are O O
highly O O
sensitive O O
to O O
CDK7 O O
inhibition O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
and O O
that O O
THZ1 O O
can O O
dismantle O O
the O O
super O O
- O O
enhancer O O
apparatus O O
at O O
MITF O O
and O O
SOX10 O O
in O O
some O O
cell O O
lines O O
, O O
thereby O O
extinguishing O O
their O O
intracellular O O
levels O O
. O O
We O O
also O O
show O O
that O O
melanoma B-CellLine B-CellLine
cells I-CellLine I-CellLine
are O O
highly O O
sensitive O O
to O O
CDK7 O O
inhibition O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
and O O
that O O
THZ1 O O
can O O
dismantle O O
the O O
super O O
- O O
enhancer O O
apparatus O O
at O O
MITF O O
and O O
SOX10 O O
in O O
some O O
cell O O
lines O O
, O O
thereby O O
extinguishing O O
their O O
intracellular O O
levels O O
. O O

Our O O
results O O
show O O
a O O
dimension O O
to O O
MITF O O
regulation O O
in O O
melanoma B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
point O O
to O O
CDK7 O O
inhibition O O
as O O
a O O
potential O O
strategy O O
to O O
deprive O O
oncogenic O O
transcription O O
and O O
suppress O O
tumor O O
growth O O
in O O
melanoma O O
. O O

Targeted O O
Enhancer O O
Activation O O
by O O
a O O
Subunit O O
of O O
the O O
Integrator O O
Complex O O
. O O

The O O
control O O
of O O
cell O O
fate O O
is O O
an O O
epigenetic O O
process O O
initiated O O
by O O
transcription O O
factors O O
( O O
TFs O O
) O O
that O O
recognize O O
DNA O O
motifs O O
and O O
recruit O O
activator O O
complexes O O
and O O
transcriptional O O
machineries O O
to O O
chromatin O O
. O O

Lineage O O
specificity O O
is O O
thought O O
to O O
be O O
provided O O
solely O O
by O O
TF O O
- O O
motif O O
pairing O O
, O O
while O O
the O O
recruited O O
activators O O
are O O
passive O O
. O O

Here O O
, O O
we O O
show O O
that O O
INTS13 O O
, O O
a O O
subunit O O
of O O
the O O
Integrator O O
complex O O
, O O
operates O O
as O O
monocytic O B-CellLine
/ O O
macrophagic O B-CellLine
differentiation O O
factor O O
. O O

Integrator O O
is O O
a O O
general O O
activator O O
of O O
transcription O O
at O O
coding O O
genes O O
and O O
is O O
required O O
for O O
eRNA O O
maturation O O
. O O

Here O O
, O O
we O O
show O O
that O O
INTS13 O O
functions O O
as O O
an O O
independent O O
sub O O
- O O
module O O
and O O
targets O O
enhancers O O
through O O
Early O O
Growth O O
Response O O
( O O
EGR1 O O
/ O O
2 O O
) O O
TFs O O
and O O
their O O
co O O
- O O
factor O O
NAB2 O O
. O O
INTS13 O O
binds O O
poised O O
monocytic O B-CellLine
enhancers O O
eliciting O O
chromatin O O
looping O O
and O O
activation O O
. O O

Independent O O
depletion O O
of O O
INTS13 O O
, O O
EGR1 O O
, O O
or O O
NAB2 O O
impairs O O
monocytic O B-CellLine
differentiation O O
of O O
cell O O
lines O O
and O O
primary O O
human O O
progenitors O O
. O O

Our O O
data O O
demonstrate O O
that O O
Integrator O O
is O O
not O O
functionally O O
homogeneous O O
and O O
has O O
TF O O
- O O
specific O O
regulatory O O
potential O O
, O O
revealing O O
a O O
new O O
enhancer O O
regulatory O O
axis O O
that O O
controls O O
myeloid B-CellLine B-CellLine
differentiation O O
. O O

Functional O O
Dissection O O
of O O
the O O
Enhancer O O
Repertoire O O
in O O
Human B-CellLine B-CellLine
Embryonic I-CellLine I-CellLine
Stem I-CellLine I-CellLine
Cells I-CellLine I-CellLine
. O O

Enhancers O O
are O O
genetic O O
elements O O
that O O
regulate O O
spatiotemporal O O
gene O O
expression O O
. O O

Enhancer O O
function O O
requires O O
transcription O O
factor O O
( O O
TF O O
) O O
binding O O
and O O
correlates O O
with O O
histone O O
modifications O O
. O O

However O O
, O O
the O O
extent O O
to O O
which O O
TF O O
binding O O
and O O
histone O O
modifications O O
functionally O O
define O O
active O O
enhancers O O
remains O O
unclear O O
. O O

Here O O
, O O
we O O
combine O O
chromatin O O
immunoprecipitation O O
with O O
a O O
massively O O
parallel O O
reporter O O
assay O O
( O O
ChIP O O
- O O
STARR O O
- O O
seq O O
) O O
to O O
identify O O
functional O O
enhancers O O
in O O
human B-CellLine B-CellLine
embryonic I-CellLine I-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
ESCs B-CellLine B-CellLine
) O O
genome O O
- O O
wide O O
in O O
a O O
quantitative O O
unbiased O O
manner O O
. O O

Although O O
active O O
enhancers O O
associate O O
with O O
TFs O O
, O O
only O O
a O O
minority O O
of O O
regions O O
marked O O
by O O
NANOG O O
, O O
OCT4 O O
, O O
H3K27ac O O
, O O
and O O
H3K4me1 O O
function O O
as O O
enhancers O O
, O O
with O O
activity O O
markedly O O
changing O O
under O O
naive O O
versus O O
primed O O
culture O O
conditions O O
. O O

We O O
identify O O
an O O
enhancer O O
set O O
associated O O
with O O
functions O O
extending O O
to O O
non O O
- O O
ESC B-CellLine B-CellLine
- O O
specific O O
processes O O
. O O

Moreover O O
, O O
although O O
transposable O O
elements O O
associate O O
with O O
putative O O
enhancers O O
, O O
only O O
some O O
exhibit O O
activity O O
. O O

Similarly O O
, O O
within O O
super O O
- O O
enhancers O O
, O O
large O O
tracts O O
are O O
non O O
- O O
functional O O
, O O
with O O
activity O O
restricted O O
to O O
small O O
sub O O
- O O
domains O O
. O O

This O O
catalog O O
of O O
validated O O
enhancers O O
provides O O
a O O
valuable O O
resource O O
for O O
further O O
functional O O
dissection O O
of O O
the O O
regulatory O O
genome O O
. O O

Eradication O O
of O O
Central B-CellLine O
Nervous I-CellLine O
System I-CellLine O
Leukemia O O
of O O
T O B-CellLine
- O I-CellLine
Cell O I-CellLine
Origin O O
with O O
a O O
Brain O O
- O O
Permeable O O
LSD1 O O
Inhibitor O O
. O O

PURPOSE O O
: O O
Lysine O O
- O O
specific O O
demethylase O O
1 O O
( O O
LSD1 O O
) O O
regulates O O
several O O
biological O O
processes O O
via O O
the O O
bifunctional O O
modulation O O
of O O
enhancer O O
functions O O
. O O

Recently O O
, O O
we O O
reported O O
that O O
LSD1 O O
overexpression O O
is O O
a O O
founder O O
abnormality O O
of O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
leukemogenesis O O
and O O
is O O
maintained O O
in O O
fully O O
transformed O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
acute I-CellLine I-CellLine
lymphoblastic I-CellLine I-CellLine
leukemia I-CellLine I-CellLine
( I-CellLine I-CellLine
T I-CellLine I-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
) I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

On O O
the O O
basis O O
of O O
this O O
finding O O
, O O
we O O
attempted O O
to O O
develop O O
novel O O
LSD1 O O
inhibitors O O
effective O O
for O O
T O O
- O O
ALL O O
with O O
central B-CellLine O
nervous I-CellLine O
system I-CellLine O
( O O
CNS B-CellLine O
) O O
involvement O O
. O O

EXPERIMENTAL O O
DESIGN O O
: O O
We O O
chemically O O
modified O O
the O O
prototype O O
LSD O O
inhibitor O O
tranylcypromine O O
( O O
TCP O O
) O O
and O O
screened O O
for O O
cytotoxicity O O
against O O
TCP O O
- O O
resistant O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
. O O

In O O
vivo O O
efficacy O O
of O O
novel O O
LSD1 O O
inhibitors O O
was O O
examined O O
in O O
immunodeficient O O
mice O O
transplanted O O
with O O
luciferase O O
- O O
expressing O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
, O O
which O O
faithfully O O
reproduce O O
human O O
T O O
- O O
ALL O O
with O O
CNS B-CellLine O
involvement O O
. O O

RESULTS O O
: O O
We O O
found O O
robust O O
cytotoxicity O O
against O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
but O O
not O O
normal O O
bone O B-CellLine
marrow O I-CellLine
progenitors O I-CellLine
, O O
for O O
two O O
N O O
- O O
alkylated O O
TCP O O
derivatives O O
, O O
S2116 O O
and O O
S2157 O O
. O O

The O O
two O O
compounds O O
induced O O
apoptosis O O
in O O
TCP O O
- O O
resistant O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cells I-CellLine I-CellLine
in O O
vitro O O
and O O
in O O
vivo O O
by O O
repressing O O
transcription O O
of O O
the O O
NOTCH3 O O
and O O
TAL1 O O
genes O O
through O O
increased O O
H3K9 O O
methylation O O
and O O
reciprocal O O
H3K27 O O
deacetylation O O
at O O
superenhancer O O
regions O O
. O O

Both O O
S2116 O O
and O O
S2157 O O
significantly O O
retarded O O
the O O
growth O O
of O O
T B-CellLine B-CellLine
- I-CellLine I-CellLine
ALL I-CellLine I-CellLine
cells I-CellLine I-CellLine
in O O
xenotransplanted O O
mice O O
and O O
prolonged O O
the O O
survival O O
of O O
recipients O O
as O O
monotherapy O O
and O O
in O O
combination O O
with O O
dexamethasone O O
. O O

Notably O O
, O O
S2157 O O
could O O
almost O O
completely O O
eradicate O O
CNS O O
leukemia O O
because O O
of O O
its O O
ability O O
to O O
efficiently O O
pass O O
through O O
the O O
blood B-CellLine B-CellLine
- O I-CellLine
brain B-CellLine I-CellLine
barrier O O
. O O

CONCLUSIONS O O
: O O
These O O
findings O O
provide O O
a O O
molecular O O
basis O O
and O O
rationale O O
for O O
the O O
inclusion O O
of O O
a O O
brain O O
- O O
permeable O O
LSD1 O O
inhibitor O O
, O O
S2157 O O
, O O
in O O
treatment O O
strategies O O
for O O
T O O
- O O
ALL O O
with O O
CNS B-CellLine O
involvement O O
. O O

Temporal O O
enhancer O O
profiling O O
of O O
parallel O O
lineages O O
identifies O O
AHR O O
and O O
GLIS1 O O
as O O
regulators O O
of O O
mesenchymal O O
multipotency O O
. O O

Temporal O O
data O O
on O O
gene O O
expression O O
and O O
context O O
- O O
specific O O
open O O
chromatin O O
states O O
can O O
improve O O
identification O O
of O O
key O O
transcription O O
factors O O
( O O
TFs O O
) O O
and O O
the O O
gene O O
regulatory O O
networks O O
( O O
GRNs O O
) O O
controlling O O
cellular O O
differentiation O O
. O O

However O O
, O O
their O O
integration O O
remains O O
challenging O O
. O O

Here O O
, O O
we O O
delineate O O
a O O
general O O
approach O O
for O O
data O O
- O O
driven O O
and O O
unbiased O O
identification O O
of O O
key O O
TFs O O
and O O
dynamic O O
GRNs O O
, O O
called O O
EPIC O O
- O O
DREM O O
. O O

We O O
generated O O
time O O
- O O
series O O
transcriptomic O O
and O O
epigenomic O O
profiles O O
during O O
differentiation O O
of O O
mouse O O
multipotent O O
bone B-CellLine B-CellLine
marrow I-CellLine I-CellLine
stromal I-CellLine I-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
( O O
ST2 B-CellLine B-CellLine
) O O
toward O O
adipocytes B-CellLine B-CellLine
and O O
osteoblasts B-CellLine B-CellLine
. O O

Using O O
our O O
novel O O
approach O O
we O O
constructed O O
time O O
- O O
resolved O O
GRNs O O
for O O
both O O
lineages O O
and O O
identifed O O
the O O
shared O O
TFs O O
involved O O
in O O
both O O
differentiation O O
processes O O
. O O

To O O
take O O
an O O
alternative O O
approach O O
to O O
prioritize O O
the O O
identified O O
shared O O
regulators O O
, O O
we O O
mapped O O
dynamic O O
super O O
- O O
enhancers O O
in O O
both O O
lineages O O
and O O
associated O O
them O O
to O O
target O O
genes O O
with O O
correlated O O
expression O O
profiles O O
. O O

The O O
combination O O
of O O
the O O
two O O
approaches O O
identified O O
aryl O O
hydrocarbon O O
receptor O O
( O O
AHR O O
) O O
and O O
Glis O O
family O O
zinc O O
finger O O
1 O O
( O O
GLIS1 O O
) O O
as O O
mesenchymal O O
key O O
TFs O O
controlled O O
by O O
dynamic O O
cell O O
type O O
- O O
specific O O
super O O
- O O
enhancers O O
that O O
become O O
repressed O O
in O O
both O O
lineages O O
. O O
AHR O O
and O O
GLIS1 O O
control O O
differentiation O O
- O O
induced O O
genes O O
and O O
their O O
overexpression O O
can O O
inhibit O O
the O O
lineage O O
commitment O O
of O O
the O O
multipotent O O
bone B-CellLine B-CellLine
marrow I-CellLine I-CellLine
- I-CellLine O
derived I-CellLine O
ST2 I-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

The O O
TFAP2C O O
- O O
Regulated O O
OCT4 O O
Naive O O
Enhancer O O
Is O O
Involved O O
in O O
Human O O
Germline B-CellLine O
Formation O O
. O O
Human B-CellLine O
primordial I-CellLine B-CellLine
germ I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
hPGCs B-CellLine B-CellLine
) O O
are O O
the O O
first O O
embryonic B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
in O O
the O O
germ B-CellLine B-CellLine
cell I-CellLine I-CellLine
lineage O O
, O O
yet O O
the O O
molecular O O
mechanisms O O
required O O
for O O
hPGC B-CellLine B-CellLine
formation O O
are O O
not O O
well O O
characterized O O
. O O
The O O
TFAP2C O O
- O O
Regulated O O
OCT4 O O
Naive O O
Enhancer O O
Is O O
Involved O O
in O O
Human O O
Germline B-CellLine O
Formation O O
. O O
Human B-CellLine O
primordial I-CellLine B-CellLine
germ I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
hPGCs B-CellLine B-CellLine
) O O
are O O
the O O
first O O
embryonic B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
in O O
the O O
germ B-CellLine B-CellLine
cell I-CellLine I-CellLine
lineage O O
, O O
yet O O
the O O
molecular O O
mechanisms O O
required O O
for O O
hPGC B-CellLine B-CellLine
formation O O
are O O
not O O
well O O
characterized O O
. O O

To O O
identify O O
regulatory O O
regions O O
in O O
hPGC B-CellLine O
development O O
, O O
we O O
used O O
the O O
assay O O
for O O
transposase O O
- O O
accessible O O
chromatin O O
using O O
sequencing O O
( O O
ATAC O O
- O O
seq O O
) O O
to O O
systematically O O
characterize O O
regions O O
of O O
open O O
chromatin O O
in O O
hPGCs B-CellLine B-CellLine
and O O
hPGC B-CellLine B-CellLine
- I-CellLine I-CellLine
like I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
hPGCLCs B-CellLine B-CellLine
) O O
differentiated O O
from O O
human B-CellLine B-CellLine
embryonic I-CellLine I-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
hESCs B-CellLine B-CellLine
) O O
. O O

We O O
discovered O O
regions O O
of O O
open O O
chromatin O O
unique O O
to O O
hPGCs B-CellLine B-CellLine
and O O
hPGCLCs B-CellLine B-CellLine
that O O
significantly O O
overlap O O
with O O
TFAP2C O O
- O O
bound O O
enhancers O O
identified O O
in O O
the O O
naive O O
ground O O
state O O
of O O
pluripotency O O
. O O
We O O
discovered O O
regions O O
of O O
open O O
chromatin O O
unique O O
to O O
hPGCs B-CellLine B-CellLine
and O O
hPGCLCs B-CellLine B-CellLine
that O O
significantly O O
overlap O O
with O O
TFAP2C O O
- O O
bound O O
enhancers O O
identified O O
in O O
the O O
naive O O
ground O O
state O O
of O O
pluripotency O O
. O O

Using O O
CRISPR O O
/ O O
Cas9 O O
, O O
we O O
show O O
that O O
deleting O O
the O O
TFAP2C O O
- O O
bound O O
naive O O
enhancer O O
at O O
the O O
OCT4 O O
locus O O
( O O
also O O
called O O
POU5F1 O O
) O O
results O O
in O O
impaired O O
OCT4 O O
expression O O
and O O
a O O
negative O O
effect O O
on O O
hPGCLC B-CellLine B-CellLine
identity O O
. O O
Using O O
CRISPR O O
/ O O
Cas9 O O
, O O
we O O
show O O
that O O
deleting O O
the O O
TFAP2C O O
- O O
bound O O
naive O O
enhancer O O
at O O
the O O
OCT4 O O
locus O O
( O O
also O O
called O O
POU5F1 O O
) O O
results O O
in O O
impaired O O
OCT4 O O
expression O O
and O O
a O O
negative O O
effect O O
on O O
hPGCLC B-CellLine B-CellLine
identity O O
. O O

